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The Jaagsiekte Sheep Retrovirus (JSRV), an exogenous type BID-retrovirus with about 10-
15 endogenous counterparts in all normal sheep genomes, causes Jaagsiekte (JS) or ovine 
pulmonary adenocarcinoma (OP A), a contagious lung cancer of sheep. This sheep lung 
cancer has been identified as the best natural out-bred model that can be used to study 
human epithelial tumours. The close similarity between the pathology of the sheep disease 
and Human Bronchiolo-alveolar carcinoma are highly suggestive that the human disease 
could have a similar aetiology and mechanism to the sheep disease. However, in the case 
of sheep at the time of the study there was a need for an assay that could be used to screen 
for infected sheep. 
The isolation, cloning and subsequent sequencing of the first full- length exogenous and 
endogenous forms of JSRV contributed greatly towards JSRV research. Until recently the 
diagnosis of OP A was based mostly on clinical presentation with confirmation by micro 
and macro examination of the affected lungs by expert pathologists. In the absence of a 
specific humoral response no serology-based tests were available to diagnose the disease 
early in live animals. Control and management of the disease was primarily by regular 
flock inspections and prompt culling ofthe suspected cases. 
The objective of this research project was therefore to assess and investigate the 
serological and molecular diagnosis of JSRV. In an attempt to develop a serology based 
assay three proteins were identified as candidate diagnostic antigens, the group specific 
antigen JSRVp26, the transmembrane and the orfX proteins. Genes coding for all three 
proteins were isolated, cloned and expressed. The JSRV p26 was sufficiently purified and 
XXVll 
its potential as a diagnostic antigen was evaluated in both a Western blot and ELISA. Our 
studies confirmed that there were no circulating antibodies to the JSRV capsid protein. 
Evidence suggested that the immune response was localised to the lungs. Lung lavage 
samples were therefore collected from infected and normal sheep and analysed for the 
presence of JSRV p26 antibodies using an in-house JSp26 peroxidase conjugate in an 
antigen capture assay. This assay lacked sensitivity but the results indicated that there was 
a specific localised immune response to JSRV in the lungs of OP A affected sheep. This 
was confirmed with an in-house antigen capture assay that we developed. JS antigen was 
detected in the lung and nasal fluid of affected sheep, but not in equivalent samples from 
normal sheep. 
Three molecular assays were investigated for their sensitivity and specificity, the LTR-gag 
peR, U3/LTR hemi-nested peR and the peR that covered the VIN2 region. The U3/LTR 
hemi-nested assay was 2 logs more sensitive than the LTR-gag peR. However, it detected 
the endogenous JSRV5.9Alloci at higher concentrations. This was overcome by designing 
a more specific primer P3M for the first step of the U3/LTR hemi-nested peR and the use 
of the AmpliTaq Gold DNA polymerase. This assay proved to be both sensitive and 
specific enough to screen for the infectious exogenous JSRV in peripheral blood samples 
from individual sheep. 
It is now possible to use this assay to selectively eradicate the disease from a flock through 
a selective culling programme. Furthermore, the assay could be made quantitative by the 




REVIEW OF THE LITERATURE 
1 INTRODUCTION 
Jaagsiekte Sheep Retrovirus (JSRV) is the causative agent of a contagious lung cancer in 
sheep that is known as Ovine Pulmonary Adenocarcinoma (OP A). The disease has been 
called by many other names including Ovine Pulmonary Carcinoma (OPC), Sheep 
Pulmonary Adenomatosis (SPA) and Bronchioloalveolar carcinoma (BAC) (Done, 1990; 
Hecht et aI, 1996; De Martini et aI, 1997; Palmarini et aI, 1997 and Palmarini et aI, 2001). 
In South Africa the disease is often referred to as jaagsiekte, a Dutch term used to describe 
the accelerated respiration that is so pronounced towards the latter stages of the disease that 
the animal appears to have been rapidly chased (jagt: to drive or chase; ziekte: a sickness), 
hence the name jagtziekte (Mitchell, 1915). However, OPA is now the official name to be 
used when referring to the Jaagsiekte sheep retrovirus induced disease. This was decided 
upon at an international workshop on JSRV /OPA that was held in Missillac, France in June 
of 2001 when all the researchers in this field were brought together (York et aI, 2003a). 
OP A has been one of the most intensively studied lung tumours of domestic animals (de 
Kock, 1929; Dungal, 1938; Tustin, 1969; Hod et aI, 1977; Nobel and Perk, 1978). Liebow 
1960, defined Bronchioloalveolar (peripheral) carcinoma as "one whose cells tend to line 
the walls of distal airspaces without destroying them and spread via aerogenous and 
lymphatic routes" (Liebow, 1960). OPA is nonnally associated with different breeds of 
sheep and more rarely in goats and wild moufflon (Sharp et aI, 1986 and De Las Heras et 
aI, 1991). OPA shares pathological characteristics with human bronchiolar-alveolar cell 
carcinoma, an epithelial tumour that is not significantly associated with smoking and 
represents a quarter of human lung cancer cases (Wu et aI, 1988 and Barsky et aI, 1994). 
Recently the World Health Organisation (WHO) conveyed a more precise definition of 
human lung tumours. With regard to this new classification OP A would be defined as a 
'mixed adenocarcinoma showing acinar, papillary and bronchioloalveolar growth patterns' 
(Palmarini et aI, 2001). 
2 
JSRV is closely related to a retrovirus, Enzootic Nasal Tumour Virus (ENTV), the agent 
responsible for enzootic nasal tumours (nasal adenocarcinomas) of both sheep and goats 
(Cousens et aI, 1999). The disease pathologies though distinctly different, are caused by 
two very similar viruses that would allow any control strategies that are designed for the 
one, including vaccination control, to be used for the other (De Las Heras et aI, 2003b). 
The same would apply for both serology and molecular based diagnostic assay. 
OPA Gaagsiekte) is important as a natural animal model ofretroviral carginogenesis of the 
secretory epithelium of the respiratory system, as epithelial neoplasms occur less 
frequently in animals as compared to humans (De Martini and York, 1997). OP A is 
characterised by a long incubation period and once the typical symptoms of the disease 
manifests, recoveries do not occur (Hecht et aI, 1996). Much research has been undertaken 
in understanding the pathogenesis of OP A and the biology of its causative agent. This has 
resulted in OP A being selected as a model system to study a lung cancer at the molecular 
level (Palmarini et aI, 2001). Therefore, the purpose of this study is to utilize the 
. information available to establish a possible serological as well as a molecular technique to 
detect the aetiological agent as early as possible. 
1.1 HISTORY 
The earliest reports of OP A appeared in a letter written in 1825 by Veldkomet P. Aucampi 
in the Rhenoster district of the Cape of Good Hope where 800 sheep were reported to have 
died of OP A (Tustin, 1969). Hutcheon, a veterinarian employed by the Cape Government, 
first described symptoms and macroscopic pathology in 1891 (Hutcheon, 1891 cited by 
Tustin 1969). The disease was known to be contagious and Hutcheon advised farmers that 
the slaughter of affected animal was essential to prevent spread of the disease. The 
incidence of OPA as reported by these farmers at that time (late 1890's to early 1900's) 
was about two percent. The disease was probably brought into South Africa when merino 
sheep were imported from Spain in the early 1800's and the sheep developed the disease at 
about four years of age. In March 1912, Sir Amold Theiler, Director of Veterinary 
Research at Ondersterpoort carried out a series of experiments that were later continued by 
Mitchell to deduce the possible mode of transmission of the disease. After a series of 
experimental transmission attempts using blood, bronchial exudates, and suspensions of 
affected lung tissue as inoculum and by placing healthy sheep in contact with the affected 
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sheep, Mitchell was confident that the disease was capable of being transmitted by physical 
contact (Mitchell, 1915). Various aspects of Mitchell' s experimental procedure, especially 
the short incubation period, led De Kock in 1929 to disclaim that Mitchell had transmitted 
the disease by physical contact of diseased sheep with normal sheep (Tustin, 1969). De 
Kock described a form of ovine interstitial pneumonia characterised by an excessive 
accumulation of round cells of the lymphoid series, and an atypical proliferation of 
bronchiolar epithelium referred to as Graaf Reinet Disease. What De Kock described was 
different to the proliferation seen in Jaagsiekte sheep and Chronic Catarrhal Pneumonia 
with the presence of giant cell formations in the alveolar exudates. He stated that there 
might be two lung diseases affecting the sheep, namely, a form of pneumonia called "Graaf 
Reinet Disease" and OP A "Graaf Reinet" disease and Montana Progressive Pneumonia 
were histopathologically similar (Tustin, 1969). De Kock in 1929 concluded that the 
neoplasms in OP A were probably of the nature of multiple papilliform cyst-adenomata. He 
also tried to determine the infectiousness of OP A by exposing healthy sheep to affected 
sheep. He was the first to transmit the disease successfully in this way, that is, by co-
habitation (De Kock, 1929). 
1.2 DISTRIBUTION 
Ovine pulmonary adenocarcinoma (OP A) and progressive interstitial pneumonia (maedi) 
caused great confusion because both diseases existed in sheep and native languages or 
place names were used to describe the diseases (Shirlaw, 1959; Wandera, 1971). Despite 
the variation in the description of adenomatous lesions of Jaagsiekte, it is a specific disease 
and is found worldwide (Wandera, 1971). Jaagsiekte was first reported in England in 1888 
by both McFadyean and Dykes, when they thought the lesions were caused by lungworms, 
and in Germany by Eber A. in 1899 (cited from Tustin, 1969). During the 1930's large-
scale outbreaks were reported in Iceland where Dungal and associates were the first to 
transmit the disease by means of parenteral inoculation of suspensions containing the 
infectious agent. OP A is the most common pulmonary tumour of sheep and occurs in many 
countries. It is unexplainable why countries like Australia and New Zealand have escaped. 
Both these countries have imported sheep (merino) directly and via Britain and South 
Africa from Spain (De Kock, 1929). A possible explanation for this occurrence is that the 
sheep which were imported into both these countries served as flock founders that may 
have created a bottleneck such that one of the parent viruses needed to generate the 
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infectious viruses was not present in one of the flocks (Bai et ai, 1999). Based on 
circumstantial evidence the original home of OP A could be Spain, France or Germany. 
1.3 INCIDENCE AND ECONOMIC IMPORTANCE 
The incidence of OP A in sheep farming communities will vary depending on the 
management of the flock (Sharp, 1981), susceptibility to the environment, that is, 
confinement in close winter quarters; and breed or strain of sheep. OP A was found to be 
most serious in flocks not previously exposed and lowest in those exposed longest (Hutt, 
1964). A typical example is the epidemic suffered by Iceland during the 1930's and 1940's 
when there were widespread outbreaks due to OP A, which caused enormous losses to the 
farmers (Dungal, 1946). 
In 1933,20 Karakul sheep from Haile, Germany were imported into Iceland. These sheep 
were kept in quarantine for two months before distribution throughout 14 sheep farms in 
Iceland. Epidemiological studies show that two of the rams were carriers of a chronic 
pulmonary infection of the lungs, maedi, and one of them a carrier of OP A. In the winter of 
1934, OPA started to appear on many of the farms and losses greater than 50% were 
reported over the next two or three years. The Gottorp strain of sheep was particularly 
susceptible while the Adolbol stock was conspicuously resistant but not widely distributed 
when the disease struck (Perk, 1982). The epizootic was at its peak from 1936- 1945. OPA 
was eradicated from Iceland by destroying all sheep in the infected areas in the period 
1944 to 1951. This eradication campaign was successful and no cases of OP A have been 
seen in Iceland since 1952 (Sigurdsson, 1958). 
The actual mortality or number of animals involved in OP A infected flocks has varied in 
different countries and can actually be as much as up to 50%. It tends to drop to 1 % to 5% 
in flocks where it is endemic (Wandera, 1971). In Scotland, 20% of all mature sheep 
necropsied at the Veterinary Investigation centres had OP A (cited from York, 1987). The 
prevalence rate in Scotland is much higher than in England and this suggests that there are 
breed differences in susceptibility. Lately it has become a significant problem in the UK, 
especially in East Anglia and on the east coast and Scottish Borders (Kayne, 2004). In 
South Africa, Merino and Karakul and their crossbreeds are possibly more susceptible than 
English breeds. The sex of the animal does not seem to play a role in its susceptibility 
5 
(Verwoerd et ai, 1994). Losses of30% or more in certain flocks were not unusual when the 
disease was fIrst introduced into South Africa in the 1800's (Tustin, 1969). 
Early reports on the natural occurrence of OP A in goats were controversial because of the 
unconvincing data and inadequate differentiation between alveolar epithe1ialisation and 
true adenocarcinomatous lesions (Tustin, 1969). OP A does occur naturally in goats in 
some countries where the prevalence is low, but it has not been diagnosed naturally in the 
Southern African species (Verwoerd et ai, 1994). However, it has been experimentally 
transmitted to kids in South Africa. It appears that goats are less susceptible to JSRV than 
sheep, because in one experiment a viral inoculum of OP A that produced extensive lesions 
in more than 90% of newborn lambs after two to three months produced only small-
circumscribed lesions in two out of five kids after nine to thirteen months (Tustin et ai, 
1988). Transmission studies in Europe provided similar results (Verwoerd et ai, 1994). 
Further support for the natura110w prevalence rate amongst goats is the epidemic of OP A 
in Iceland in the 1930's and 1940's. OPA was not seen in goats even though the goats were 
in close contact with the JS affected sheep (Tustin, 1969). 
1.4 TRANSMISSION 
De Koch, 1929 and Dungal, 1946 showed that the disease could be transmitted by co-
habitation of healthy sheep with affected ones. Dungal experimentally proved in two ways 
that the exhaled air of an affected sheep contained the infectious agent. According to 
Tustin, 1969, Dunga1 and Markson as well as the others successfully transmitted the 
disease by exposing sheep to droplet infection by means of an aerosol spray. Tustin in his 
review of OP A found that transmission by means of parenteral inoculations of suspensions 
of diseased lung tissue and filtrates was also successful. This was accomplished by 
intrapulmonary, intrapleural, intratracheal or subcutaneous routes or by various 
combinations of these routes together with others such as intranasal. In an experiment 
carried out by Tustin at Onderstepoort, OP A was transmitted using neoplastic cells grown 
in tissue culture. Of the two day-old lambs that were inoculated one died of OP A after 249 
days and the other was sacrificed after 253 days. Advanced lesions were present in the 
lungs. On repetition of this experiment using cells from another sheep, the transmission 
experiment failed (Tustin, 1969). 
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Experimental data therefore indicate that the mam natural route of transmission IS 
aerogenous and the spread of infection is facilitated by close contact. An attempt was made 
to determine whether intra-uterine infection took place. Results based on experimental 
evidence of OP A indicated that prenatal infection was not of significance (Tustin, 1969) 
1.5 AETIOLOGY 
Years of research in many countries failed to reveal the agent responsible for the disease, 
though many theories were put forward regarding the infectious, neoplastic nature and 
causal agent of OP A (Wandera, 1971). De Kock was the first to report on the successful 
experimental transmission of the disease by contact of healthy sheep with sick sheep in 
1929 (Verwoerd et aI, 1994). These results were later confirmed by Dungal in 1946. His 
experiments were designed so as to exclude all other possibilities of infection except 
through inhalation (Dungal, 1946). 
The first ever report of a possible retroviral involvement in the aetiology of OP A was made 
in Israel when typical retrovirus particles were observed in adenomatous lesions (perk et 
aI, 1971). Retroviruses were found in cell cultures established from OPA lungs (Malmquist 
et aI, 1972) and reverse transcriptase activity in purified extracts of lung tumour tissue. 
Transmission studies were not carried out and the probable presence of maedi-visna 
lentivirus in the material studied posed a problem as far as interpretation of results was 
concerned (Perk et aI, 1974). Martin Scott and Sharp were the first to report the 
transmission of Jaagsiekte with lung extracts containing reverse transcriptase (Martin et ai, 
1976). Their findings were confirmed later (Verwoerd et aI, 1980). 
Several factors have emerged that clearly implicate retroviral involvement in OP A. A viral 
aetiology was suggested when lung tumours were induced with cell free filtrates of the 
lung discharge, lung lavage fluid or tumour homogenate (Martin et aI, 1976). Secondly, 
reverse transcriptase activities with magnesium preference, associated with material of the 
density of retroviral particles of 1.175-1.18 glml, were found in the tumour material (Perk 
et ai, 1974; Verwoerd et aI, 1980; Herring et ai, 1983). Thirdly, the same tumour derived 
materials contain proteins that cross-react with antisera to the capsid (Sharp et aI, 1983; 
Kajikawa et ai, 1990) and nUcleocapsid proteins (He et ai, 1992) of Mason-Pfizer Monkey 
Virus (MPMV) and Mouse Mammary Tumour Virus (MMTV), a Type D and Type B 
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oncovirus, respectively. Fourthly, retrovirus particles can be seen by electron microscopy 
in lung tumours and lung fluid (Payne et aI, 1983; De Martini, 1988). Fifthly, the 
incubation period in the experimental studies is inversely proportional to the reverse 
transcriptase level in the inoculum, and may be as short as a few days to weeks (Verwoerd 
et ai, 1980; Herring et ai, 1983). Reverse transcriptase and viral proteins have been found 
only in tumour and lung fluid, never in other tissues, strengthening the physical linkage 
between the virus and the tumour. Further, the complete genome of the Jaagsiekte Sheep 
Retrovirus (JSRV) has been cloned from viral particles secreted in lung exudates of 
affected animals and sequenced. The genome is 7,462 nucleotides long and exhibits a 
genetic organization characteristic of the Type B and D oncoviruses (York et ai, 1991; 
York et aI, 1992). The exogenous form of JSRV has been consistently and exclusively 
found to be present in tumours and lung fluids and also on occasions used as inocula to 
induce OP A (Palrnarini et aI, 1996). These factors clearly implicate a retrovirus (exJSRV) 
of probably Type B or D classification in the pathogenesis ofOPA (York et ai, 1991; York 
et ai, 1992). 
The final confirmation that JSRV is exclusively responsible for the disease and 
transformation was provided by Palmarini et al (1999). They constructed an infectious and 
pathogenic full length JSRV proviral clone pJSRV21 from a tumour genomic DNA library 
derived from a natural case of OP A. The U3 region of the upstream L TR in pJSRV 21 was 
replaced with the human cytomegalovirus (CMV), which is the immediate early promoter 
that is highly active in these cells. The CMV promoter was positioned so that the resulting 
RNA transcript would be very similar to wild-type JSRV RNA. When the resulting 
plasmid (pCMV2JS21 ) was transfected into 293T cells substantial amounts of JSRV21 virus 
were released into the supernatant. Four newborn blackface lambs were inoculated 
intratracheally with concentrated JSRV21 stocks obtained from transfected 293T cells. The 
resulting tumours were histologically identical to spontaneous and experimentally induced 
OPA, and the tumour cells expressed JSRV CA antigen. Infection with OPA was also 
confirmed molecularly. This proved conclusively that JSRV is the aetiological agent of 
OP A and that it is necessary and sufficient to induce OP A (Palmarini et aI, 1999). Recently 
another infectious molecular clone JSRVJS7 was obtained from a sheep lung cell line JS 7. 
(De Martini et ai, 2001). His group constructed an infectious clone and managed to infect 
sheep and recover the virus from the infected sheep. Thus fulfilling Kochs postulates 
(Palmarini et a12000; De Martini et aI, 2001). 
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Other tumours that are associated with retroviruses and have similarities to OP A art? the 
Caprine and Ovine nasal adenocarcinomas (De Las Heras et ai, 1991; De Las Heras et ai, 
1991). Similarities such as experimental transmission using cell-free filtrate (De Las Heras 
et ai, 1995), retroviral particles, particle-associated reverse transcriptase activity and 
antigenic cross-reactivity of ENT V capsid proteins with that ofMPMV capsid proteins p27 
and recombinant JSRV capsid proteins exist, indicating that ENTV has a Type D retroviral 
capsid (De Las Heras et ai, 1991; De Las Heras et ai, 1993). These studies have found that 
the goat viral products appear to be different from the OP A virus with a slightly different 
antigenic cross-reactivity. A type D-related virus has also been isolated from bovine cells, 
but its classification is uncertain and its role in disease, if any, is unknown (York et ai, 
1989). The sheep and goat nasal adenocarcinoma and OP A models emphasise the need for 
research into the mechanisms of transformation of secretory cells of the respiratory tract 
caused by a family of ungulate retroviruses. These ENTV's have been shown to be 
antigentically and genomic ally related to JSRV (Cousens et ai, 1999). 
1.6 CLINICAL SIGNS AND PATHOLOGICAL FEATURES 
For natural infections the incubation period varies from about nine months to two to three 
years (Dungal, 1938). Experimentally, because of the large number of lesions induced, the 
incubation period in lambs can be reduced to as little as three weeks by inoculation of 
concentrated lung rinse material containing the aetiological agent in high concentration 
(Verwoerd et ai, 1994). 
The onset of clinical signs is insidious in natural cases. Although the physical condition of 
the animal may appear to be good, the respiratory rate is more rapid than normal after an 
animal has been driven. As the disease progresses, affected animals have a reduced 
appetite, body weight decreases and the animal tends to lag behind the flock when it is 
driven. Marked respiratory distress is evident on exercise, the respiratory movements being 
short and jerky. Tachypnoea and dyspnoea eventually become evident even at rest. 
Spasmodic bouts of coughing occur and there is a great increase in the amount of secretion 
from the lungs, resulting in the production of a watery nasal fluid. This is regarded as 
almost pathognomic for OPA (Mitchell, 1915; Dungal, 1938; Verwoerd et ai, 1994). In 
countries where OP A is endemic, a clinical diagnosis of OP A is based on inducing flow of 
this fluid (up to 300ml can be collected) by raising the rear legs and lowering the head of 
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animals suspected to have the disease (referred to as the wheelbarrow test), upon thoracic 
auscultation, moist rales may be heard (Tustin, 1969). 
There is generally no fever, but pyrexia may occur as a result of pneumonia following 
secondary bacterial infection (Verwoerd et ai, 1994). Because no convenient test for 
detection of infected sheep existed, estimating the incubation period accurately has been 
difficult, although it is estimated at about five to six months. Lambs as young as three 
months have been diagnosed with OP A, but two to four year old sheep are most commonly 
affected (Tustin, 1969). In clinically affected animals a peripheral lymphopenia is marked 
by a decrease in CD4 T lymphocytes and a corresponding neutrophilia can assist 
clinician's diagnosis but the changes are not pathognomic (Sharp, 2000). Anatomic 
diagnosis of OP A is based on gross lesions and histopathology, but differentiation from 
other causes of chronic pneumonopathies of sheep is not always easy (De Martini and 
York, 1997). In advanced cases of Jaagsiekte the lungs are three or more times their 
normal weight (up to 2kg) and fluid almost fills the thoracic cavity. Interestingly the lungs 
do not collapse when the thorax is opened (Verwoerd et aI, 1994). Lungs affected by OP A 
contain large, firm, gray masses in the anterioventral regions of one or both lungs, 
occasionally with similar, smaller (1-2 centimetres) nodules in posterodorsal parts of the 
lung. The intermediate lobe is frequently involved (De Martini and York, 1997). The lungs 
commonly exude clear fluid from the cut surface of the bronchioles of the affected areas 
and the trachea may be filled with foamy fluid. This is seen in the classical pathological 
form of OP A (De Las Heras et aI, 2003b). Some cases are complicated by areas of necrosis 
in the tumour masses and by chronic or acute bacterial pneumonia that may hide or 
overshadow the tumour lesion pattern (De Las Heras et aI, 2003b). 
Another pathological form of OP A is more nodular and is referred to as being atypical. 
Nodules and areas of diseased tissue of various sizes (smallest being less than Imm in 
diameter) are sometimes scattered throughout the normal lung tissue. Large lesions consist 
of very dense tumorous tissue with a relatively firm consistency, and may protrude slightly 
above the affected lung tissue. The distribution of lesions suggests that the primary lesion 
or lesions grow by expansion. Intrapulmonary spread of the infection with the development 
of new foci probably occurs both aerogenously and via the lymph and blood streams. Each 
new focus is seen grossly as a small greyish- white, semi-transparent nodule which at first 
is barely visible to the naked eye. These new foci expand and coalesce with neighbouring 
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nodules to develop into larger lesions. Lesions of experimentally induced cases tend to be 
more multicentric than those caused by natural infection (Verwoerd et aI, 1994). 
Intra- and extra- thoracic metastasis of the tumour may occur (Tustin, 1969; Verwoerd et 
aI, 1994). In South Africa extrapulmonary metastasis is rare, whereas it frequently occurs 
in Awassi or fat- tailed sheep in Israel, where metastasis both within and outside the thorax 
may be found in 30% to 50% of cases (Herring et ai, 1983; De Martini et ai, 1988). The 
ability of OP A tumours to metastasize has led to them being transplanted in mice, thereby 
deriving cell lines from nude mice. This supports the theory that OP A tumours are 
neoplastic rather than proliferative in nature (Palmarini et aI, 2001). About 10% of OPA 
tumours metastasise to regional pulmonary lymph nodes and metastasis to heart and 
skeletal muscle have been found less frequently. Neoplastic masses of OP A are composed 
of cuboidal to columnar epithelial cells in single layers or proliferating to form projections 
(or acinar-like structures) into the alveoli. Surrounding normal alveoli are usually 
compressed and may contain infiltrates of large alveolar macrophages with foamy 
cytoplasm (De Martini and York, 1997). 
Ultra structural studies of OP A lesions indicate that tumour cells of Type 11 cell origin are 
usually well differentiated maintaining the appearance of the cells from which they 
originated (Verwoerd et ai, 1994; Palmarini et ai, 2001), with microvilli, desmosomes, and 
intracellular lamellar bodies. Tumour cells of Clara--cell origin contain cytoplasmic dense 
bodies instead of lamellar bodies (De Martini and York, 1997). 
Scanning electron microscopy reveals that the surfaces of the neoplastic cells are usually 
covered by abundant microvilli, in stark contrast to the smooth surface of normal alveolar 
epithelial cells. A single transformed cell proliferates to form a single layer lining the 
alveolar lumen, which then develops into a grape-like cluster with papilliform projections 
eventually filling the alveolar space and spreading to adjacent alveoli. The most common 
non-malignant cells, found mainly in advanced lesions, are macrophages. They have an 
"angry" appearance, being large and possessing a ruffled surface indicating a state of 
activity (Verwoerd et aI, 1994). 
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1.7 PATHOGENESIS 
The natural route of infection is the respiratory route. The primary lesion in OP A is 
neoplastic transfonnation of Type II secretory epithelial cells (pneumocytes) and possibly 
also of the non-ciliated tenninal bronchiolar epithelial cells (Verwoerd et ai, 1994). Cells 
that have been transfonned and where viral replication has occurred (Payne et ai, 1983) 
proliferate and fonn clusters that invade and eventually obliterate the alveolar lumen, 
resulting in death due to hypoxia. Type II pneumocytes produce large amounts of 
surfactant containing clear and viscous fluid, which is stored in the air passages and 
aggravates respiratory distress. This surfactant leads to coughing and the fonnation of 
aerosol droplets containing the virus or tumour cells. Clara cells on the other hand are 
considered to synthesise, store and secrete protein elements of the extracellular lining layer 
ofthe bronchioles (Verwoerd et ai, 1994; Palmarini et ai, 2001) 
OP A transcripts and to a lesser extent proviral DNA have been demonstrated in the 
draining lymph nodes and also in several anatomically dispersed lymphoid tissues such as 
the spleen, thymus, bone marrow and PBMC's (peripheral blood monocytes) indicating 
that JSRV probably establishes a disseminated infection. It has been found that the virus is 
exposed at much higher levels in OP A tumours than in lymphoid tissues particularly those 
at the non-local sites. The significance of JSRV in the overall pathogenesis of OPA is 
unknown. Presently sheep with clinical signs of OP A have been examined and therefore it 
is not known whether lymphoid infection precedes or is a result of JSRV replication in the 
pulmonary epithelium. Further studies will be required to define which cell types are 
involved, at which stages during the period between infection and the appearance of 
clinical illness, and the effect of JSRV on effector functions of the infected lymphoid cells 
(Sharp, 1997). A characteristic feature of OP A is a presence of large numbers of alveolar 
macrophages (AMs) usually in areas adjacent to the adenomatous lesions. The exact role of 
the AMs in the pathogenesis of OP A is not known, but one of its roles according to Eckert, 
1983, is to take up the excess surfactant in the lungs (Eckert et ai, 1983). The nonnal 
pathway leading to the proliferation of AMs is via the pulmonary interstitium. Blood 
monocytes enter the alveolus via the pulmonary interstitium and become macrophage 
precursors. These macrophage precursors differentiate into AMs under the influence of a 
growth factor supplied by mature AMs (Myer et ai, 1987). The activated macrophages 
produce substances that stimulate the proliferation of Type II cells. 
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In the OP A lungs, the increase in AMs is due to the tumour cells secreting a chemotactic 
factor, which stimulates the proliferation of AMs. The chemotactic factor secreted by OP A 
belongs to the category of polypeptide lymphokines that includes the growth and tumour 
cell necrosis factors. After chemotactic stimulation, macrophages have been shown to 
produce both growth-stimulatory and inhibitory factors, depending on their interaction 
with other lymphoid cells (Verwoerd et ai, 1994). 
OPA is often closely associated with the lentivirus infection (Payne et ai, 1986; De Martini 
et ai, 1988). This lentivirus remains in a latent form in the monocytes, which are activated 
during their maturation. The presence of large numbers of activated macrophages in OP A 
lungs creates an ideal environment for lentivirus replication. Further, there is a possibility 
that JSRV has an immunosuppressive effect, similar to that of MPMV to which it is 
related. This effect makes adenomatous lungs more susceptible to lentivirus infection than 
normal lungs (payne et al, 1986). It has been shown that the South African lentivirus 
isolate causes mild immunosuppression in sheep. The degree to which this happens 
coincides with the latent period before the appearance of signs of OP A in co-infected 
animals. Lentiviruses, in addition to causing mild interstitial pneumonia may lead to 
secondary infections in animal (Myer et al, 1988). 
1.8 OVINE PULMONARY ADENOCARCINOMA (OPA) AND HUMAN 
BRONCHIOLO-ALVEOLAR CARCINOMA (HBAC) 
Human Bronchiolo-Alveolar Cell Carcinoma (HBAC) is a rare tumour, which arises from 
both bronchiolar and alveolar epithelium. No apparent or yet detectable cause for lung 
damage has been proved, though an infective basis for these tumours has been suggested 
(Della et al, 1976). The 1999 World Health Organisation (WHO) imparts a more defined 
classification upon human lung cancer and classifies it into five major sUbtypes-acinar 
(gland forming), papillary, bronchiolo-alveolar, solid with mucous formation and mixed 
adenocarcinoma (Travis et aI, 2000). Human Bronchiolo-alveolar carcinoma (HBAC) is 
defined as 'a type of adenocarcinoma with a pure bronchiolar-alveolar carcinoma growth 
pattern and no evidence of stromal, vascular or pleural invasion' (Palmarini et ai, 2001). 
HBAC being one of the subtypes of adenocarcinoma represents 2% to 6% of all lung 
cancers. 
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HBAC consists of uniform cuboidal cells that arise distal to the terminal bronchioles and 
spreads along the alveolar septae without causing significant amounts of lung destruction. 
This is known as a lepidic growth pattern (Busick et al; 2000). There are three major 
subtypes ofHBAC, namely, non-mucinous, mucinous and sclerotic HBAC (Fujimoto et ai, 
1999). Approximately 41% to 60% are mucin producing, 21% to 45% are non-mucin 
producing, 12% to 14% are a mixture and up to 7% of the cases ofthe tumours are difficult 
to classify. The mucin- producing tumours show gross and microscopic mucin production 
and tend to be multicentric. These tumours consist of tall columnar cells with abundant 
apical cytoplasmic mucin that is diastase-digested, PAS (Periodic Acid Schiff) negative 
and mucicarmine negative and small basally oriented nuclei. The tumour cells grow along 
thin alveolar septae. The surrounding airspaces are often filled with mucin, creating a 
colloid-like appearance (Travis et ai, 2000). 
Non-mucinous HBAC is more solitary. These tumours consist of cuboidal cells 
proliferating along alveolar septae giving rise to a hobnail or saw-toothed appearance. 
Nuclear inclusions are present in non-mucinous tumour cells and show certain properties. 
They are PAS positive, stain with immunohistochemistry for surfactant apoprotein, and 
ultrastructurally appear to consist of 40nm branching microtubules that are thought to arise 
from the inner nuclear membrane. This type of HBAC may consist of Clara cells or Type 
11 pneumocytes (Travis et ai, 2000). 
The third type of HBAC is termed sclerotic. This type of HBAC has the tumour cells 
radiating from a central region of scaring (Fujimoto et ai, 1999). The alveolar septae are 
thickened by fibrosis without loss of alveolar architecture (Travis et ai, 2000). HBAC 
normally progress to a multifocal pattern that results from intrapulmonary metastases. In 
some cases the different foci are multi clonal (Barsky et ai, 1994b). 
The incidence ofHBAC is increasing in the USA and Japan and represents up to 25% of 
all primary lung carcinomas (palmarini et ai, 2001). Overall primary lung cancer has 
increased drastically between 1955 and 1990 and appears to be more prevalent in men 
(74%) than women (26%). Over this 35-year period, there has been a dramatic increase of 
HBAC from less than 5% to 24% of total human lung cancers, with a male to female ratio 
of around unity. Patients with HBAC appear to be younger at diagnosis and more likely to 
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be female (Barsky et ai, 1994a) and less likely to be cigarette smokers as compared to 
those with non-HBAC. The cause ofHBAC is unknown. 
OP A is histologic ally similar to HBAC and is found to exhibit a diffuse and multifocal 
character. No cases of sheep to human infection with the retrovirus have been reported. 
There have been reports of sheep farmers developing the diffuse form ofHBAC (Barsky et 
ai, 1994b) that histologic ally bear resemblance to OP A and consequently a viral cause for 
the disease cannot be ignored and its possible link to JSRV cannot be excluded (Cremer et 
ai, 1992; Barsky et ai, 1994a; Palmarini et ai, 1997; De Las Heras et ai, 2000). 
Malassez was the first researcher in 1876 to describe HBAC (Malassez, 1876). Duran-
Reynals 1958, had reported that many scientists have observed this similarity of HBAC to 
OPA (Duran-Reynals et ai, 1958). Both OPA and HBAC are well-differentiated, 
multifocal tumours of alveolar type II (pneumocytes) or non-cilliated bronchiolar (Clara) 
cells. The neoplastic tissues are preferentially localised at the periphery of the lungs and 
tend to grow within the lung for a prolonged period terminating in a late metastatic 
process. Both share the same histological and ultrastructural features as well as having a 
peak occurrence in adults. In the human cell tumour, as in the sheep carcinoma, apical 
mucin granules, tonofibrils, microvilli and neoplastic cells with cytosomes are found. This 
tumour development is similar to bronchiolar alveolar embryogenesis. The term benign 
and malignant pulmonary adenomatosis has been applied to HBAC. In the so called 
"benign" form the constituent tumour cells lining the alveolar walls are peg-shaped and 
form a single investing layer of cells. Spread to both the hilar lymph glands and elsewhere 
is of rare and late occurrence. In the more malignant varieties the neoplastic cells form 
focal mural clumps of cells, which project, into the alveolar lumen. The neoplastic cells are 
several layers in thickness and display abnormal mitosis and other evidence of malignant 
change. The more malignant tumours are more liable to secrete mucus giving the lung a 
macroscopic appearance similar to Type Three-pneumococcal pneumonia. Intranuclear 
eosinophilic inclusion bodies may be found occasionally in some of the tumour cells, but 
upon Electron microscopic (E.M.) examination no virus aggregates were seen (Della Porta 
et ai, 1976). Lung cancer is one of the most common of human malignancies and the 
prevalence of carcinomas in human beings exceeds haematopoietic neoplasms. In domestic 
animals, most importantly sheep and goats, bronchiolar and mainly peripheral 
adenocarcinomas are the most prevalent lung neoplasms, and also in which experimentally 
15 
induced carcinomas occur (Cremer et aI, 1992). Since OPA exhibits all the criteria 
included in the defmition of Bronchiolar-alveolarcarcinoma, this spontaneous, natural 
animal model can therefore provide basic information on the cell origin of HBAC. The 
disease pathogenesis from initial infection through to the development of preneoplastic 
lesions and eventual development of neoplastic events, natural history, epidemiology, host 
susceptibility of the disease that could lead to a selection of agents and modalities for 
chemotherapy in experimental animals and humans (Hod et aI, 1977; Perk et aI, 1974; Perk 
et ai, 1982; Cremer et ai, 1992). 
1.8.1 Importance of HBAC AND JSRV 
Human Bronchioloalveolar Carcinoma (HBAC) closely resembles OP A clinically, 
histologically and ultrastructurally. This similarity has raised questions about the role that 
JSRV could be playing in the development of human lung cancer and it was thought that 
the cause of BAC might have retroviral aetiology as welL It was O'Connell et al in an 
abstract that first suggested that a retroviral connection might exist owing to the presence 
of JSRV -related sequences and major capsid proteins in human BACIP AC (peripheral 
adenocarcinoma) (O'Connell et ai, 1998). Work by De las Heras et al (2000), revealed that 
23% of 249 human lung tumours that have been tested by immunohistochemistry 
employing a rabbit antiserum towards the major capsid protein of JSRV proved to be 
immunoreactive (De Las Heras et ai, 1997; De Las Heras et aI, 2000). These results 
support the assumption that some pulmonary tumours may be associated with a JSRV-
related virus. No virologic or molecular data was available to support this view. 
Subsequently, Yousem et aI, 2001, reported that by using both PCR and RT-PCR, that the 
association of BAC with JSRV was very weak, if present at all. A follow up study 
published by Hiatt and Highsmith support the study by Yousem et aI, 2001. The former 
reported that in the 24 human lung tumours that were investigated for integrated JSRV, no 
amplifiable DNA was present in all the samples (Hiatt et aI, 2002). 
Nevertheless, OP A remains a unique animal model that can be used as a natural model to 
uncover the mechanisms of human lung adenocarcinoma. 
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1.9 OVERVIEW OF THE FAMILY RETROVIRIDAE 
Retroviruses are among the first viruses that were studied and because of HIV this family 
of viruses currently dominates research efforts worldwide. They are also the best models 
for studying carcinogenesis in the whole organism, since they induce tumours with 
extremely high efficiency. Evidence that viruses could cause cancer first came from a 
series of studies on chicken sarcoma by Peyton Rous beginning in 1911. Retroviruses are a 
large family of enveloped RNA viruses, which share the same structure, composition and 
replicative properties (Coffin, 1992a). Most of the retroviruses we currently know infect 
vertebrates, but as a group, they have been identified in virtually all organisms including 
invertebrates. Some retroviruses can induce only a benign viremia with no outward adverse 
effects and can become established in the germ line as "endogenous viruses" from 
generation to generation (Coffin, 1992a). 
1.9.1 Classification of Retrovirus 
Retroviruses are unified into a family 'The Retroviridae' by important features of virion 
structure, their replication cycle and pathogenicity (Mathews, 1982). The taxonomy of the 
Retroviridae has been divided into seven genera, and then into sub genera and species and 
two more groups have been added (the Fish retroviruses and the Gypsy group of 
endogenous viruses of insects) both await final classification. The seven genera are: 
alpharetroviruses, betaretroviruses, gammaretroviruses, deltaretroviruses, 
epsilonretroviruses, lentiviruses and spumaviruses (Hunter et aI, 2000). A listing of the 
retrovirus by genera, sub genera and species is presented in Figure 1.1 (Burmeister et ai, 
2001; Coffin et al 2000). Classification is based on sequence similarity within the pol 
(polymerase) gene, but other correlated features, including the presence or absence of 
additional genes are sometimes used. Table 1.1 provides a taxonomic organization of the 
Family Retroviridae and examples of some known retrovirus groups (Porterfield, 1989; 
Fields et aI, 1996; Coffin et aI, 1997a). 
Historically retroviruses have also been classified by appearance, morphology or by 
cellular location of the viral particles. Virions can be further described according to the 
virion structure (types A to D), utilization of particular cell receptors, lifestyle whether 
endogenous (passed from parent to offspring as a provirus integrated into the germline) or 
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exogenous by the presence or absence of oncogenes or other pathogenic properties (Fields 
et aI, 1991). Distinguishable types A to D contain A, B, C and D particles. (Paul et aI, 
1992). 
GENUS SUBGROUP SPECIES 
1. Alpharetroviruses AL V (avian leucosis virus) 
2. Betaretroviruses ~Type B viruses 
"'Type D viruses~ 
MMTV (mouse mammary tumor virus) 
MPMV (Mason-PfIzer monkey virus) 
SRV (simian retrovirus) 
3. Gammaretroviruses 
4. Deltaretroviruses 
JSRV (Jaagsiekte retrovirus) 
ENTV (sheep enzootic nasal tumor virus) 
Mammalian Type C~ MuLV (murine leukaemia virus) 
GaL V (gibbon ape leukaemia virus) 
FeLV (feline leukaemia virus) 
REV (Reticuloendotheliosis virus) 
Primate T-c~lll~pho- ~ HTLV (human T-celllymphotropic virus) 
trOPIC vlfUses STL V (simian T -celllymphotropic virus) 
BL V (bovine leukaemia virus) 
5. Epsilometroviruses ---------- Wally dermal sarcoma virus 
6. Lentiviruses·..---- Immunodeficiency viruses ~ HIV (human immunodeficiency virus) 
SlY (simian immunodeficiency virus) 
FIV (feline immunodeficiency Virus) 
BIV (bovine immunodeficiency virus) 
Ungulate Lentiviruses ~ MVV (Maedi-Visna virus) 
~ CAEV (caprine arthritis encephalitis virus) 
EIA V (equine infectious anernia virus) 
7. Spumarekoviruses ~ SFV (simian foamy virus) 
FFV (feline foamy virus) 
BFV (bovine foamy virus) 
EFV (equine foamy virus) 
(Burrneister et aI, 2001) 
Figure 1.1 A Listing of Retroviruses by genera, subgenera and species 
Type A particles, about 60 to 90 run in diameter, are only found intracellularly and are not 
as infectious as the extracellular forms (Lu et aI, 1978). These particles lack the lipid 
containing outer envelope, as they do not bud from the membrane. Type A particles are 
composed of two forms: intracisternal and intracytoplasmic. The intracytoplasmic virions 
are intermediates in assembly of Type B and D virions, subsequently associating with the 
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cell membrane to initiate budding. Intracisternal A type particles are derived from 
endogenous retrovirus-like genetic elements non-enveloped and believed to be non-
infectious (Coffin, 1992a). 
B type particles have a diameter of approximately 125-130 nm. They contain a double 
membrane that consists of phospholipids and glycoproteins. The representative form is the 
mature virions of the Mouse Mammary Tumour Virus. B type particles are assembled via 
budding of A particles into an immature form resembling an A particle with an envelope 
and mature into a virion with a condensed, eccentric core and prominent spines on its 
surface (Coffin, 1992a). The major polypeptides have a molecular weight of 28 kilo 
Daltons (kDa) (P28), 14 kDa (P14) and 10 kDa (PlO) respectively. Two majorpolypeptides 
are the glycoproteins with molecular weights of 52 kDa (gp52) and 36 kDa (gp36) that are 
probably located in the viral envelope (Tzramoto et ai, 1974). This group includes both 
endogenous and exogenous viruses. Exogenous virions are transmitted vertically via milk. 
MMTV is an unusual simple retrovirus in that it has an extra gene that has a novel and 
important role in mediating host infections and tumurogenesis. This gene is referred to as 
sag (superantigen) and is located in the 3' or! region of the LTR that encodes the mls 
superantigen. It is a cell surface protein that interacts with specific v(3 chains of the T -cell 
receptor to induce them to send an activation signal to the infected cell. When expressed 
from an endogenous MMTV provirus, Sag proteins lead to depletion of specific T -cell 
subsets (Coffin et ai, 1997a). 
Type C particles are about 80-120 nm in diameter and include two retroviral groups, the 
mammalian and avian C-type viruses. These particles are assembled entirely at the plasma 
membrane without a precursor core being formed. An electron-dense crescent on the 
membrane accumulates spikes on the outer surface and extrudes from the membrane until 
the whole particle is formed and budded off. There are two types of extracellular particles. 
"Immature" forms have a central electron-dense core about 45 nm in diameter surrounded 
by an envelope with short spikes. "Mature" forms have a central condensed, electron-dense 
core within an envelope with even shorter spikes (porterfield, 1989). 
D type particles are characteristic of most of the retroviruses which have been found in 
primates, the prototype being the Mason-Pfizer Monkey virus (MPMV) and the Simian" 
AIDS" (SAIDS) virus (Coffin, 1992a). A more recent inclusion is the Jaagsiekte Sheep 
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Retrovirus (JSRV). They resemble B particles in assembly, maturation and morphology. 
The viral cores assemble in the cytoplasm before migrating to and budding from the 
plasma membrane. D particles are produced by budding type A cytoplasmic particles. Type 
D particles have a complete intracellular nucleocapsid and an eccentric location of the core 
in mature particles, but have less prominent surface projections and a charateristic 
cylindrical core. Type D retroviruses comprise both endogenous and exogenous viruses of 
New and Old World Primates and sheep. No oncogene-containing viruses are known and 
insertional activation of cellular oncogenes has not been reported (Coffin et aI, 1997a). 
1.9.2 The Genome Organisation 
All retrovirus genomes consist of two molecules of RNA, which are single stranded 
positive sense and have 5' methylated cap structure and 3' poly (A) tail (essentially 
resembling mRNA). Retrovirus genomes have four unique features. They are the only 
viruses that are truly diploid and the only RNA virus whose genome is copied via cellular 
transcriptional machinery (without any participation from a virus-encoded polymerase). 
Retroviral genomes require a specific cellular RNA (tRNA) for replication. They are the 
only positive sense RNA virus whose genome does not serve directly as mRNA 
immediately after infection. These two molecules are physically linked as a dimer by 
hydrogen bonds. In addition, there is a third type of nucleic acid present in all particles, a 
specific type of tRNA [tryptophan (trp); proline (pro); lysine (lys); or pro-glutamine (glu)] 
required especially by mammalian type C for replication. It is the primer on which reverse 
transcriptase initiates DNA synthesis (Coffin, 1992a). 
1.9.3 Virion RNA Genome 
The various components of the viral genome are arranged in the 5' to 3' order. Figure 1.2 is 
a schematic representation of a prototype viral RNA genome. The R Region is a short 
sequence of 18 to 250 nucleotides, which forms a direct repeat at the both ends of the 
genome, which is therefore "terminally redundant". At the 5' end it is adjacent to the 
capping group and at the 3' end found immediately preceding the poly (A) tract. It plays a 
role during reverse transcription in permitting the transfer of nascent DNA from one end of 
the genome to the other. 
















Example isolates Genome 
Rous sarcoma virus (RSV) Simple 1 
Avian myeloblastosis virus(AMV) 
Avianerythroblastosisvirus(AEV) 
Avian leucosis virus (Al V) 
Rous-associated virus (RAV)1-50 
RAV..Q 
Moloney murine leukaemia virus(MoMl V) Simple 
Harvey murine sarcoma virus (Ha-MSV) 
Abelson murine leukemia virus (A-Mul V) 
Feline leukemia virus (Fel V) 
Simian sarcoma virus 
Numerous endogenous and exogenous 
viruses, mostly in mammals 
Reticuloendotheliosis virus (REV); spleen 
necrosis virus (SNV) 
Mouse mammary tumour virus (MMTV) Simple 
Mason-Pfizer monkey virus (MPMV) Simple 
'SAIDS' viruses 
Squirrel monkey retrovirus (SMRV) 


















Exogenous; oncogene- containing (src) 
Exogenous; oncogene-containing (myb) 
Exogenous; oncogene-containing (erb-A and erb-B) 
Exogenous, endogenous; causes leukemia of various sorts,osteopetrosis 
Exogenous; cause B-Iymphoma, osteopetrosis, and other diseases 
Endogenous; benign 
Exogenous, endogenous; causes T -cell lymphoma, immunodefiency, neurological and many 
other diseases 
Exogenous; oncogene-containing (H-ras) 
Exogenous; oncogene-containing (ab~ 
Exogenous, endogenous; causes T -cell lymphoma, immunodeficiency, and many other diseases; 
oncogene-containg (myc) 
Exogenous; oncogene-containing (sis) (SSV) 
Exogenous viruses of birds; causes malignancies, immunodefiency and neurological diseases 
Endogenous and exogenous; transmission vertically via milk; causes mostly mammary 
carcinoma, some T-Iymphoma; no oncogene-containing members 
Exogenous and endogenous; immunodeficiencies in monkeys 
Exogenous and endogenous; immunodefICiencies in monkeys 
Endogenous; benign 
Exogenous and endogenous; causes carcinoma 
HTlV-BlV 
group 
Human T -cell leukaemia (or 
Iymphotropic) virus (HTl V) 
Bovine leukaemia virus (Bl V) 
Complex 2 Central spherical Exogenous; causes T -cell lymphoma; associated with neurological disorders 
core 
lentivirinae lentiviruses Human immundeficiency virus (HIV-1/2) Complex Cone-shaped 
Simian immunodefiency virus (SIV) core 
Feline immunodefiency virus (FIV) 
Visna/maedi virus (MW) 
Equine infectious anaemia virus (EIAV) 
Caprine arthritis-encephalitis 
virus(CAEV) 
Spumavirinae 'Foamy' Bovine syncytial virus (BSV) Complex Central, spherical 
viruses Simian foamy virus (SFV) core 
Feline syncytium foaming virus (FSFV) 
Human foamy virus (HFV) 
1 The retroviral genome is made up of 4 major coding regions: gag, pro, pol and envelope. 
2 In addition to major coding regions have accessory regulatory coding genes e.g HTLV IBLV have tax and rex 
Causes B-celllymphoma 
Exogenous; cause of AIDS 
Exogenous; causes AIDS-like disease in certain monkeys 
Exogenous; immunodefiency 
Exogenous; causes neurological and lung disease in sheep 
Exogenous; causes anaemia 
Exogenous; arthritis; neurological disorder and pneumonia 
Exogenous, apparently benign 




The U 5 sequence is a unique, non-coding region of 75 to 250 nuc1eotides that is the first 
part of the genome to be reverse transcribed, forming the 3' end of the provirus genome or 
LTR (Long Terminal Repeats). The R and the primer-binding site flank U5 region. The 
primer-binding site is 18 nuc1eotides in length, is found perfectly complimentary to the 3'-
terminal nuc1eotides of the tRNA, and is used by the virus to begin reverse transcription. 
The Leader (L) sequence is a relatively long (90 to 500 nuc1eotides) non-translated region 
downstream of the transcription start site and therefore present at the 5' ends of all virus m 
RNA's. The leader region is found between the Primer binding site and the beginning of 
gag. 
5' 




(Coffin et ai, 2000) 
Figure 1.2 Schematic representation of a prototype Viral RNA Genome 
The above diagram shows a number of elements that participate in reverse transcription, viral gene 
expression and virion assembly. The 5' end of the viral genome has a cap structure 7Mg (7-
methylguanosine). The 3' end has a poly - A tail. R represents a short repeat at either end of the genome. U5 
is a unique sequence found after the 5 'R region. PB- is the primer site for the minus strand DNA synthesis 
(tRNA binding site). L-leader region. PB+ is the primer site for positive strand DNA synthesis and U3 is the 
unique sequence at the 3' end. Genes encoding virion polyproteins: gag, pol and env are also shown. 
This sequence has two functional roles. It contains the donor site for the generation of all 
spliced sub-genomic mRNA's encoded by the virus. The second function encoded in the L 
region is to specify incorporation of genome RNA into virions. The Polypurine Tract is a 
short run of approximately 10 adenine and guanine residues responsible for initiating 
positive strand synthesis during reverse transcription and is located downstream from the 
env. 
A unique non-coding region the U3 of 200 to 1200 nuc1eotides forms the 5' end of the 
provirus. It extends from PB to R at the 3' end of the viral genome. At the end of the 
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genome, between V3 and the poly (A) sequence, is the other copy of the R region, which 
sometimes contains the poly (A) additional signal. During the retrovirus replication cycle, 
the VS, V3 and R elements form the large, directly repeated structure found at either end of 
the retroviral genome, the long terminal repeats (LTR's). They are important for viral 
replication and essential for stable integration into the host cell genome (Coffin et ai, 
2000). 
1.9.4 Virion Structure 
The virion contains several enzymes necessary for the early events of replication that 
include reverse transcriptase (RT), ribonuclease H, integrase (IN) as well as protease (PR) 
used in processing the virion proteins. All replication competent retroviruses to date 
contain four coding domains gag, pro, pal and env, which occupy the body of the DNA. 
Gag encodes the internal structural protein of the virus (gag protein from the original name 
"group specific antigen") reflecting the so-called anti genic properties of this protein. Gag 
is proteolytic ally processed into the mature proteins of the matrix (MA), capsid (CA), and 
nucleocapsid (NC). 
Pol encodes the enzyme reverse transcriptase (RT), which contains both DNA polymerase 
and associated Rnase H activities, and integrase, which mediates replication of the 
genome. Pro encodes the viral protease which acts late in assembly of the viral particles to 
process proteolytically the proteins encoded by gag, pro and pol. Env encodes the surface 
(SU) glycoprotein and transmembrane (TM) protein ofthe virion. (Coffin et ai, 2000). 
Replication-competent retroviruses have all the functions for completing the replication 
cycle and yield infectious progeny virions. Replication-deficient retroviruses have one or 
more mutations in essential viral functions and depend on "helper" virus to provide the 
missing functions. ASLV and MuLV provide replication-functions for avian 
erythroblastosis virus (AEV) and murine sarcoma virus (MSV) respectively (paul et ai, 
1992). Figure 1.3 shows a schematic representation of a mature (prototype) virion. 
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RT Reverse Tri.th$Qriptase ----
Matrix 
Capsid 
FIGURE 1.3 Schematic Representation of a Mature (prototype) Virion (Coffin, 1992a) 
19.5 Overview of retroviral replication 
The retroviral replication cycle is divided into early and late phases. The early phase starts 
with the binding of a virus particle (virion) to a cell receptor and continues to the formation 
of an integrated provirus. The SU envelope glycoprotein binds to a specific receptor on the 
surface of the host target cell. TM causes fusion of viral and cellular membranes and the 
virion core (capsid) is released in the cell cytoplasm. When the capsid enters the cytoplasm 
the core is unmasked [inside the core is RT (reverse transcriptase), IN (integrase), +RNA 
and tRNA] and free nucleotides (from host cell) in the cytoplasm enter the core and reverse 
transcription of genomic viral RNA into double stranded linear DNA takes place. All 
reverse transcription occurs in the cytoplasm. Long terminal repeats (LTR's) found on 
either side of the viral genome, are produced during reverse transcription and remain in a 
nUcleoprotein complex. Viral DNA within the nucleoprotein complex migrates to the 
nucleus, where termini of viral DNA are covalently linked to host- cell DNA in a reaction 
to produce the provirus. This step is mediated by viral integrase. 
The late phase begins with synthesis of viral transcripts from the provirus in the nucleus 
and continues through to release of progeny virions. LTR's in the provirus provide signals 
for cellular function that control synthesis and processing of viral RNA. All viral 
transcripts serve as genomic RNA and as mRNA for viral polyproteins. Spliced as well as 
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full-length viral RNA that are transported to the cytoplasm are translated on host-cell 
polysomes into virion polyproteins (precursor polypeptides). Full-length transcripts also 
interact with virion polyproteins and are assembled into immature virus particles. Through 
the budding process, immature cores are engulfed by the cell plasma membrane and thus 
acquire a lipid bilayer membrane that contains env glycoproteins. Proteolytic processing of 
gag, protease (prt) and pol polyproteins takes place during the budding step and continues 
in newly released particles. Finally, there is assembly into mature fully infectious virus 
particle (virion). The replication process proceeds without any significant effect to the 
infected cell. The cell continues dividing and is unaltered in any way except that it is now 
continually producing new virions (Paul et ai, 1992; Coffin et ai, 1997b). 
1.9.6 Genomic Organisation of JSRV 
The complete genomic sequence of the Jaagsiekte Sheep Retrovirus is derived from viral 
particles secreted in lung exudates of OPA affected animals. JSRV is a replication 
competent simple betaretrovirus with a genome 7,462 nucleotides long (Hunter et ai, 2000; 
Palmarini et ai, 2002). It exhibits a genomic organization which is a unique chimeric 
structure consisting of a type B envelope gene such as MMTV or HERV-K, type D gag 
and pal genes with pro in a different open reading frame (orj) to pal (York et ai, 1991; 
York et ai, 1992; Palmarini et ai, 1999; Palmarini et ai, 2001), and an additional open 
reading frame orf-X that overlaps pol and is not present in any other retrovirus that 
overlaps pal (York et ai, 1991; York et ai, 1992; Bai et ai, 1996; Rosati et ai, 2000) (see 
Figure 1.4). This orf-X region has a different codon usage to other genes within JSRV and 
a very hydrophobic predicted amino acid sequence that shows no homologies with any 
other known protein. The role of orf-X is unknown. Betaretroviruses have prominent 
surface spikes and an eccentric condensed core or less dense surface spikes and a 
cylindrical core. Capsid assembly for this group occurs in the cytoplasm in structures 
previously described as A-type particles (Palmarini and Fan, 2003). 
A capsid type D retroviral sequence was isolated from an affected Peruvian sheep by a 
different approach (Hecht et ai, 1994). Comparison of the MMTV and MPMV capsid and 
nucleocapsid amino acid sequence revealed a number of conserved regions that could be 
responsible for the observed shared epitopes with the OP A agent. These were used to 
amplify by PCR; viral sequences from cDNA reverse transcribed from putative viral RNA 
25 
in lung fluids of an OP A affected sheep from Peru. The capsid sequence obtained this way 
from a Peruvian case was identical with JSRV (which originated in the Republic of South 
Africa). Furthermore, on the amino terminal end, twenty amino acids of p25 capsid protein 
purified from OPA lung fluid in Scotland were identical to JSRV (Hecht et ai, 1996). The 
identification of the infectious form of JSRV has been complicated by the presence of 15-
20 copies of endogenous sequences fixed in the genomes of all sheep and goats when 
tumour and non-tumour DNA were probed with JSRV capsid or envelope regions (Hecht 
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(Burmeister et aI, 2001; Palmarini et aI, 2004) 
Genomic structure of JSRV 
The numbered bar at the bottom indicates distances in kb. JSRV shows the canonical 
retroviral gag, prt, pol and env with prt in a different open reading frame from pol, 
the same for all betaretroviruses. An additional open reading frame (orfX) overlaps pol. 
Phylogenetic analysis of JSRV suggests that it evolved from the A-B-D lineage, diverging 
before MPMV but after MMTV and human endogenous retrovirus K (HERV-K). The 
transmembrane (TM) domain does not align with other type D virus but has a structural 
homology with MMTV and HERV -K 57(Palmarini et ai, 1997). 
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1.10 DIAGNOSIS 
1.10.1 Virus Host Interaction-Serological based diagnosis 
The long pre-clinical incubation period of OP A and the short life span of sheep under 
modem management systems allows the disease to disseminate widely in a flock before it 
is recognised. Further the absence of an in vitro culture system makes diagnosis of this 
disease solely dependent on the end stage clinical signs and characteristic lung pathology. 
At the time this study commenced there was no specific pre-clinical detection system. 
Consequently the sub-clinical infection rate within the individual flocks and countries 
remained unknown and the options to enforce some sort of control were limited. 
Knowledge about the immune response in sheep is limited and circulating antibodies to the 
virus have not been found (Sharp et aI, 1983; De Martini et aI, 1988; Verwoerd, 1990; De 
Las Heras et aI, 1995). A 25-28kda polypeptide (OP A p27) obtained from OP A lung fluid 
and tumour homogenates was shown to cross-react on Western immunoblots with antisera 
to the major capsid protein of Mason Pfizer monkey virus (MPMV) and mouse mammary 
tumour virus (MMTV), the prototype type D and type B retroviruses, respectively, as well 
as other type D retroviruses (Sharp et aI, 1983; Perk et aI, 1985; De Martini et aI, 1987; He 
et aI, 1992). The MPMV capsid-related antigen p27 is internationally accepted as a marker 
for JSRV and OP A. An immunoblotting and an enzyme linked immunoassay technique 
(ELISA) based on the recombinant capsid protein MPMV p27 of Mason Pfizer monkey 
virus (as a glutathione S-transferase (GST) fusion protein) was used as an antigen to detect 
antibodies against the homologous viral protein both in Italian sheep flocks with a 
prevalence of OP A and in north American sheep flocks with a high prevalence of chronic 
pneumonia (Kwang et aI, 1995). Positive reactions were detected in sera from animals 
suffering from OP A. 
Based on the results of previous experiments (Sharp et aI, 1983; Kajikawa et aI, 1990; He 
et aI, 1992; Kwang et aI, 1995) the usefulness of a recombinant JSRV-CA protein was 
evaluated as a potential diagnostic antigen in an immunoblotting assay. The study was 
designed to assess the antibody response in animals naturally affected with OP A and in 
animals free of the disease. The results of our study concurred with that of Kwang and 
associates (Kwang et aI, 1995) where positive reactions were detected in sheep suffering 
from OP A. This study however also found positive reactions with sera from animals with 
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no detectable tumours at necroscopy that originated from flocks with no clinical history of 
OP A. This lack of correlation between disease status and reactivity with the recombinant 
fusion proteins raised doubts concerning the specificity of the reaction and supported a 
view that this reaction was not specific to JSRV. Confirmation of this view was realised 
when the sera that was absorbed with lysates of clone pGEX- NM522 that contained GST 
but no proteins related to JSRV resulted in the complete abolition of all positive reactions. 
Sera that were absorbed with recombinant JSRV-CA, had reactivity abolished in only a 
few animals. This proved the non-specificity ofthe reaction (Ortin et ai, 1998). 
In further analysis of the JSRV viral proteins, a JSRV specific capsid antibody (CA) was 
generated. Palmarini and co-workers in 1995 developed a blocking enzyme linked 
immunosorbent assay ((j-ELISA) and an immunohistochemical assay for the detection of 
JSRV major capsid proteins at the tissue and cellular level. Briefly, (j-gal CA and GST-CA 
fusion proteins expressed in E coli (Escherichia coli) were used to immunize rabbits to 
generate a JSRV specific capsid (CA) antibody. (j-gal-CA and the specific rabbit antiserum 
were used in the assay to detect JSRV-CA. Rabbit antiserum to JSRV-CA was used for the 
immunohistochemical technique. JSRV was detected only in the respiratory tract of sheep 
affected by OP A and specifically in the transformed epithelial cells of the alveoli of OP A-
affected sheep (Palmarini et ai, 1995). 
1.10.2 Molecular Diagnosis 
The ability to distinguish between exogenous JSRV from the endogenous background has 
allowed the introduction of more sensitive molecular techniques for the detection of the 
virus. The use of the Polymerase Chain Reaction (PCR) has extended previous 
observations based on immunological detection methods and such advanced techniques 
that can be used to detect JSRV RNA or DNA in OP A affected sheep or carrier sheep. 
A Self-Sustained Sequence Replication (3SR) assay has been used to detect exogenous 
JSRV based on its single stranded RNA genome (York et ai, 1993; De Martini et ai, 1997). 
It is an isothermal reaction that uses three enzymes and a virus specific primer to 
synthesise many copies of cDNA of the single stranded target, but not double stranded 
endogenous viral DNA (Fahy et ai, 1991). The reaction is highly efficient and within one 
hour can amplify the target more than a million-fold. The target is then detected in a slot-
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blot using an internal probe. This technique has been used to detect the exogenous JSRV in 
lung lavage fluid and nasal exudates of OP A affected sheep, but not in samples from 
unaffected sheep. The specificity of this assay is limited by the presence of 15 to 20 copies 
of endogenous sheep retrovirus loci (ESRV) in normal sheep that may hybridise to JSRV 
DNA probes (York et ai, 1993). As the gene targeted in the above assay was to be the 
JSRV p26 capsid protein this assay would also detect endogenous RNA transcripts if and 
when they were expressed, as the p26 gene is present in some of the endogenous JSRV 
loci. Evidence is available that suggests that the transcripts of the endogenous viruses are 
expressed. 
The presence of these endogenous sequences has hampered studies at the molecular level. 
So an investigation was carried out to determine if the exogenous form of JSRV was 
associated with neoplasia in OP A affected animals. Initially, ESRV loci were found 
transcribed in a wide variety of normal sheep tissues. Molecular studies have demonstrated 
that JSRV is an exogenous virus distinct from the transcriptionally active endogenous 
retroviral sequences present in the ovine genome (York et ai, 1992; Bai et ai, 1996; 
Palmarini et ai, 1996). To clarify the aetiological roles of ESRV (endogenous virus) and an 
exogenous JSRV-like retrovirus (ex JSRV) in OPA, ESRV proviral sequences where 
characterised and compared to ex JSRV. Molecular characterization of six ESRV loci 
revealed restriction sites specific for JSRV. Nucleotide sequences of ESRV's from sheep 
of different breeds were similar to those of JSRV in structural genes, but divergent in the 
U3 region. The most remarkable difference between the two types of sequences was that 
the endogenous U3 region was 47 base pairs longer than that of JSRV (York et ai, 1992). 
Molecular markers that could be used to distinguish JSRV from ESRV were identified as 
Kpn1, Nde1, Hind11l, Seal, BamHI and Xha1 sites in gag, a Cla1 site in the gag-pal 
junction and an EeaR1 site in the envelope transmembrane region. The ex-JSRV of the 
South African, Kenyan, Wyoming and Scotland had two common Seal sites whilst ESRV 
only had the first Seal site (Bai et ai, 1996). These restriction sites were identified using 
endogenous JSRV proviral sequences. With the isolation of three endogenous JSRV 
retroviruses JS5.6A1, JS5Fl6 and JS5.9A1 and comparison to the South African strain, 
these restriction sites are no longer used to differentiate the exogenous JSRV from that of 
the endogenous virus. The only restriction site that is still valid is the Sea 1 restriction site. 
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Sequencing part of the gag gene of endogenous (ESVR) and JSRV revealed a Seal 
restriction site in the gag gene of JSRV (nucleotide position 1729) that was absent in 
ESRV (York et ai, 1992; Palmarini et ai, 1996). The gag gene of the ESRV is a conserved 
612 amino-acid polypeptide corresponding to the boundaries of the capsid proteins (CA) of 
MPMV, Squirrel Monkey Retrovirus (SMRV) and MMTV. RT PCR of this region 
amplified a 229 base pair product in both affected and unaffected tissues. Seal restriction 
of the products revealed that the exogenous form JSRV was exclusively and consistently 
present in tumour tissues and lung secretions of the affected animals. JSRV was not 
detected outside the respiratory tissues of OP A affected sheep nor in any tissue of the 
control sheep. Amplification of both endogenous and exogenous sequences can mask the 
detection of low copies of exogenous JSRV due to the relatively high background formed 
by ESRV. To address this question an exogenous virus specific hemi-nested PCR was 
developed utilizing primers in the D3 region of the LTR of JSRV where, as mentioned 
previously, major differences between endogenous and exogenous sequences exist. This 
technique is more sensitive than the previous gag PCR and Seal digestion method. This 
assay has been used to analyse the tissue distribution of JSRV in sheep with natural and 
experimentally induced OP A (Palmarini et ai, 1996). 
1.11 AIMS OF THE STUDY 
OPA is widespread in various parts of the world, except Australia and New Zealand. In the 
countries where it is known to occur, farmers have incurred considerable sheep losses. 
Since the mode of transmission appears to be aerogenous and the spread of disease 
facilitated by close contact, it is a particular hazard of intensified sheep husbandry 
(Mackay, 1966). Currently, there is no vaccine to protect sheep against Jaagsiekte. 
Eradication of the disease reqUIres the development of fast, sensitive and efficient 
serological andlor molecular assays which can confirm the early presence of the disease in 
living animals. The early diagnosis could ensure that all infected animals are removed 
immediately to eradicate the disease from the infected flock. The goal is a reliable assay 
that can diagnose OPA early. The Jaagsiekte Sheep Retrovirus does not produce detectable 
circulating antibodies; hence the inability to detect a JSRV -specific humoral response 
(Summers et aI, 2002). Furthermore, the presence of 15 to 20 copies of sheep genome of 
the JSRV-related endogenous sequences compared with possibly only 1 exogenous copy 
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per neoplastic cell has caused great difficulty in detecting integrated exogenous JSRV 
(Sharp, 1997). Moreover, neoplastic cells are approximately only 40% to 50% of the total 
number of cells present in the neoplastic tissue, therefore increasing the ratio of 
endogenous to exogenous sequences (Palmarini et ai, 1996). Thus the need to develop and 
test new, effective and sensitive assays for the identification of JSRV in sheep would be of 
enormous benefit to commercial breeding flock owners and emergent farmers in the 
underdeveloped areas in South Africa and elsewhere in the world. Farmers would be able 
to selectively identify and eliminate positive sheep from the affected flocks. This would 
reduce the prevalence of the disease and perhaps permit eradication of OP A from the flock. 
Further before new sheep are introduced into a flock, pretesting of all sheep could ensure 
that the flock remains free of the disease (De Martini et aI, 1997). 
In the light of what has been discussed above, the purpose of this study was to investigate 
the potential to develop both a serological and molecular diagnostic assay to help in the 
early diagnosis and removal of carriers of the OPA disease. To achieve these objectives the 
following approach was undertaken. 
Specific primers based on the JSRV published sequence will be designed to target the 
conserved region of the gag (group-specific antigen) polyprotein and the transmembrane 
region of the env encoded proteins. The amplified products will be cloned and expressed. 
The expressed protein will then be investigated for their diagnostic potential in various 
assay formats. 
The second objective will focus on a molecular diagnostic approach. Various molecular 
assays will be optimised and assessed for their ability to detect the exogenous infectious 




A SEROLOGICAL APPROACH TO THE DIAGNOSIS OF JSRV: 
ISOLATION, CLONING AND EXPRESSION OF THE JSRV GENES 
(JSP26 CAPSID GENE, JSTM AND JSORF-X) 
2.1 INTRODUCTION 
A major obstacle facing JSRV research was the inability to cultivate the etiological agent 
of JSRV in vitro. This made diagnosis of the disease entirely dependent on clinical signs 
that only appeared at the terminal stages of the disease. Sheep died very shortly after they 
showed symptoms of the disease. Confirmation of the disease was dependant upon micro-
and macroscopic pathology, which required that the sheep be slaughtered. Without any 
specific type of testing procedure, the subclinical infection rate within individual flocks 
and flocks in different countries remained unknown and the means of managing the 
infection were limited and non-scientific (Kwang et ai, 1995). 
2.1.1 Production of Antibodies against semi-purified JS 
The absence of an in vitro culture system to produce the virus meant that initially the only 
source of virus was that obtained from lambs that were experimentally infected with lung 
and nasal extracts from JSRV affected sheep lung material. Virus could be recovered from 
experimental and or natural cases of JS; however the virus was in low concentrations and 
was either associated with or attached to non-viral lung debris, which were difficult to 
remove from the virus. One of the common methods used to purify the virus involved rate 
zonal and isopycnic centrifugation of JSRV lung rinse material through sucrose gradients 
(Perk, 1982; York, 1984b). This procedure provided sufficient purification of the virus to 
identify the viral proteins. However, even the best purification procedures resulted in the 
virus co-purifying with significant amounts of immunoglobulins (Ig) and other non-viral 
material. Eight to ten polypeptides were constantly observed when JSRV lung rinse 
material was analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-P AGE) and reverse transcriptase assay. Those proteins consistently present on SDS-
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PAGE that were associated with high reverse transcriptase activity were considered as 
likely JSRV polypeptides. 
The Western immunoblot technique, although useful in identifying specific antigens, is 
limited by the specificity and purity of the serum used. As there was no pure and specific 
serum available against all JSRV polypeptides at that time, a rabbit serum was made 
against semi-purified JSRV proteins and after extensive adsorption against nonnal sheep 
lung proteins and Mycoplasma species, only three possible JSRV antigens were identified 
as p26, p32 and p38 polypeptides. The higher molecular weight polypeptides were difficult 
to identify because of the non-specific staining in sheep lung extracts. This was probably 
due to the serum components being against lipopolysaccharides and proteins of surfactant 
origin as well as serum proteins. Further polypeptides p35, p50, p61, p75, p77, p81 and 
p84 were also identified because of their constant appearance in stained polypeptide 
patterns of OP A lung rinse material, following purification using different methods 
((Verwoerd et aI, 1983; York, 1984c) 
2.1.2 Expression of Viral Proteins and their Use in ELISA Assays 
Possibly one of the most useful breakthroughs in JSRV research was the observation by 
Sharp and Herring; 1983, who showed that JS lung fluid and tumour homogenates 
contained a 25 to 28 kDa) polypeptide that cross-reacted on Western Blots when they used 
antisera to the major capsid protein (P27) of Mason Pfizer monkey virus (MPMV), a type 
D oncovirus. A similar polypeptide with a molecular weight of 25 to 26 kDa was detected 
at the Ondersterpoort Veterinary Institute in Pretoria using the rabbit antiserum to JSRV 
(Sharp and Herring, 1983; York, 1984c). The MPMV capsid related antigen p27 became 
an internationally accepted OP A marker protein as it was present in the lung and nasal 
fluid of all JS affected sheep. The capsid protein (CA) JSp26 is antigentically similar to the 
major capsid protein p27 of MPMV. In the case of MPMV, p27 is the most abundant 
protein (0.33% of total weight of virus particle) in the virus particle (Turner and Summers, 
1999). The group specific antigen (gag) precursor poly protein has a calculated molecular 
weight of68 kDa (York et aI, 1992). 
In the early 90's the JSRV genome was isolated, cloned and sequenced (York et aI, 1992). 
It thereafter became a major focus to develop a diagnostic assay to detect the virus. 
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Unfortunately, very similar endogenous counterparts to the exogenous infectious JSRV 
were present in all sheep genomes. This made the classical molecular approach more 
difficult. At the same time that the molecular approach to develop a diagnostic assay was 
taking place, so was the cloning and expression of various JSRV genes and the production 
of antibodies to the virus and its proteins (York et aI, 1992). 
This chapter focuses on the approaches that were taken to isolate, clone, express and purify 
some key JSRV proteins so as to investigate their potential as diagnostic antigens. The 
approach is divided into two parts: 
1. The cloning, expression and purification of JSRVp26 from both endogenous and 
exogenous forms of JSRV and to investigate its use as a diagnostic antigen 
2. To develop antibodies to JSp26 and to investigate their potential in an antigen assay. 
2.2 MATERIALS AND METHODS 
2.2.1 Sources of DNA 
Dr. York provided the following JSRV cDNA clones, namely, JS 382 and JS 107. Other 
sources of DNA included JS 4844 (South African sheep with JSRV); NLDNA (DNA from 
normal sheep) and JS DNA 7 (a cell line from Dr Mike Sharp, Scotland). Genomic DNA 
was isolated from three different Australian sheep designated MSCU, LPW and 230909. 
Additional normal sheep lung was obtained from the local abattoir. 
2.2.1.1 DNA Extraction from Tissue 
A number of protocols have been used to isolate nucleic acids. For the purposes of 
extracting DNA for PCR, genomic DNA was extracted from tissue using two methods, the 
BIO 101 Fast DNA Kit (BIO 101, Inc., La Jolla, CA, USA: Southern Cr~ss 
Biotechnology) with the Fast Prep ™ Instrument as well as the Salting Out Procedure by 
Millar et aI, 1988. 
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2.2.1.1.1 Fast PrepTM DNA System 
The principle behind the FastPrep DNA procedure is the ability to lyse cells with minimal 
shearing of the nucleic acid by shaking the tube up and down (and with a slight twisting 
motion) at very high speeds. The lysing matrix contains a chaotropic DNA stabilising 
solution that is a mixture of detergents and salts. These detergents contribute to nuclease 
inactivity and provide lubrication during the lysing step to prevent DNA from being 
sheared. The rise in temperature during the lysing step contributes towards the inactivation 
of the nucleases and does not harm the DNA. 
The Fast Prep system disrupts whole tissue, lyses cells and stabilises nucleic acid from 
tissues by the use of highly energetic mechanical means and careful choice of reagents, 
thus eliminating the need for lysing enzymes or grinding and homogenising equipment). 
The method outlined below was used following the manufacturer's instructions (BIO 101 
Fast DNA Kit protocol). Briefly, 200 milligram (mg) of tissue was sandwiched between a 
small and large bead in a homogenisation tube. This formed the lysing matrix. One 
millilitre of cell lysis /DNA solubilising solution was added to the tube. The samples were 
placed in the Fast Prep 120 instrument and processed for 5-15 seconds (sec) at a speed of 
five. The tubes were removed and spun in a Sorvall MC 12V (Du Pont) centrifuge at 
13,000 revolutions per minute (rpm) for 5 minutes (min) to pellet protein and any cell 
debris. The supematant (600fll) was transferred to a clean 1.5ml Eppendorf tube. An equal 
volume of DNA Binding solution was added and incubated at room temperature for 5 min. 
The samples were spun for 1 min, the supematant removed and discarded. The pellet was 
gently resuspended in 500 microlitre (fll) of SEWS-M solution, which is a salt/ethanol 
combination to wash the pellet. The pellet was washed for 1 min and the supematant 
discarded. DNA elution buffer (100fll) was added to the pellet and allowed to incubate for 
2-3 min at room temperature. After centrifugation for 1 min, the resuspended DNA was 
transferred to a clean tube using a large bore tip to avoid mechanical shearing of the DNA 
(BIO 101 Fast DNA Kit protocol). 
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2.2.1.1.2 Extraction of DNA from Tissue or Cells using a Salting out Procedure 
A high salt concentration was used to dehydrate and precipitate the cellular proteins, while 
the DNA remains soluble. The yield of DNA obtained from this technique is comparable to 
that obtained using the phenol-chloroform method. 
Tissue from sheep lung was weighed out (100mg) and sliced finely using a scalpel blade. 
This was added to a 50ml centrifuge tube containing 5ml of nuclei lysis buffer A 
(Appendix Dl). About 600 micro grams (Ilg) of Proteinase K (Roche Diagnostics GmbH, 
Mannheim Germany) in lysis buffer and 4ml of 10% (w/v) SDS (Appendix D2) (8001l1/ml 
buffer A) was added to the tissue and incubated overnight at 37°C. RNase (20)11 of 
10mg/lll stock RNase (Roche Diagnostics, Germany) was added to the tissue. Once the 
tissue was digested, 1.5ml of a 6M sodium chloride (NaCl) solution (final concentration 
IM NaCl) was then added. The tube was gently inverted for 10 min at room temperature. 
NaCI was added to the solution until it had turned milky and become very viscous. The 
solution was centrifuged at 2500 rpm for 15 minutes at room temperature using a Sorvall 
MC 12V (Du Pont) centrifuge to remove the proteins. The clear supernatant was removed 
to a 50ml centrifuge tube. To this an equal volume of chloroformlisoamylalcohol 
(24:lIAppendix D3) was added and mixed as before, but for 5 min. The tubes were 
centrifuged at 2500 rpm for 10 min at 8°C. The supernatant was transferred to a clean tube, 
and an equal quantity of chloroform was added. The solution was mixed as before by 
gentle inversion and then centrifuged at 3500g (gravity) for 10 min at 8°C. The supernatant 
was transferred to a clean McCartney bottle. The addition of equal quantities of 
isopropanol resulted in the precipitation of strands of DNA upon gentle inversion. These 
strands were hooked out with a sealed hooked Pasteur pipette and dipped into 70% ice-cold 
ethanol (Appendix D4) to wash the DNA. The DNA was resuspended in 400111 Tris-EDTA 
buffer pH 8 (Appendix D5) (MiIlar et ai, 1988). 
2.2.1.2 Measurement of DNA Concentration 
A popular method to determine the DNA concentration and its purity is the use of 
ultraviolet absorbance spectrophotometry. The amount of ultraviolet radiation absorbed by 
a solution of DNA or protein is directly proportional to the amount present in the sample. 
Nucleic acid solutions are measured at 260 nanometre (nm) and proteins at 280 nm. Pure 
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DNA in solution should have an A26o/ A280 ratio of purity ranging from 1.8 to 2.0. A ratio 
less than 1.8 indicates the presence of contaminants such as proteins or phenols and these 
samples should be purified further. The concentrated DNA solution was diluted one in two 
hundred using water as the diluent and to zero the spectrophotometer. Absorbance 
measurements were determined at both 260 nm and 280 nm using a Beckman DuR-5 
spectrophotometer (Beckman Instruments Inc. Fullerton, California). DNA with an 
absorbance value at A260 of 1 has a concentration of 50Jlg/ml. This together with the 
dilution factor was used to determine the exact concentration of DNA in solution (Brown, 
1986a; Sambrook et ai, 1989a). 
2.2.1.3 Designing of Primers to amplify and clone the genes into pGEX Expression 
Plasmids 
A standard method that is used to isolate and clone genes is the Polymerase Chain Reaction 
(PCR) technique. This is an extremely useful technique since very small amounts of target 
material is required. Primers were synthesised by the Department of Biochemistry of the 
University of Cape Town using the Milligen Oligonucleotide Synthesiser. The primers were 
to amplify the JSRVp26 capsid gene, JSRVTM (transmembrane) and the JSRVorfX (open 
reading frame unknown (X)). The DNA starting materials were from plasmids JS 382 and 
JS 107. Genomic DNA included JS 4844, JS sheep lung and JS 7 DNA (cell line from 
Scotland where each cell has one integrated exogenous JSRV genome). 
The fragments amplified included the capsid regIOn of the gag gene (653 bp), the 
transmembrane region of the env gene (710 bp) and the orfX gene (497 bp). The capsid 
gene has a molecular weight of between 25-27 kDa. 
The primers were designed so that the amplicons would have specific restriction sites at 
their 5' ends to facilitate cloning of the amplicons in frame with the expression vector. Table 
2.1 outlines the nucleotide sequence and genomic locations of the PCR primer pairs used to 
amplify JSp26, TM (Transmembrane) and orfX (open reading frame) genes. The PCR 
primers used were designed to flank the codons of the genes to be expressed. The orf X 
primers were designed solely for the study (York et ai, 1992). 
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Table 2.1 Primer Sequences and Genomic Locations of PCR Primers for the amplification of 
JSp26, TM and orf-X Genes 
PRIMER SEQUENCE 5'-3' GENE *LOCATION 
JSp26 Barn HI forward ttaaggatcctgtcttcgaaaataacaa Gag 1035-1053 
JSRTp26 Barn HI rev. ggatcctgcatagcaatgcctgca Gag 1699-1679 
JSp26 Barn HI tataggatccccgtcttcgaaaataacaac Gag 1034-1054 
JSRTp26 EcoR1 2aattctgcatagcaatgcctgca Gag 1699-1679 
JSTMBarnH1 Tcccggatc~ggcttgagcttaattat Env 6483-6500 
JSRT env Barn HI ttaaggatcccgggtcgtcccccgca Env 7194-7176 
JSorf X Barn HI aattggatccatgcagcccgaaaatcccat orfX 4606-4625 
JSorfX SaIl actagtcgacttaataattgatgtctaaggcgttg orfX 5106-5082 
gaattc EeoRl restriction site; ggatcc BamHI restnctlOn SIte; gtcgac Sail restnctIon 
site 
*Nucleotide locations refer to JSRV sequence published by York et ai, 1992 
2.2.1.4 The Standard peR Reaction 
2.2.1.4.1 Amplification of JSp26 Gag Gene 
The capsid region of the gag gene was amplified from plasmid JS 382 using primers JSp26 
(nucleotide position 1034-10S4) and antisense primer JSRTp26 (nucleotide position 1699-
1679). Both primers had restriction sites designed into their S' ends. JS 382 was a cDNA 
clone ofa segment ofa South African exogenous JSRV (York et ai, 1992). 
The PCR master mix solution was made up of 10J.lI of 10x PCR buffer containing ISmM 
Magnesium chloride (MgCb) [Roche Diagnostics], 6J.ll MgCb (2SmM-Sigma stock), SJ.ll 
each of JSp26 (20 pmoles/ul) and JSRTp26, 8J.lI of 2.SmM (200J.lM) deoxynucleoside 
triphosphates (dNTPs) (Appendix D6) and IJ.lI (lu/J.ll) of Taq DNA polymerase (Roche 
Diagnostics). To avoid contamination, the PCR mix was added to the required number of 
O.2ml PCR tubes in a sterile hood. Template DNA was not added to the solution at this 
stage. A known amount of DNA (see Table 2.2) was added to each tube. 
2.2.1.4.2 Amplification of JS orf-X gene 
The main emphasis of this thesis is the cloning and expression of the JSp26 gene. However, 
we also attempted to clone and express additional genes such as open reading frame x (or} 
X) and a section of the transmembrane (TM). A lot of work was performed in cloning these 
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genes; unfortunately we had great difficulty expressing them due to the hydrophobic nature 
ofthe expressed proteins. For completion they have been included in this thesis. 
The arf-X gene is a novel open reading frame that was identified while analysing the 
genomic sequence. It is found at nucleotide positions 4465 to 5103. It theoretically codes 
for a protein that does not share homology with any known oncogene of viral protein. Orf-X 
is very hydrophobic (York et ai, 1992). The arf-X gene was amplified from 500 nanograms 
(ng) of both exogenous and endogenous sources of DNA. The source of exogenous DNA 
was JS 7 cell DNA and JS 4844 (JS affected sheep lung). The source for the endogenous 
virus was three normal Australian sheep muscle tissue (LPW, MSCU and 230909). Primers 
JSorf-X (position 4606-4625) and anti-sense primer JSRTorf-X located at nucleotide 
position 5106-5082. The orf-X primer set has a BamHl restriction site on the 5' end of the 
forward primer and Sail on the 5' end of the reverse primer. The primer sequence and gene 
location can be found in Table 2.1. The PCR reaction conditions were as discussed in 
2.2.1.4. The expected amplicon size was 497 base pairs. 
2.2.1.4.3 Amplification of the JS transmembrane (JSTM) gene 
Plasmid JS 107 is a cDNA clone that covers the exogenous JRSV envelope region. This 
cDNA fragment had EeaRI linkers added to facilitate (about 2000 bases in length) cloning 
in AZAPll (York et ai, 1992). Direct amplification of the plasmid did not result in any 
product. Upon analysis of the plasmid sequence, it was discovered that the cDNA fragment, 
which had EeaR! restriction sites at both the 5' ends, besides being ligated in a manner 
opposite to what had been expected, had a further EeaRl restriction site identified at 
nucleotide position 6900. In order to amplify the correct TM fragment, the plasmid was 
digested with EeaR! and re-ligated hoping to obtain the correct alignment of the digested 
fragments. The ligated product was then used as template to amplify the TM gene. 
2.2.1.5 Plasmid Digest. 
Plasmid JS 107 was digested with restriction enzyme EeaRI as follows: to 1 J.1g of plasmid 
DNA, IJ.11 of 10% Buffer H (Roche Diagnostics), 8J.11 of dH20 and IJ.11 of EeaRl enzyme 
(lOunits/J.1l) was added. This sample was incubated at 37°C for 120 minutes. The digested 
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sample was denatured at 65°C to inactivate the enzyme. The denatured sample was made up 
to a volume of Iml with deionised water. 
2.2.1.6 Ligation 
About 9JlI (9ng) of the digested product was ligated using I JlI of 10% ligase buffer and 
0.5JlI ofT4 DNA ligase enzyme (Pharmacia Biotech). This sample was incubated at room 
temperature for 120 minutes and then kept at 4°C. IJlI of the ligated product was used to 
amplify a 710 base pair fragment using primers JSTM (nucleotide position 6483 to 6500) 
and JSRTENV (nucleotide position 7194 to 7176) in a standard PCR reaction as described 
in section 2.2.1.4. 
Table 2.2 DNA Templates and Concentrations 
TEMPLATE CONCENTRATION OF TYPE OF DNA JSP26PCR JSTM ORFX 
DNA DNA PCR PCR 
JS 382 Ing/1l1 (exogenous) Plasmid (gag) 2111 2111 
JS7DNA 57ng/1l1 (exogenous) Scottish-transformed 10111 10111 
sheep 
JS 4844 200ngllll(exogenous) S.A. sheep plasmid 3111 3111 
JSNL I 600ng/Il1 Normal lung 1111 1111 
LPW2 455ng/1l1 Genomic DNA 1111 1111 
MSCU2 95ng/1l1 Genomic DNA 5111 5111 
239092 382.5ng/1l1 Genomic DNA 1.3!l1 1.3111 
JS 107 61lg/1l1 (exogenous) Plasmid (envelope) Ing/1l1 
1 Saltmg out method used 
2 Fastprep DNA extraction method 
2.2.1.7 PCR Cycling Conditions 
The PCR reaction mix was denatured by heating to 94°C for 5 min. in a Perkin Elmer 2400 
thermocycler. The samples were amplified for 35 cycles. Each cycle consisted of a 
denaturation step at 94°C for 30 sec., followed by annealing at 55°C for 30 sec and an 
extension at 72°C for 30 sec. The final extension step at 72°C for 10 min was to allow 
complete extension of all DNA products. The PCR products were kept at 4°C until they 
were removed from the thermocycler. 
Verification of the correct size of each amplified product was established by running each 
completed PCR reaction product through a 1% (w/v) agarose gel containing a 0.005% 
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Ethidium Bromide (Appendix D7) in Tris Borate EDTA (TBE) buffer (Appendix D8). 
These products were compared to a Standard DNA molecular weight marker VI or marker 
11 (Roche Diagnostics, Germany) and visualized by using a UV Gel Documentation 
system (GDS 5000 Gel Documentation system, Ultraviolet Products Ltd) that is attached to 
a Sony Thermal Printer linked to a computer. Once the image has been captured, it could 
be improved using the Imagestore 5000 and ultimately printed. 
2.2.1.8 Separation and Detection of DNA Molecules 
Electrophoresis is a technique used to detect and separate DNA molecules of different 
sizes, either for isolation, cloning, identification or restriction analysis. Before the 1970's, 
it had been difficult to visualise DNA. The weight of DNA molecules was based solely on 
the viscosity of the solution .The larger the DNA molecule, the more viscous the solution 
compared to smaller molecules. 
DNA molecules like proteins and many other biological compounds carry an electrical 
charge. At neutral pH DNA molecules carry a negative charge and when placed in an 
electrical field migrate from the cathode towards the positive pole or anode. The rate of 
migration of a molecule depends on its shape and its electrical charge. Since most of the 
DNA molecules are the same shape and have very similar electrical charges, fragments of 
different sizes cannot be separated by standard electrophoresis. Fragments do separate out, 
if the electrophoresis is performed in a gel that is usually made of agarose, polyacrylamide 
or a mixture of both. A gel comprises a complex network of pores through which the DNA 
molecules must travel to reach the positive electrode. The smaller the DNA molecule, the 
faster it can migrate through the gel (Brown, 1986b). Larger molecules migrate more 
slowly because of frictional drag and their ability to worm their way through pores of the 
gel less efficiently than smaller molecules. Gel electrophoresis separates DNA molecules 
according to their size. The size of DNA fragment determines the type of gel support that 
is needed and the resolution required is determined by the concentration of agarose or 
polyacrylamide used. Table 2.3 shows the range of separation in gels containing different 
amounts of agarose. 
The ability of polyacrylamide gels in separating small fragments of DNA 5-500 base pairs 
(bp) is due to their high resolving power. Fragments of DNA that differ in size by as little 
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as 1 bp can be separated from one another. The only disadvantage of polyacrylamide over 
agarose gels is that they are more difficult to prepare and handle (Sambrook et ai, 1989b). 
Table 2.3 Range of Separation in Gels Containing Different Amounts of Agarose 
Amount of agarose in gel % (w/v) Efficient range of separation of linear DNA molecules 








DNA has different conformations such as super helical, circular, nicked circular and linear 
forms that migrate at different rates through the gel even though their molecular weights 
are the same. Maximum resolution of DNA is obtained by running gels at no more than 5V 
per cm ( centimetre). Before any sample of DNA is loaded into the wells of the agarose gel, 
the DNA is mixed with a gel-loading buffer (Appendix D9) containing Bromophenol blue. 
This gel-loading buffer serves three purposes. It increases the density of the sample, 
thereby ensuring even loading of sample into wells. Colour is added to the sample to 
simplify the loading process and dyes are present such that in an electric field, they move 
towards the anode at a known rate. Bromophenol blue migrates at 300 bp independent of 
agarose concentration between 0.5% and 1.4% in 0.5% TBE (Sambrook et ai, 1989b). 
DNA in both agarose and polyacrylamide gels can be visualised directly by the use of a 
fluorescent dye, Ethidium bromide. The dye intercalates between stacked base pairs, 
extending the length of linear and nicked circular DNA molecules and making them more 
rigid. The electrophoretic mobility of linear DNA is reduced by about 15%. Ethidium 
bromide is a carcinogen and care should be taken when being handled and disposed. 
The composition and ionic strength of the electrophoresis buffer affects the electrophoretic 
mobility of DNA. The two most commonly used electrophoresis buffers are Tris-acetate-
ethylenediaminetetraacetate (T AE) and Tris-borate-ethylenediaminetetraacetate (TBE). 
TBE is the buffer of choice because of its higher buffering capacity compared to TAE. 
T AE tends to become exhausted during extended electrophoresis (the anode becomes 
alkaline and the cathode acidic). 
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Double stranded linear DNA fragments migrate approximately 10% faster through TAB 
than TBE, although the resolving powers of both systems are almost identical. Resolution 
of supercoiled DNA is better in TAB than in TBE (Sambrook et aI, 1989b). 
2.2.1.8.1 Agarose Gel Electrophoresis 
For a 0.8% agarose gel, 0.8g ofagarose was weighed out and added to 100ml of 0.5% TBE 
buffer in an Erlenmeyer flask. The flask was weighed (weight noted) and covered with 
cling wrap. A hole was made in the centre of the cling to allow evaporation to occur. The 
Erlenmeyer flask was heated in a microwave oven for 1 min on high. The solution was not 
allowed to overheat, as it would have foamed over the sides of the flask when agitated. The 
flask was removed from the oven; contents swirled to dissolve agarose and then reheated 
for a further 1 min until all the agarose had dissolved. The flask was re-weighed and the 
original weight made up by adding hot water. The solution was cooled to 60°C before 
adding 5111 (final concentration 0.51lg/ml) of a 10mg/ml of ethidium bromide solution. The 
agarose was left to cool before being poured into a rectangular- shaped gel-casting 
apparatus containing a 12 well comb. The agarose was allowed to set, and then left at 4°C 
for 15 min before the comb could be removed. The gel electrophoresis system used was the 
Hybaid Electro-4 electrophoresis system (S.A. Scientific, S.A.). 
The gel was placed in an electrophoresis tank and about 450ml of 0.5% TBE buffer was 
added, so that the buffer was 3-5mm over the gel. The samples (10111) containing 
Bromophenol blue loading buffer (2111) was loaded along with a DNA molecular weight 
marker (Boerhinger Mannheim, Mannheim Germany). A Hoeffer power pack was used to 
run the gel. The voltage was set at 80Volts (V) for approximately an hour or until the blue 
front had reached about half the way of the casting tray. The gel is removed from the tank 
using gloves and placed on a Transilluminator so that the gel could be viewed using a UV 
Gel Documentation system (GDS 5000 Gel Documentation system Ultraviolet Products 
Ltd) that is attached to a Sony Thermal Printer linked to a computer. Once the image is 
captured, it could be improved using the Imagestore 5000 and ultimately printed. 
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2.2.1.9 Restriction Enzymes 
2.2.1.9.1 Restriction Digest 
A restriction digest is performed by adding to the DNA a buffer to ensure maximal activity 
of the restriction enzyme that is usually at pH 4, the correct ionic strength provided by 
Sodium Chloride (NaCI) and Magnesium ion (Mg2) concentration. Included is also a 
reducing agent like Dithiothreitol (DTT) that can stabilise the enzyme and prevent its 
inactivation. One unit of enzyme is sufficient to cut one micro gram (J.lg) of DNA in 1 hour 
at 37 QC (temperature at which most restriction enzymes work best). After a restriction 
digest, incubating the solution at 65°C for 15 min inactivates the enzyme. This ensures 
complete inactivation of the enzyme and guards against accidental digest of other DNA 
molecules that may be added at a later stage (Brown, 1986b). 
2.2.1.10 Purification of amplified fragments 
The amplified PCR products were purified using the Wizard PCR DNA purification 
System (promega Corporation, Madison, USA; Catalogue No.A7170) as well as the 
Qiagen PCR DNA Purification system (Qiagen, GmbH, Hilden, Germany). The methods 
followed were according to the manufacturer's instructions. PCR products were purified to 
remove the enzymes, primers, nucleotides, salts, ethidium-bromide detergents or any other 
impurities of PCR. For purposes of this study, the purification of one PCR product, JSp26 
will be described using the Qiagen PCR purification kit. The PCR product was transferred 
to a clean 1.5ml microcentrifuge tube for direct purification. A purification buffer (PB) 
was added such that its volume was 5% that of the PCR product. The sample was vortexed 
briefly and then transferred to a 2ml micro-centrifuge fitted with a spin column. The 
column contains a silica-gel membrane for binding up to 10J.lg of DNA in high-salt buffer 
and elution in low-salt buffer. The contents of the micro-centrifuge tube were spun for 30-
60 sec. The supematant is discarded and 750J.lI of a wash buffer PE (ethanol wash) is 
added to the column. The tube with the column is centrifuged as before, and the 
supematant discarded. The column is given a further spin to remove all traces of ethanol. 
The DNA is eluted with either Tris-EDTA (TE) buffer or sterile distilled water depending 
on the application that it is used for. For instance, TE would be suitable for cloning 
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purposes and water for sequencing. Since the product was being used for cloning, I used 
50J.lI TE as the elution buffer. The product was stored at _20DC until it was required. 
2.2.1.11 Cloning of PCR Products 
The amplified purified products from Section 2.2.1.10 were cloned into Amersham's 
pMoss Blue T Vector (Amersham Life Sciences, UK; RPN 1719) according to the 
manufacturer's instructions. This vector was designed for simplified cloning of PCR 
products. Many thermostable DNA polymerases such as Taq DNA polymerase leave single 
3' A ( adenosine) nucleotide overhangs on their reaction products and so are able to be 
ligated directly to the vector containing compatible single T (thymidine) nucleotides 
overhangs. The pMoss Blue T vector has been specifically constructed by digestion with 
EcoRV followed by the addition of a single 3' dT residue at each end. There are many steps 
to the process of construction of a recombinant DNA molecule. The most important and 
critical being the ligation, which is the joining of pieces of DNA by an enzyme called 
ligase. No further manipulation ofthis vector is required for ligation with amplified DNA. 
An advantage of the pMoss Blue T vector is that it allows for blue-white selection of 
recombinants through insertional inactivation of the lac Z gene that it carries. The bacterial 
and plasmid genes complement each other to produce functional B-galactosidase 
molecules. Successful transformation of plasmid into the bacterial host results in a blue 
colony (B-galactosidase is synthesised). If, however, should the expression of the lac Z 
gene fragment be altered by disruption of the reading frame by cloning a gene into the 
fragment, the colony would be white (B-galactosidase is not synthesised). In other words, 
when X-gal and an inducer of the enzyme such as IPTG is added to the agar, along with 
ampicillin, then non-recombinant colonies will be coloured blue and recombinants with a 
disrupted lac Z gene will be white (Brown, 1986c). 
The amplified JMTM and JSorf-X amplicons were subjected to the same experimental 
manipUlations as JSp26, the gag fragment, which is the example to be used from Section 
2.2.1.10 for cloning into pMOSS Blue T vector and for cloning into the pGEX Expression 
system. Thereafter the experimental procedures differed. 
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The concentration of the PCR products was estimated by running the product on an 
agarose gel and comparing it to a DNA molecular marker VI. The vector to insert ratio 
used should be in the range of 1:5, 1:7.5 or 1:10 for optimal cloning. The amount of insert 
that was required for ligation into the standard amount of 50ng of vector was calculated by 
simply multiplying the size of the insert, which in this case was 653 bp, by 1.3 x 10-
1
. 
This amount of JSp26 DNA was added to a tube containing IJ.lI of 10% ligase buffer, 0.5J.lI 
of 100mM DTT, 0.5J.lI of 10mM ATP, IJ.lI of 50ng/J.lI vector and 0.5J.lI ofT4 DNA ligase 
representing 2-3 Weiss units. The volume was made up to lOJ.lI with nuclease free water. 
The ligation reactions were prepared on ice. The ligation reaction was mixed gently with a 
pipette tip and then incubated at 16°C overnight. Further to test the efficiency of the 
ligation reaction 2J.lI (4.5ng/J.lI) of the positive control insert provided was also used in the 
ligation reaction. 
The ligation reactions were then transformed, using antibiotic sensitive Echerichia coli 
(E.coli) cells. All the cells in each antibiotic-resistant clone that remained after selection 
contains plasmids with the same inserted DNA fragment, but different clones carry 
different fragments (Lodish et ai, 1999b). The ligated samples were then used to transform 
MOS BLUE competent cells. A sufficient number of 82mm petri dishes with Luria Bertani 
agar (LB-Appendix DlO) containing 100J.lglml ampicillin (Appendix Dll) and 15J.lllml 
tetracycline (Appendix D12) were prepared in advance and kept at 4°C away from the 
light. Before being used, the plates were kept at 37°C so that they were warm enough for 
plating of the transformation mix. A suitable number of micro-centrifuge tubes were pre-
chilled on ice. A tube of frozen MOSS Blue competent cells was thawed on ice and mixed 
to suspend the cells evenly. 20J.lI of competent cells was pipetted into each of the pre-
chilled tubes. To each tube of competent cells, IJ.lI of ligation mix and test plasmid 
(provided in the cloning kit) was added directly to the cells and mixed very gently. The 
tubes were left on ice for 30 min. The cells were heat shocked at 42°C for 40 sec in a water 
bath. The tubes were immediately placed on ice for 2 min. SOC medium (Appendix D15) 
(80J.lI) pre-warmed to 37°C was added to each tube. The tubes were shaken at 250 rpm at 
37°C for 1 hour (hr) in a Brunswick Orbital Shaker. Meanwhile the LB agar plates 
containing ampicillin (Appendix D16) were prepared for blue-white screening of 
recombinants by spreading 35 J.lI of20mglml X-gal (Appendix D13) and 20J.lI (lOOmM) of 
IPTG (Appendix D14) per plate. The plates were left for at least half an hour to allow the 
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X-gaI/IPTG to soak before plating the transformation mix. 100J,l1 of each transformation 
mix was spread onto each plate. The plates were incubated overnight at 37°C. 
Recombinants were screened in two ways. Firstly, the colonies were screened by direct 
colony PCR. Secondly, the positive colonies from that screening process were then 
screened using the standard mini-prep method. 
Ten white colonies were selected from the LB agar plate. Sterile water (50J,l1) was added to 
ten 1.5J,l1 micro-centrifuge tubes. Using a sterile loop, colonies were picked by touching 
the loop tip to a colony then to an agar stock plate. For PCR analysis the tip of the loop 
was then transferred to a tube containing water. The agar plate containing ampicillin was 
incubated overnight at 37°C. The tubes were vortexed to disperse the bacteria and boiled at 
lOO°C on a dry block (Techne Dri-block DB2A) for 5 min to lyse the cells and expose the 
DNA. The tubes were centrifuged at 12,000 rpm for 1 min to pellet the cell debris. To a 
0.2ml thin-walled PCR tube containing 40J,l1 of PCR master mix, 10J,l1 of the supernatant 
was added and the tubes placed in a thermal cycler with the same cycling conditions as in 
2.2.1.7 being followed. The amplified products were run on a 1 % agarose gel and the size 
of the products determined as 653 bp. Once the clones on the plates were identified as that 
producing the correct product, these clones were then grown in 3mls of liquid LB medium 
(Appendix D24) with lOOJ,lg/ml of ampicillin and incubated overnight at 37°C. 
The alkaline lysis mini-prep method was used for the rapid isolation of small amounts of 
plasmid DNA without the need for column purification or banding in CsCI gradients 
(Krieg and Melton, 1984). This procedure takes advantage of the rapid alkaline 
denaturation of plasmid and chromosomal DNA and the selective renaturation of plasmid 
DNA following neutralization of the solution. Cells from the overnight culture were 
harvested by centrifugation at 12,000g, for 2 min and resuspended in 100J,l1 Solution I 
(Appendix D 17) by vortexing vigorously. The function of this step is to lyse the bacteria 
by hyperlytic osmosis, releasing DNA and other contents. To this 200J,l1 of Solution II 
(Appendix D18) was added and mixed by inverting the tube several times. This step 
denatures chromosomal DNA and proteins. The solution was incubated for 5 min at room 
temperature, neutralized with 150J,l1 of Solution III (Appendix D19) and mixed by 
inverting the tube several times. The idea behind this step is to selectively precipitate 
proteins, polysaccharides and genomic DNA. The use of this buffer allows plasmid DNA 
to remain in the supernatant, without being precipitated. The solution was incubated on ice 
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for 5 min, centrifuged (12,000g x 5 min) and the DNA containing supernatant transferred 
to a clean tube. An equal volume of phenol-chloroform-isoamylalcohol pH 8 (24: 1: 1-
Bisolve) was added to the supernatant and vortexed for 15 sec. The solution was 
centrifuged as before for 2 min and the aqueous phase transferred to another clean tube. 
800J-lI of absolute ethanol (AR Merck) was added to the aqueous layer, vortexed and 
allowed to settle for 2 min. The solution was centrifuged as before, but for 5 min and the 
supernatant discarded. The pellet was washed with Iml of 70% ethanol (ambient 
temperature) (Appendix D4) and centrifuged for 5 min. The washed pellet was allowed to 
air dry at room temperature for IOmin and then resuspended in 25J-lI of TE (PH8) buffer 
containing 20J-lglml of RNase (Roche Diagnostics, Germany). This step ensures that the 
total RNA's is degraded from the sample. The tubes were incubated at 37°C for 15 min. To 
verify the presence of the correct size of the insert, IJ-lI (+1-160nglJ-lI) of DNA was digested 
with the appropriate restriction enzymes for 1 hr at 37°C. To IJ-lI of DNA extracted, IJ-lI of 
1 % restriction buffer Band 1 J-lI of the enzyme BamHI (Roche) was added in a total volume 
of 10J-lI that excluded the enzymes and analysed by agarose gel electrophoresis as 
described in 2.2.1.8.1. 
2.2.1.11.1 Large Scale Isolation ofpMOSS DNA 
The plasmid containing the cloned fragment pMOSS JSp26 was grown overnight at 37°C 
in a large volume (100ml) of LB broth containing 100J-lglml of ampicillin. The plasmid 
was purified using the Qiagen® plasmid maxi kit (Southern Cross Biotechnology,Cape 
Town) according to the manufacturers' method. This extraction provided a large stock of 
DNA plasmid for further procedures such as cloning into a pGEX expression vector. About 
lOJ-lg (34J-ll) of plasmid DNA was digested in a total volume of 50J-lI using the appropriate 
restriction enzyme (25 units) and 10% enzyme buffer (5J-lI) for 2 hrs at 37°C. The amount 
of restriction enzyme that was used was equivalent to less than 5% of the total volume of 
the digest. The restriction digest was run on a 1 % agarose gel and the insert excised out of 
the gel using a clean sterile scalpel blade. The DNA was extracted from the low melting 
gel using the Wizard® PCR Preps DNA Purification System (Promega Coroporation, 
Madison, USA). 
Briefly, the excised DNA fragment was transferred to a 1.5ml micro-centrifuge tube, 
weighed and incubated at 70°C until the agarose had melted completely. One millilitre of 
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resin was added to the melted agarose slice and mixed thoroughly for 20 sec. The DNA 
was purified using Promega's Vac Man ® Lab vacuum manifold (catalogue number 
A7231) as follows. A wizard mini-column was prepared by attaching the syringe barrel 
that was provided to the luer-Iok extension of the mini-column. The top of the mini-
column! syringe barrel assembly was inserted into the vacuum manifold. The resin! DNA 
mixture was pipetted into the syringe barrel and a vacuum applied to draw the resin DNA 
into the mini-column. The vacuum to the column was broken and the column washed by 
adding 2ml of 80% isopropanol (Merck) to the syringe barrel and reapplying the vacuum to 
draw the solution through the column. The resin was dried, by continuing to draw the 
vacuum for a further 30 sec. The syringe barrel was removed and the mini-column 
transferred to a clean 1.5ml that was centrifuged (10,000 x 2 min.) to remove any residual 
isopropanol. The mini-column was transferred to a fresh tube and 50J.ll of TE added. After 
a waiting period of 1 min the mini-column was centrifuged (10,000 x 20sec) to elute the 
DNA fragment. The DNA was stored at -20°C. 
2.2.1.12 The pGEX Plasmid Expression Vector System 
The expreSSIOn of foreign genes from plasmids transformed into E.coli is a tool 
increasingly used in the investigation of the functions of proteins (Grieco et aI, 1992). 
Plasmid expression vectors have therefore been constructed that direct the synthesis of 
foreign polypeptides in E.coli as fusions with the C-terminus of Sj26, a 26 kDa 
gluthathione S-transferase (GST) encoded by the parasitic helminth Schistosoma 
japonicum. The plasmid pSj5 directs the synthesis of Sj26 in E.coli under the control of the 
IPTG-inducible tac promoter. Through a series of manipulations, pSj5 was modified into 
the expression vector pGEX-l. This vector contains a tacpromoter (for chemically 
inducible high level protein expression), followed by the complete coding sequence of 
Sj26 in which the normal termination codon is replaced by a polylinker containing unique 
recognition sites for BamHl, Smal and EcoRl. The polylinker is followed by TGA 
translation termination codons in all three reading frames; the {3-lactamase coding gene ApR 
(for ampicillin resistance); ori (origin of DNA replication); a fragment of the lac operon 
containing the over-expressed lac JG allele of the lac repressor and part of the lacZ with 
very mild elution conditions for release of fusion proteins from the affinity matrix, thus 
minimising effects on antigenicity and functional activity. The resultant fusion protein 
gene is expressed as an intracellular product and is able to be purified under non-
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denaturing conditions by glutathione affinity chromatography. The protein of interest can 
then be cleaved from the GST by using a specific protease if it has been included in the 
expression vector like factor Xa for pGEX 3X or thrombin (pGEX 2-T) and Pre-Scission 
fusion proteins that possess the complete amino-acid sequence of GST also demonstrate 
GST enzymatic activity and can undergo dimerisation similar to that observed in nature. 
Mammalian GST isozymes can be purified by affinity chromatography on immobilized 
glutathione followed by competitive-elution with excess reduced glutathione, a property 
shared both by the native Sj26 and Sj26 synthesised in E.coli. It is this observation that has 
led to the development of the pGEX expression system. The crystal structure of the 
recombinant Schistosoma japonicum GST from the pGEX vectors has been determined 
and matches that of the native protein (Smith and Johnson, 1988). In this study pGEX-l, its 
derivative pGEX 2-t and pGEX 4-t were used as expression vectors for JSp26, JSTM and 
orf-X viral proteins respectively. 
2.2.1.12.1 Restriction Enzyme and Dephosphorylation of pGEX Vector DNA 
The pGEX vector DNA (Pharmacia, Uppsala, Sweden) was linearised, by digesting 
maximally 51lg of DNA in a total volume of 50111 with 20 units of appropriate restriction 
enzyme for 5 hr at 37°C .The One-Phor-All buffer Plus™ (OPA-Appendix D20) from 
Amersham Pharmacia Biotech was used, since it is compatible with virtually all restriction 
enzymes and many modifying enzymes. A small aliquot of the digested mixture was 
examined by agarose gel electrophoresis as described in 2.2.1.8, to ensure that the pGEX 
DNA had been digested to completion. Since the pGEX DNA was digested with a single 
restriction enzyme, the 5' -phosphate group had to be removed before ligation to prevent 
recircularisation of the vector. Calf-intestinal alkaline phosphatase (Amersham-Pharmacia 
Biotech) was diluted in OP A buffer such that a total of 0.1 units (1-2 III of diluted enzyme) 
were added to the digested pGEX DNA, which was then incubated for 30 min at 37°C. The 
alkaline phosphatase was heat inactivated at 85°C for 15 min. The de-phosphorylated 
product was purified by ethanol precipitation. An equal volume of phenol-chloroform-
isoamyl alcohol (Sigma Capital, Durban. 24: 1 : 1) was added to the product, vortexed and 
centrifuged (12,000g for 1 min) to separate the phases. The upper aqueous phase was 
transferred to a fresh tube and an equal amount of chloroform-isopropanol v/v (24:1) was 
added. The solution was mixed and centrifuged as before to separate the phases. The 
aqueous layer was transferred to a clean tube and one-tenth volume of the aqueous layer of 
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3M Sodium Acetate (PH 5.2) (Appendix D21) and 2.5 volumes of95% ethanol added. The 
solution was mixedfand placed at -20°C overnight or at -70°C for 30 min. The sample was 
centrifuged (12,000 x 15 min) and the supematant removed. The pellet was washed with 
1ml 70% ethanol and re-centrifuged for 2 min, and every drop of ethanol removed. The 
pellet was air-dried at 37°C and dissolved in 20111 of TE. The pGEX DNA was stored at -
20°C for use later. 
2.2.1.12.2 Ligation of Insert to pGEX-l DNA 
The linearised vector and insert DNA was used at a vector insert molar ratio of 1:5 (7.5). 
The molar number of ends of linear DNA was calculated according to the following 
formula where I optical density (OD) unit at 260nm is equivalent to 50Ilg/ml of linear 
double stranded pGEX DNA consisting of 4900 bp were moles of ends is equal to 2 times 
(g of DNA) divided by number of bp times 649daltonslbp. 
The finalligation reaction mix consisted of not more than 200ng of DNA, 1mM ATP, 5 
units ofFPLC pure T4 DNA ligase, 2111 of 10 x One-Phor-All buffer Plus (OPA+) in a total 
volume of 20ll1. The ligation mix was incubated overnight at 16°C and thereafter was 
terminated by heating at 65°C for 10 min. The ligation mix was used to transform 
competent cells. 
2.2.1.12.3 Preparation of Competent Cells and Transformation with pGEX DNA 
The protocol followed was based on the procedure described by (Hanahan, 1983). The 
compositions of buffer and media used are described in the Appendix D. Using sterile 
techniques, a loopful of E.coli strain JM105 from frozen glycerol stocks, was streaked onto 
a SOB agar plate and grown overnight at 37°C. The following day, polypropylene tubes 
were pre-cooled on ice. A streak of well-isolated colonies was transferred from the SOB 
(Appendix D22) plate using a sterile plastic loop and resuspended in TFB (Appendix D23) 
by vortexing at a moderate speed. The cells were incubated on ice for 30 min. DMSO was 
added to the resuspended culture and gently vortexed and incubated on ice for 5 min. DTT 
was added next and incubated as before, but for 10 min. Finally DMSO was added, and 
incubated for a further 5 min on ice. The cells (200IlI) were aliquoted into pre-cooled 
polypropylene tubes. For transformation, the pGEX DNA to a maximum volume of 20111 
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(10-50ng) was added to the competent cells and incubated on ice for 30 min. The cells 
were heat shocked for exactly 45 sec in a 42°C water bath. The tubes were immediately 
chilled on ice for 2 min and 800111 of sac medium (Appendix D15) warmed to 37°C was 
added and the tubes incubated at 37°C for 60 min with moderate agitation using an Orbital 
shaker. The incubated cells were spread onto LB agar plates (Appendix D10) containing 
l0011g/ml ampicillin and incubated overnight (Hanahan, 1983). 
2.2.1.12.4 Small-scale Isolation of pGEX DNA 
Colonies appearing after incubation as described above were picked and screened as in 
section 2.2.1.11 using the two methods to determine which clones were recombinants. 
There was no blue white screening of recombinants with this plasmid as it lacked the F 
containing Lac ZaMI5 gene. To further verify the presence of the correct sized insert about 
2111 of the recombinant pGEX DNA was digested as described in section 2.2.1.9.1 and 
analysed by agarose gel electrophoresis as described previously in section 2.2.1.8.1. 
2.2.1.12.5 Large-scale Screening of pGEX DNA 
Since the insert was cloned into one restriction enzyme site and therefore required 
digestion with one enzyme, the isolated recombinant clones were further investigated to 
ensure that the insert was in the correct reading frame. The plasmids containing the cloned 
fragments were purified using the Qiagen maxi preparation method (Qiagen GmbH, 
Hilden, Germany). A 100ml volume of each culture was grown overnight in LB broth 
(Appendix D24) containing ampicillin and incubated at 37°C with shaking. The plasmid 
was purified according to the manufacturer's instructions and sequenced using an Autoread 
sequencing kit (Pharmacia Biotech), and the A.L.FTM (Automated Laser Fluorescent) DNA 
Sequencer (Pharmacia Biotech) with a few modifications. 
2.2.2 Sequencing as a Tool to Confirm Cloning 
Initially the A.L.fTM DNA Sequencer was used in this study to confirm that the insert was 
cloned into the correct reading frame of the pGEX 1 expression vector, thereafter, the ABI 
PRISM 310 Genetic analyser (P.E. Biosystems) was used for subsequent analysis of 
recombinant clones. Because of this, both methods will be briefly discussed. 
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2.2.2.1 The A.L.FI'M DNA Sequencer and the ABI PRISM 310 Genetic Analyser 
The A.L.FTM DNA Sequencer employs a non-radiochemical approach to sequencing. A 
Fluore-dATP Labelling Mix (fluorescein-15-dATP in solution with dCTP, dGTP and 
dTTP) is used in combination with the AutoRead Sequencing Kit and Automated Laser 
Fluorescent A.L.F. DNA Sequencer from Pharmacia Biotech. This mix allows primers that 
are not fluorescein labelled to be used in the sequencing reactions, since fluorescein-
labelled dATP is incorporated during the labelling reaction (Voss et ai, 1992). Using 
standard dideoxy sequencing methods, the fluorescently labelled primer is extended by T7 
DNA Polymerase in four separate dideoxy reactions (A, C, G, and T), creating four 
separate populations of fluorescently labelled chain-terminated fragments. The reactions 
are then loaded into four adjacent lanes on a sequencing gel and electrophoresed. As the 
DNA fragments in each lane migrate through the gel, they pass a fixed laser beam that 
excites the fluorescent signals that are stored automatically for subsequent sequence 
analysis. Frederick Sanger and Andrew Coulson of the Medical Research Council 
Laboratory developed the chain-terminating method for Molecular Biology at Cambridge 
(Sanger et ai, 1977). WaIter Gilbert and Allan Maxam of Harvard developed an alternate 
method of sequencing, the chemical degradation method. Both methods were first 
published in 1977 (Brown, 1994). 
Dideoxy sequencing has become the preferred method of sequencing. Instead of the use of 
one type of fluorescein label and four separate dideoxy reactions, four different fluorescent 
labels, one for each dideoxy reaction, which is all mixed in one tube, are ' then 
electrophoresed in one lane. As each band passes the detector, the imaging system can 
determine the wavelength of the fluorescence, thereby identifying which family the band 
belongs (prober et ai, 1987). This method is utilized in the Perkin Elmer ABI PRISMTM 
Big Dye™ Terminator Cycle Sequencing Ready Reaction Kit (p.E.Biosystems.). 
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2.2.2.2 The ALFfM DNA Sequencer 
2.2.2.2.1 The Autoread Sequencing Reaction 
One micro gram per kilobase of plasmid/insert DNA was sequenced using the pGEX 5' and 
pGEX 3' sequencing primers (2pmole/J.ll) and a Fluoro-dATP mix (Pharmacia Biotech). 
To the tubes containing the template DNA and primers, 1.5J.ll of freshly prepared IM 
NaOH was added in a total volume of 12.5J.ll. The tubes were vortexed, centrifuged briefly 
and incubated at 70°C for 4 min. The tubes were spun briefly and transferred to a 37°C 
incubator for 15 min. During this time, 1.5J.lI of IM HCl was added and the contents 
mixed. The annealing buffer (2J.lI) was added, samples were mixed and the tubes left to 
incubate for 15 min at 37°C. Meanwhile the A, C, T, and G termination mixes were 
prepared. For each sample 3J.ll of each termination mix, IJ.lI of DMSO and 0.5J.ll of 
extension buffer was added and left at 4°C. After the incubation at 37°C, 1J.lI fluorescein-
15-dATP, and IJ.ll of T7 DNA polymerase was added to the template tube and this tube 
was incubated for 10 min at 37°C. 3.5J.ll of template was added per termination mix (4J.ll) 
that had been warmed to 37°C for 3 min. These reactions were transferred to a nunc plate 
and incubated for 15 min at 40°C. The plate was sealed to prevent evaporation of samples. 
Stop solution (4J.ll) was added to end the reaction. The reactions were stored on ice until 
they could be loaded into the gel. Sequencing was performed using the Automated Laser 
Fluorescent (ALF) DNA Sequencer. Sequencing data was analysed using the DNASIS 
software (Hitachi Software Engineering USA) and Genbank data bank sequences. Internal 
primers were used to confirm sequence in both directions. 
2.2.2.2.2 Preparation of Gel and Sequencing Apparatus 
A 6% Long Ranger gel was prepared as follows: 42g of Urea (ALF grade) was dissolved in 
12ml of 10X TBE (Appendix D26), and 12ml of50% Long Ranger concentrate (FMC Bio 
Products, USA). This gel mix was made up to 100ml with filtered distilled water and 
placed on a magnetic stirrer at slow speed for 30 min. The solution was filtered with a 
0.45J.lm filter into an Erlenmeyer flask, degassed for 15 min and then transferred to a 
Pharmacia Biotech gel mix bottle that was suitable for pouring the gel. Meanwhile the gel 
plates, spacers, combs, upper and lower buffer chambers were cleaned with water. The gel 
plates were further cleaned and polished using water, absolute ethanol and lint free tissue 
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wipes. The first 5cm of the notched plate where the comb wells will be positioned was 
treated with bind silane for a few minutes and then rinsed with water to remove any acetic 
acid present. The gel cassette was assembled and ready for the gel. Before pouring the gel, 
50111 Temed (BioRad Laboratories, Inc, USA) and 500111 of 10% (w/v) ammonium 
persulfite (Appendix D25) was added to the gel solution and gently mixed. The gel 
solution was applied by moving the nozzle of the bottle in an even movement back and 
forth along the lower edge (furthest edge) in the glass plate using even pressure. Capillary 
action drew the solution front upwards to fill the entire space between the plates. The gel 
was left for 2 hours at room temperature to polymerise. The gel cassette was mounted on 
the sequencing apparatus according to the manufacturer's instructions. The upper and 
lower buffer chambers were filled with 0.6% TBE. The system was connected to the water 
circulation and the laser was activated. The A.L.FTM Sequencer is linked to a computer 
terminal where the data is captured and processed using specific software packages. A new 
file was opened for the run and named accordingly. The optimum settings selected was an 
operating voltage of 1900V, current of 65mA, power at 35W, sampling interval of 2.5 sec, 
laser power at 4m W, temperature between 45° to 48°C and running time of 600 minutes. 
Once the temperature was reached, the comb was removed and the wells washed 
thoroughly with buffer to remove any acrylamide or urea that may be present in the wells. 
Before loading the samples onto the sequencing gel, they were heat denatured at 85°C for 3 
min. The electrodes were connected to the sequencer and the lid was closed. The run was 
started once the temperature and laser values were stable. The sequencing results were 
saved to file on to a stiffy disk as well as being printed for analysis. 
2.2.2.3 The ABI PRISM 310 Genetic Analyser 
The ABI PRISM BigDye™ Terminator Cycle Sequencing Ready Reaction Kit provide dye 
terminators, deoxynucleoside triphosphates, AmpliTaq DNA Polymerase, FS, rTth 
pyrophosphatase (a component in AmpliTaq DNA Polymerase, FS), magnesium chloride, 
and buffer that are premixed into a single tube of ready reaction mix and is ready to use. 
The enzyme used is a variant of Thermus aquaticus DNA polymerase that contains a point 
mutation in the active site that results in less discrimination against dideoxynucleotides. 
Further, the second mutation in the amino terminal domain eliminates the 5'-+ 3' nuclease 
activity of the enzyme. The set of dye terminators are labelled with novel, high-sensitivity 
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dRhodamine acceptor dyes and each sequencing reaction is a single tube reaction with all 
four terminators. 
The reagents are suitable for performing fluorescence-based cycle sequencing reactions on 
double-stranded DNA templates or on polymerase chain reaction fragments. The template 
to be analysed had to be of good quality. Since plasmids were being analysed, they needed 
to be purified using a Qiagen plasmid preparation kit. The plasmid was run on a 1 % 
agarose gel together with a molecular weight marker to ascertain the concentration of 
plasmid. About 500ng of template DNA was used in a cycle sequencing reaction using the 
ABI PRISM® BigDye™ Terminaor Ready Reaction Kit (PE Applied Biosystems). The 
reaction was carried out according to the manufacturer's instructions. After the sequencing 
reaction, the extension products were purified. The reaction tubes were centrifuged so that 
the products could be collected easily. The reactants were transferred to 1.5ml micro-
centrifuge tubes and the volume determined (20111). Sterile water was added to make up the 
volume to 36111 and 64111 ethanol (95%) was added to precipitate the extension products. 
The contents of the tubes were vortexed and left at room temperature for 15 min. The tubes 
were centrifuged for 15 min at 12000 rpm. Every drop of supernatant was removed as all 
unincorporated dye terminators are dissolved in them. Freshly prepared 70% ethanol 
(100111) was added to the pellet, tubes vortexed and centrifuged for 10 min as before. After 
a second spin with 70% ethanol, the supernatant was removed. The pellet was dried at 
90°C for 2 min. Each pellet was re-suspended in 20111 of Template Suppression reagent 
that is supplied with the polymer. The tubes were vortexed, centrifuged, and heat denatured 
for 2 min at 100°C. The samples were chilled on ice for 2 min and then transferred to 
O.5ml sample tubes and stored at 4°C in the dark until ready for sequencing on the ABI 
Prism 310 Genetic Analyser. The ABI Prism 310 Genetic Analyzer is a laser-induced 
fluorescence capillary electrophoresis system. DNA samples are loaded onto the 
autosampler. These samples are then automatically introduced into a polymer-filled 
capillary for electrophoresis. The dye-labelled DNA fragments electrophorese through the 
polymer, and separate according to size. As the labelled samples travel through the 
capillary and into the window, they are illuminated. The fluorescent dyes attached to the 
fragments are excited by the laser and emit light at a specific wavelength for each dye. The 
light is collected and separated by a spectrograph according to the wavelength. It is 
collected onto a charge-coupled device (CCD) camera; so all four types of fluorescent 
emissions can be detected simultaneously. The data collection software collects the light 
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intensities usmg software filters and stores them as electrical signals that is further 
processed. At the end of the run, the computer automatically analyses the collected data 
and electropherograms are printed. Correct colour interpretation of the collected data was 
dependent on the use of matrix files (Sequencing Analysis), which were created for each 
specific separation and dye chemistry. The analysed data was then edited and printed 
(Anon, 1998). 
2.2.3 Optimization of Protein Expression 
pGEX recombinant clones were screened for fusion protein expression prior to large scale 
purification to check clones for expression of the desired fusion protein. Several colonies 
of E.coU transformed with pGEX recombinants were picked into separate 15ml green-
capped tubes containing 2ml of LB broth with ampicillin. A separate control tube with 
bacteria transformed with the parenteral pGEX was also inoculated. The cultures were 
grown overnight at 37°C with shaking. The next day a 1/10 dilution was made of the 
overnight culture and grown to an A600 of between 0.6-0.8 (2 to 2.5 hr) with vigorous 
agitation at 37°C. Fusion protein expression was induced, by adding 1).11 of IM IPTG (final 
concentration 0.5mM-Appendix D27). fucubation was continued for an additional 4 hr. 
The liquid culture was transferred to a clean micro-centrifuge tube that was centrifuged for 
10 min at 3000 rpm and the supernatant discarded. Each pellet was resuspended in 150).11 
of ice-cold 1 % PBS (Appendix C28). The cells were lysed using the Branson Sonnicator 
that was equipped with a fine bore probe used for small volumes. The cells were 
sonnicated at 50% output, and at 5-6 for 10 sec. Triton X-lOO (20%) was added to a final 
concentration of 1 % and left on ice for 30 min before centrifugation (5 min x 10,000 rpm). 
Lysis was complete when the cloudy cell suspension became translucent without frothing 
which can denature the protein. The supernatant was transferred to a clean tube and 10).11 of 
this supernatant was added to an equivalent amount of 2% SDS sample buffer (Appendix 
D29) and heated at 95°C for 5 min before being cooled on ice. The samples together with a 
protein calibrator were run on 12% SDS-PAGE (Appendix D31) at a constant voltage of 
130V on ice for 1 hr. After the electrophoresis was completed, the gel was stained with 
Coomassie© Brilliant Blue G 250 (BIORAD) to visualize the polypeptide bands. 
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2.2.4 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The tenn electrophoresis is defined as the separation of molecules based on their mobility 
in an electric field. For SDS-P AGE analysis, proteins need to be disrupted to their primary 
structures by using the right detergents. SDS is an anionic detergent that binds to 
hydrophobic regions of protein molecules and causes them to unfold into extended 
polypeptide chains. As a result, the individual proteins are dissociated from other proteins 
and are freely soluble in the SDS-solution (Wu et ai, 1997). The protein sample is 
denatured with heat in the presence of SDS and a reducing agent (2-mercaptoethanol-
which breaks any S-S bonds present in proteins). The SDS coats the proteins, providing 
them with a net negative charge proportional to their length. When the coated sample is run 
on an SDS page gel, the proteins separate by charge and migrate towards the positive 
electrode (anode) and by the sieving effect of the gel matrix. Sharp banding of the proteins 
is achieved using a discontinuous gel system that has stacking and separating gel layers 
that differ in salt concentration, pH, acrylamide concentration or a combination of these 
(Anon, 1993). 
The effective range of separation of SDS-page gels depends on the concentration of 
polyacrylamide used to cast the gel and on the amount of cross-linking. Cross-links fonned 
from bis-acrylamde add rigidity and tensile strength to the gel and fonn pores through 
which the SDS- page complexes must pass. The size of these pores decreases as the bis-
acrylamide/acrylamide ratio increases reaching a minimum when the ratio is approximately 
1 :20. Most page gels are cast with a molar ratio of bis-acrylamide:acrylamide of 1 :29, 
which is capable of resolving polypeptides that differ in size by as little as 3%. Sieving 
properties of the gel are detennined by the size of the pores (detennined by the bis-
acrylamide/acrylamide ratio). Table 2.4 shows the linear range of separations obtained 
with gels cast with concentration of acrylamide that range from 8% to 14% (Sambrook et 
aI, 1989c). 
TABLE 2.4 Effective Range of Separation of SDS-PAGE Gels 
Protein size 8% 10% 12% 14% 
Optimal size range KDa 25-150 15-100 10-70 5-50 
Resolvable size range KDa 15-300 5-200 5-150 2-100 
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The primary uses for page are the determination of the size of a protein component, the 
estimation of protein purity in a solution, the purification of a protein species for other 
procedures and the fractionation of a complex protein mixture before immunoblotting 
(Western blots). After electrophoresis, the gel is stained with Coomassie Blue R-250 to 
visualize the polypeptide bands. The molecular weight of the polypeptide is inversely 
proportional to its mobility. The molecular weights of the polypeptide can be estimated by 
the use of calibration proteins of known molecular weights (Sambrook et aI, 1989c). 
2.2.4.1 Assembly of the Glass Plate Sandwich 
The first step in SDS-P AGE is the casting of a discontinuous page gel that consists of a 
resolving or separation (lower) gel and a stacking (upper) gel. This study made use of the 
Mini-Protean® 11 Dual Slab Cell (Bio-Rad Laboratories, Inc, USA). Glass plates were 
wiped clean with ethanol and allowed to air dry. The gel cassette was assembled according 
to the manufacturers' instructions. Briefly, the glass plate sandwich was assembled, by 
placing the longer glass plate down first. Two spaces of equal thickness were placed along 
the short edges of the glass plate. The shorter plate was placed on top of the spacers so that 
the bottom ends of the spacers and the bottom of the glass plates were aligned. The spacers 
were left sticking up above the long glass plate about 5 mm. The glass plate sandwich was 
held in such a way that the longer plate was facing away from me, so that I could slide it 
gently into the clamp assembly. The two top screws of the clamp assembly were tightened, 
but not too tightly. The clamp assembly was placed into the alignment slot on the casting 
stand with the clamp screws facing away from me. The two top screws were loosened and 
the glass plates and spacers set flush against the casting stand. Both pairs of screws on the 
clamp assembly were gently tightened. The clamp assembly was transferred to the casting 
slot on the casting stand. Since two gels were always cast, the clamp assembly was placed 
on the side opposite the alignment slot to make aligning the next sandwich easier. Placing 
the bottom first and gently pushing the assembly by pressing against the white portions of 
the clamps until it snapped into place attached the sandwich. 
Combs were placed into the assembled gel sandwich until the teeth were about % into the 
sandwich. A mark was made lcm below the teeth of the comb on the glass plate. The 
separating gel was poured to this level. The combs were then removed (Anon, 1989). 
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2.2.4.2 Casting the Discontinuous Polyacrylamide Gel 
The formulations for the preparation of the stock solutions are included in the Appendix. A 
12% separating gel monomer (Appendix D31) was prepared by combining 6.7ml of 
distilled water, 5ml of a 1.5M TrisHCl pH 8.8 (Appendix D33), 200111 of 10% (w/v) SDS 
stock solution (room temperature), 8ml acrylamidelbis-acrylamide (30% stock Appendix 
D30), and 8111 of Temed in a clean beaker or Erlenmeyer flask and mixed thoroughly. This 
percentage gives good separation of the proteins in the 10,000 to 70,000dalton range. 
Gloves were worn at all times during the handling of the reagents because of the toxicity of 
acrylamide and Temed. Finally 200111 of ammonium persulfite (APS-IO% solution 
prepared fresh Appendix D25) was added to the solution and mixed. The concentration of 
APS that was used was high to eliminate the need for degassing the acrylamide. Degassing 
means the removal of any dissolved oxygen from the acrylamide, which can retard 
polymerisation. The resolving gel solution was poured between the glass plates until the 
mark on the glass plate was reached. Water-saturated n-butanol (Appendix D32) was 
layered along the surface of the gel solution with a pipette. This prevented the oxygen from 
diffusing into the gel, thereby inhibiting polymerisation. The gel was allowed to 
polymerise, the n-butanol was removed and that space rinsed completely with distilled 
water. The excess fluid was removed with a blotting paper. 
A 5% stacking gel (Appendix D35) was prepared by combining 2.57ml water, 0.83ml 
acrylamidelbis-acrylamide mix, 1.26ml of a IM TrisHCI pH 6.8 (Appendix D34), 0.05ml 
SDS and 0.005ml Temed. The solution was mixed thoroughly, before adding 0.05ml APS. 
The stacking gel solution was poured on top of the resolving gel using a pipette. The 10-
well comb was inserted and more gel solution added to fill the cassette completely. The gel 
was allowed to polymerize for 30-40 min at room temperature. After polymerisation, the 
combs were removed and the wells rinsed with distilled water and the gel was ready for 
loading (Anon, 1989). 
2.2.4.3 Assembling the Upper Buffer Chamber 
After the stacking gel polymerised, the clamp assembly/ gel sandwich was released from 
the casting stand. The inner cooling core was laid down on the bench. The clamp assembly 
with the screws was facing out while the wedges faced towards the top of the cooling core. 
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The clamp assembly wedges were slid underneath the locator slots on the cooling core 
until the inner plate of the sandwich was against the notch in the gasket. The clamp 
assembly was snapped until the cooling core latch engaged each side of the clamp 
assemblY. The other clamp assembly/ gel sandwich was attached to the other side of the 
cooling core. The cooling core was placed into the lower buffer chamber of the 
electrophoretic cell. The upper and lower chamber was filled with 1 % electrode buffer 
(Appendix D38). The samples were prepared for electrophoresis by diluting the sample 
with an equal volume of 2% SDS sample buffer and heating at 95°C for 5 min in a heating 
block. A protein molecular weight marker (Combithek Cat. no. 1317474 Boehringer 
Mannheim, GmbH, Mannheim, West Germany) was loaded into lane 1 using a gel-loading 
tip (Eppendorf, Netheler-Hinz. GmbH, Germany). Empty wells were loaded with an equal 
volume of 1% sample buffer to prevent spreading of adjacent samples during 
electrophoresis. The voltage was set at a constant of 130V for 1 hr and run under cold 
conditions. The electrophoresis was stopped once the tracking dye reached the bottom of 
the resolving gel. The protein gel cassette was removed from the apparatus and the buffer 
was discarded. The two plates were separated carefully and the orientation of the gel 
marked by trimming a corner of the gel so that sample order was not lost during the 
staining step. The gel was removed from the glass plate and stained for protein detection 
only or kept for transfer onto a nitrocellulose membrane (for immunoblotting without 
staining). The gel was placed in a staining gel dish containing Coomassie Blue staining 
solution (Appendix D36) for 30 min. The gel was de stained with the destaining solution 
(Appendix D37) from 1 hr to 3 hr. The gel was then photographed. The gel was soaked in 
destaining solution containing glycerol and dried onto Whatman paper for long-term 
storage. 
2.2.5 Preparation for Large Scale Protein Expression and Purification 
Before proceeding with large-scale expression and purification, a small pilot experiment 
was run to establish optimal conditions for expression. A single colony of E.coli containing 
a recombinant pGEX plasmid was used to inoculate 150ml of LB broth containing 
ampicillin. The culture was incubated for 16 hr at 37°C with vigorous shaking. The next 
day the culture was diluted 11100 into fresh pre-warmed LB broth and grown at 37°C with 
shaking until the culture reached an ~oo of 0.6 to 0.8. For lL of culture, a 2L flask was 
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used for proper aeration of the culture. Once the appropriate optical density was reached, 
10ml of the culture was removed and growth was allowed to continue. To the remaining 
culture 1M IPTG (Sigma-Appendix D27) was added to a final concentration of O.5mM to 
induce expression of the recombinant protein. The culture was transferred to appropriate 
centrifuge containers and centrifuged (8000g x 10 min) in a Beckman JA 21120 rotor to 
sediment the cells. The supematant was discarded and the pellet drained onto a paper 
towel. The pellet was re-suspended in 1120 of the original culture volume with ice-cold 
PBS. The solution was placed on ice. The suspended cells were disrupted using a Branson 
sonicator with a suitable probe. The cells were disrupted with short bursts of 30 sec at 30 
sec intervals at a Duty cycle of between 70-80% and an output of between 4-5 for a total of 
3 min. Triton X-lOO was added to a final concentration of 1 % and the sonicate kept on ice 
for 30 min to aid solubilisation of the protein. Pefabloc (Pharmacia Biotech, UK-Appendix 
D39) was added to a final concentration of 5mM.The sonicate was centrifuged (10,000g) 
for 30 min at 4°C and the supematant transferred to a clean container. An aliquot of the 
supematant and the cell debris (pellet) was saved for analysis by SDS-page as described in 
2.2.4. 
2.2.6 Chromatography 
Chromatography refers to the technique used in the separation and purification of one or 
more biological compounds from a mixture of such compounds. The selection of a 
chromatographic technique is based on the particular material to be isolated. In this study, 
the technique used was based on affinity chromatography, as proteins were the 
macromolecules that required purification and the unique property of biological specificity 
was being exploited (Williams and Wilson, 1979). All chromatographic separations depend 
upon the differential partition of solutes between phases, a mobile phase and a stationary 
phase. Such partition between two phases is described by the so-called partition coefficient 
or distribution coefficient. The distribution coefficient describes the distribution between 
any two phases, be it a liquid! solid or gas/ liquid phase. In chromatography there is always 
a distribution between two such phases, one kept stationary while the other, the mobile 
phase, flows over or through it. In the situation with affinity chromatography, the 
stationary phase is the immobilised bimolecule that is packed into a tubular column and the 
mobile phase is liquid that flows through the packed column. Affinity chromatography 
exploits a specific relationship between a protein and a ligand, to select out the desired 
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protein from a crude mixture, in a single step. The ligand in question is glutathione, which 
is immobilized by conjugation to an insoluble matrix being agarose beads or resin, in a 
manner that does not interfere with its interaction with the protein. The resin or agarose 
beads have three parts to it, namely, the matrix that is linked to a ligand via a spacer arm of 
about six to ten carbon atoms. The sample solution is passed through the column and by its 
specific interaction with the immobilised ligand the protein of interest is retained, while all 
other proteins pass straight through the column (Dennison, 1999). The protein is 
subsequently eluted by a free competing ligand that is 50mM Tris HCI (PH 8.0) (Appendix 
D40) containing lOmM reduced glutathione (Sigma) (final pH 7.5 freshly prepared 
(Appendix D41) (Smith and Johnson, 1988). The protein of interest is usually immobilised 
in a small volume of agarose beads, therefore affinity chromatography columns are quite 
small. The volume of solution in which the protein occurs, is quite large and to pass this 
volume through the column in a reasonable time, while maintaining the linear flow rate 
within limits, the column is thus relatively wide [15mm in diameter] (Dennison, 1999). 
2.2.6.1 Preparation of Glutathione Agarose for Purification of Fusion Protein 
Fifty percent pre-swollen slurry of glutathione agarose beads (Sigma catalogue number 
G4510) was prepared by allowing the lyophilised powder (200ml/g) to swell for 2 hr (90-
95% swelling occurs during this period). The gel was packed into an affinity 
chromatography column and washed with 10 volumes of water. The column was 
equilibrated with several column washes of ice-cold PBS. The suspension was allowed to 
pass through the 50% pre-swollen slurry of glutathione. The supernatant was passed 
through twice. The column was washed three times with 50ml ice-cold PBS. The fusion 
proteins were eluted with lml elution buffer (50mM TrisHCI pH8, lOmm reduced 
glutathione) with gentle mixing for 2 min. The elution step was repeated four times and the 
eluates pooled. The glutathione agarose gel was regenerated with 3M NaCI (Appendix 
D46) for re-use. The purity and relative molecular size of the recombinant proteins were 
analysed by SDS-PAGE (section 2.2.4). Yields of fusion protein were calculated using the 
Bio-Rad DC Protein Assay Kit II (Bio-Rad Laboratories: Life Science Group, USA) and 
bovine serum albumen as a protein standard. 
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2.2.6.2 Estimation of Protein Concentration 
The Bio-Rad DC Protein Assay (Bio-Rad DC Protein Assay Kit II. Bio-Rad Laboratories, 
Life Science Group, USA) is a colorimetric assay for protein concentration following 
detergent solubilisation. The assay is based on the reaction of protein with an alkaline 
copper tartrate solution and Folin reagent. Two steps lead to colour development: The 
reaction between protein and copper in an alkaline medium, and the subsequent reduction 
of Folin reagent by the copper-treated protein. Colour development is primarily due to the 
amino-acids tyrosine and tryptophan, and to a lesser extent, cystine, cysteine and histidine. 
Proteins effect a reduction of the Folin reagent by loss of 1,2, or 3 oxygen atoms, thereby 
producing the characteristic blue colour with a maximum absorbance at 750nm and 
minimum absorbance at 405nm. 
The protein standard was obtained in a lyophilized form. Sterile water was added to the 
bovine serum standard to obtain a concentration of 1 Ilg/ml. Whenever the concentration of 
an unknown protein was required; it had to be measured against a known standard, and this 
standard was diluted with water to obtain a concentration of 100ng/lll. Dilutions of the 
protein standard were made starting from zero concentration (Olll) of BSA, IOIlI, 20IlI, 
40IlI, 60IlI, 80111 and IOOll1 or 10,OOOng. Dilutions of the unknown protein were made in a 
similar manner. 500111 of reagent A, an alkaline copper tartrate solution, was added to each 
tube. Reagent B, a dilute Folin Reagent (4ml) was thereafter added. The tubes were mixed 
and incubated in the dark at room temperature for 15 min. The absorbance of the protein 
samples were read at 750nm using a Beckman spectrophotometer. A standard curve of 
absorbance versus wavelength was drawn from which the concentration of the unknown 
protein was obtained. 
2.2.7 Western Blot Analysis of Fusion Proteins 
The major principle of Western Blotting is the interaction between a specific antibody and 
its target protein on the membrane. An antibody is aY-shaped molecule containing two 
heavy chains; two light chains, and two identical antigen-binding sites or bivalency at the 
tip of two arms. These binding sites are specific for a particular antigen. It is the antigen-
binding sites that allow an antibody to cross-link the antigenic determinant of the target 
antigen or protein in immunoblotting. Many antigens have multiple anti genic determinants 
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or epitopes that enable the antigen to fonn linear chains or cyclic complexes with the 
antibody (Wu et aI, 1997). 
Western blotting (Towbin et aI, 1979) is a technique whereby proteins that have been 
electrophoretically separated, are transferred from a gel to an insoluble matrix 
(nitrocellulose membrane) and probed with reagents that are specific for particular 
sequences of amino acids. Probes that are utilized for the detection are antibodies that react 
specifically with antigenic epitopes displayed by the target protein attached to the 
nitrocellulose. Electrophoretic separation of proteins is always carried out under denaturing 
conditions whereby problems of solubilisation, aggregation and co-precipitation of the 
target protein with adventitious proteins are eliminated. Western blotting is extremely 
useful for the identification of specific proteins in complex mixtures and simultaneously 
detennining its molecular weight. 
2.2.7.1 Method 
Fusion proteins that were separated usmg SDS-page in section 2.2.4 were 
electrophoretic ally transferred from the gels onto nitrocellulose membranes (MSI-Micron 
Separations Inc. Catalogue number NJOHYOOOlO) using a trans-blot semi-dry 
electrophoretic transfer cell (Bio-Rad Laboratories, Inc, USA). A piece of nitrocellulose 
membrane and six pieces of 3mm Whatman paper, the size of SDS-page gel was cut and 
equilibrated in transfer buffer (Appendix D42) for 10 min. One corner of the filter paper 
was marked with a soft lead pencil. The gel and the nitrocellulose membrane were 
sandwiched between the layers of the filter paper. This sandwich was placed between 
graphite plate electrodes, with the nitrocellulose filter on the anodic side. A glass roller was 
used to squeeze out any air bubbles or lumps in the sandwich. The area of the gel was 
calculated and a current of 5mA1cm2 was applied for 1 hr. During the transfer, ice packs 
were placed on top of the transfer apparatus to prevent it from overheating. After transfer, 
the gel was stained with Coomassie Brilliant Blue G 250 as described previously in section 
2.2.4.3 and de-stained to ensure that the transfer was complete. 
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2.2.7.2 Immunoblot Detection 
For immunoblot detection of the transferred membrane, the nitrocellulose membrane was 
blocked in 5% w/v solution of Elite non-fat milk powder in 0.1% PBS-Tween (Appendix 
D43) with gentle rocking for 1 hr. Blocking of membrane is to seal potential binding sites 
to reduce background of non-specific binding of irrelevant proteins with antibody. The 
membrane was washed twice with phosphate buffered saline containing 0.05% (w/v) 
Tween 20 (Appendix D44). It was then incubated overnight with the primary antibody 
(goat anti-GST or Mason Pfizer Monkey Virus (MPMV) diluted 111000 in PBS-Tween 20 
with gentle agitation on a rocking platform at room temperature. This antibody binds 
directly to the antigen. The membrane was washed as before (2 x 15min) with PBS-Tween 
and incubated with the secondary antibody, an enzyme conjugate, anti-goat peroxidase 
conjugate (promega Corporation, Madison, USA) diluted 111000 for 1 hr at room 
temperature in blocking buffer. This secondary antibody interacts with the first antibody. 
The membrane was washed as before and then immersed in a substrate solution (4-chloro-
I-napthol in methanol and peroxidase-Appendix D45). This substrate detects the complex 
formed, that is, the protein-primary antibody-secondary antibody which is formed on the 
blotted membrane (Wu et aI, 1997). The membrane was incubated in the dark for 20 min 
or until bands were clearly visible against a lightly stained background. Once the bands 
developed, the membrane was rinsed with deionised water, and dried and mounted onto 
Whatman paper and then photographed. 
2.2.8 Enzyme-linked Immunosorbent Assays (ELISAs) 
ELlS As are heterogenous assays that were first described in 1971 by Engvall and Perlman 
and Van Weemen and Schuurs to detect antigen (Ag) or antibody (Ab) presence in variety 
of biological samples (Engvall and Perlman, 1971; Van Weemen and Schuurs, 1971). 
Many variations in the methodology of the ELISA have evolved since its inception in the 
1960's, but the basic concept is still the immunological detection and quantification of a 
single or multiple Ag or Ab in a patient's sample (usually serum). The ELISA technique 
employs the sensitivity of a spectrophotometric assay of an enzyme and the specificity of 
antibodies. For this purpose, a stable enzyme that can be easily measured and which has a 
high turnover number is covalently linked to an immunoreactive molecule (antibody or 
antigen). Thus, when an Ab binds with its target molecule, it carries with it an enzyme 
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"label". By measuring the amount of enzyme associated with the target molecule, a 
measure of the amount of target molecule present is available (Barker et aI, 1993). 
A number of methods are available for the performance of ELlS As, and are classified as 
indirect, competitive, sandwich or capture assays. The assays are conducted in microtitre 
plates containing 96 wells or strips. A typical assay consists of the antigen or antibody 
attached on a solid phase (support), and conjugate and substrate detection system. The 
solid support can be 96 well microtitre plates, strips, plastic beads, polyvinylchloride or 
polystryene surfaces. Polyvinylchloride microtitre plates are considered a more suitable 
surface for protein binding in the standard EIAs, competitive and sandwich assays that 
have been used in this study. Microparticles and beads have increased surface areas and 
can therefore absorb larger quantities of antigen 
2.2.8.1 Indirect Enzyme-linked Immunoassay 
The most often used assay is the standard indirect ELISA. In the standard assay GST-
JSp26 protein was bound overnight at 4°C onto Nunc microsorb strips «Nunc-Immuno 
Module MaxiSorp F8 Frame, catalogue no. 469949 NUNC Brand products, Denmark). A 
1/5 dilution (125JLg) of the antigen in question was made in 0.05M carbonate bicarbonate 
buffer pH 9.6 (Sigma) and added in a serial dilution starting from 1/5 (25JLg) to 1/640 
(0. 19JLg). The following day the excess antigen was shaken off, and washed three times 
with one times wash buffer (20% Genelavia wash buffer used at a 1/10 dilution). The wells 
were blocked with 200111 of blocking buffer (5% Elite milk powder in 1% washing buffer 
(20 X Genelavia wash buffer) for 30 min at 37°C. Excess blocking buffer was removed 
and lOOll1 of a 1/5 and 1/10 dilution of each antibody sample were added to each vertical 
row. The reaction was incubated at 37°C for 1 hr and washed as before using the PW40 
(Sanoffi Diagnostics Pasteur, France)) microtiter plate washer. Horseradish peroxidase 
labelled Protein G conjugate (lOOIlI-Sigma-Aldrich, USA) diluted at a concentration of 
1/4000 was added. After washing, 50111 of OPD substrate (10 mg in O.lM sodium citrate 
buffer pH 4.5 and 6111 H20 2) was added and incubated in the dark for 5 min. 0.05M 
Sulphuric Acid was added to stop the reaction, which was read at a wavelength of 492 nm 
and 630 nm using a Bio-Rad 580 Plate reader (Bio-Rad Laboratories, Inc, USA). 
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2.2.8.1.1 Use of Indirect ELISA to Determine Specificity of the GST -JSp26 Fusion 
Protein 
Microtitre plate wells were coated with GST-JSp26 (0.250qg) and GST-HIVp24 (0.650qg) 
antigens in a serial dilution starting at 1110 (12.5p,g) down each vertical row and ending at 
111280 (0.097Ilg). Adsorption of the antigen occurred by immobilization onto the walls of 
the plate. The enzyme-linked immunoassay was conducted in a manner similar to that 
outlined in 2.2.8.1, except serum from a naturally affected sheep named Bruwer was used 
at a dilution of 111 0 and titrated across the plate, with the most concentrated solution to the 
left ofthe plate and the most dilute to the right (11320). 
2.2.8.1.2A Competitive Enzyme-linked Immunoassay 
Two strips of microtitre plate wells were each coated with a 1110 dilution (12.5p,g) of GST-
HIVp24 and GST-JSp26 antigen, respectively. The ELISA protocol adopted here was the 
same as in section 2.2.8.1, except for the antibody step using antiserum from a sheep 
naturally infected with JSRV (Bruwer anti serum), were there were a few changes. To the 
first well of each strip 100111 of a 1/5 dilution of antibody was added. The rest of the wells 
had 100111 of blocking antibody added. A 1120 dilution of GST -HIVp24 antigen (1Op,1 of 
0.65p,g/p,1 antigen in 190p,1 of blocking buffer) was added as a competitor in a serial 
dilution vertically down the rows. 
2.2.8.1.2B Competitive Enzyme-linked Immunoassay 
In this experiment, five rows of microtitre plate wells were coated with a 1110 dilution of 
GST-JSp26 (0.25p,g/p,1) and five with a 1130 dilution of GST-HIVp24 antigen (0.65p,g/p,1) 
as outlined in section 2.2.8.1. Two different tests were carried out. The only difference is in 
the antibody stage of the ELlS A test. 
1. GST-HIVp24 was added as a competitor at a 11100 dilution (0.65p,g/p,1) to only one 
row each of the antigens (100111). To the same row Bruwer antiserum (100111) was 
added serially starting at a 115 dilution till 11640. The second row of each antigen had 
only 100 III of blocking buffer added. 
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2. Two different antibodies, namely, MPMV and R3 were used. MPMV used at a starting 
dilution of 112000 till 11256000. R3 was used at a dilution starting at 1110 and going 
down to 111280. 
Both the above two ELISA tests were completed as in section 2.2.8.1. 
2.2.8.2 Preparation and Use of an In-house Conjugate Using GST -JSp26 
2.2.8.2.1 Preparation of In-house Enzyme-labelled Conjugate 
The second assay used in the study was the antibody capture assay. For this assay, an in-
house enzyme-labelled conjugate was prepared using Pierce's E-LinkTM Plus activated 
Peroxidase Kit (31487). One mg of affinity purified GST -JSp26 protein was added to 
0.5ml of conjugation buffer (0.2M Buph Carbonate Bicarbonate Buffer pH 9.4). The 
protein sample was added to 1mg of lyophilised E-Z linkTM Plus activated Peroxidase that 
had been reconstituted with lOOll1 of water. The solution was incubated at room 
temperature for 1 hr. To this mix lOlll of Reductant Solution (Sodium cyanoborohydride-
Na-CNBH3) was added to the protein solution with a further incubation of 15 min at room 
temperature. Quenching Buffer Solution (20IlI) was added and the protein solution 
incubated as before. 
The prepared conjugate solution was de salted using the Pharmacia de salting columns. The 
top cap of the column was removed and the excess liquid poured off. The bottom cap was 
removed and the column was supported using a special rack. The gel was equilibrated with 
three column washes of water (3% x Sml). The equilibration buffer was allowed to 
completely enter the gel bed. The sample was added to the column in a maximum volume 
of 1ml (sample was made up to lml with distilled water). The conjugate was diluted with 
1.5ml-distilled water. To this an equal volume (1.Sml) of2x PBS was added. For long-term 
storage at -20cC, glycerol to a final concentration of 50% (3ml) was added to the 
conjugate. 
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, 2.2.8.2.2 Indirect ELISA to Determine Working Dilution of Conjugate 
Before using the conjugate (JSp26-HRP), it was titrated to obtain that dilution that gave the 
best signal to noise ratio. A 1150 dilution was made and titrated 50-fold from 1150 to 
113906250. GST-JSp26 protein (0.25p.glp.l) was titrated from 115 to 11640 in coating buffer 
and incubated overnight at room temperature. The plates were washed as before and then 
blocked with 200)11 of blocking buffer at 37°C for 30 min. The washing procedure was 
followed as before (section 2.2.8.1). The MPMV antiserum was used at a dilution of 1150 
and incubated at 37°C for I hr. After washing the plates, 50)11 of substrate (HRPO 
substrate-one tablet to 10ml of 0.03% H20 2 substrate) was added to each well. The plate 
was incubated for 5 min at room temperature in the dark. The reaction was stopped with 
0.05M Sulphuric Acid and the plates read at 492 nm. 
2.2.8.2.3 Antibody Capture ELISA 
The principle behind the antibody capture assay or the antibody sandwich assay is that an 
antigen is coated onto the microtitre plate; this is followed by the addition of the antibody 
to the plate. Should there be a reaction between the antigen and the antibody this complex 
is detected by an antigen that is labelled with for example horseradish peroxidase. Addition 
of the substrate would light up the wells positive containing the antigen/antibody/antigen 
complex. The principle is that one arm of the antibody binds tightly to the antigen on the 
micotitre plate whilst the other arm is free to be bind to another antigen that has been 
labelled with an indicator enzyme. In this way one by passes the need to use an indirect 
conjugate step. 
Once the working dilution of the in-house conjugate (JSp26-HRP) was determined, an 
antibody capture ELISA technique was used against infected and non-infected JSRV 
samples. The wells were coated with 100)11 of GST -JSp26 antigen in 0.05M carbonate 
bicarbonate pH 9.6 at a dilution of 1180 (0.39p.glwell). After an overnight incubation at 
room temperature, the plates were washed and blocked as before for 30 min at 37°C. Eight 
samples negative for JSRV, and eight positive for JSRV were tested. All samples were 
tested at a 1150 dilution. The conjugate (JSp26-HRP) was also used at a 1150 dilution. 
Horseradish peroxidase substrate was used and the reaction stopped with 0.05M Sulphuric-
acid and the test read at a wavelength of 492nm. 
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This antibody capture assay was utilized against a batch of 39 JSRV positive sera and 41 
JSRV negative sera and the test performed as in section 2.2.8.1. These positive and 
negative sera were obtained from the Ondersterpoort Veterinary Research Institute. The 
positive sera were obtained from sheep diagnosed with OP A upon post-mortem. 
2.2.8.3 Indirect ELISA Utilising Monoclonal Antibodies 
Nunc microsorp microtitre plates were used. The wells were coated with different antigens 
at a 1110 and 11100 dilution. These antigens were lung lavage samples from affected and 
normal sheep that were hundred times concentrated and used at two different 
concentrations to cover a range of dilutions. The dilutions were made in 0.05M Carbonate 
bicarbonate buffer and the plates incubated overnight at room temperature. The following 
day the strips were washed three times with Bio Whitiker 20% wash buffer used at a 1 % 
fmal concentration. Blocking buffer (wash buffer with 5% Elite fat free milk powder) was 
used as a blocking reagent to block the non-reactive sites on the plate, membrane or tissue 
and reduce non-specific binding of proteins during subsequent steps in the assay. Blocking 
buffers improve the sensitivity of the assay and reduce background interference (Pratt and 
Roser, 1984). Further they have no active part in the specified immunochemical reaction of 
a particular assay. The plate was blocked at 37°C for 30 min. Excess blocking buffer was 
removed and the mono clonal antibody 59G 11 was diluted at 1150, of which 100111 was 
added to each well. The plate was incubated at 37°C for 1 hr. After the plate had been 
washed, a goat anti-mouse HRP conjugate (Sigma) was used at a dilution of 1/3000. 100111 
of conjugate was added per well and the plate incubated as before. The substrate (OPD) 
was added and incubated at room temperature for 30 min. Later the reaction was stopped 
as above and read at 492 run using a Bio-Rad 580 plate reader. 
2.2.8.4 Gold Conjugates 
An additional method utilised in this study, was gold labelling. Following the use of gold 
colloids as a marker in 1971, gold labelling has become an important tool for the detection 
and quantification of proteins, antigens, and nucleic acids. Gold labels can also be used 
with numerous techniques such as blotting (nitrocellulose or polyvinyldifluride). Recently, 
gold conjugates have been incorporated into rapid test immunoassays. In these techniques 
the unique red colour of the accumulated gold label, when observed by lateral or transverse 
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flow along a membrane on which the antigen is captured, or by observation of the red 
colour intensity in solution, provides an extremely sensitive method for detecting sub-
nanogram quantities of proteins in solution. Gold conjugates act as markers for molecules 
that are otherwise invisible by eye or through other detection systems. A colloidal gold 
conjugate consists of a suspension of gold particles coated with a selected protein or 
macromolecules (such as an antibody). The gold particle may be manufactured to any 
chosen size from 1-250nm. This gold conjugate when incubated with a specific target will 
reveal the target through the visibility of the gold particles themselves. For detection by 
eye, gold particles will reveal immobilized protein on a solid phase, such as a membrane, 
through the accumulation of the gold at the reaction site. This is observed as an 
increasingly intense red band. The protein bands are easily separated. It appears silver 
enhancement of this gold precipitate can also further enhance the sensitivity of detection 
(Anon, 2000). 
The conjugation of selected proteins to gold particles depends upon at least three physical 
phenomena: charge attraction of the negative gold particles to positively charged protein, 
hydrophobic absorption of the protein to the gold particle surface and binding of the gold 
to sulphur (dative binding) where this may exist within the structure of the macromolecule. 
The condition under which a gold conjugate is manufactured affects its performance and 
stability. Firstly, all antibodies and proteins used for conjugation should be affinity purified 
and of the highest quality. They must possess very strong affinity for the specific antibody 
or antigen and have high avidity to withstand severe incubation and washing conditions. 
Cross-reactivity must be the lowest possible. Gold conjugates should be consistent from 
batch to batch and give the same high performance time after time. The gold conjugate 
should produce a strong specific signal together with a low background. For this to occur, 
the conjugation of the antibody to gold particles must be complete and stable under a 
variety of incubating conditions. The gold particle must have the minimum effect on the 
activity of the antibody to which it is conjugated, but must be strongly enough absorbed to 
the surface to remain stable for years. Gold conjugates should be capable of being frozen 
without loss of the antibody or antigen activity (Anon, 2000). 
The question is, why use gold? Well, there are several advantages. Less than 10pg of 
protein is detected with each gold conjugate. Inm gold conjugate produces even higher 
sensitivity. Primary antibodies can therefore be used at high dilutions. The optical density 
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of 20nm gold conjugate at 520 nm is 4 OD. For Inm gold conjugate, the optical density is 
not measurable as it is a clear liquid. The Inm gold conjugate has a protein concentration 
of 50Ilg/ml. A low background is obtained and crisp well-defined bands can be seen which 
ensures accurate identification. The specific labelling produced in this way can be 
compared and quantified with a total protein stain obtained from a duplicate sample 
analysed in parallel. This is a much more accurate technique for protein identification on 
membranes compared with Coomassie blue method for staining gels where distortion can 
occur between the gel and the membrane during protein transfer (Anon, 2001). 
While fluorescent labels and enzyme based colour reactions may fade with time and light 
exposure, gold particles do not disappear, but give a permanent label (Moeremans et ai, 
1984). 
The conjugation of the rabbit viral capsid antibody to gold was performed in an outside 
laboratory (MDS Medical Diagnostic Services, Westville, KwaZulu-Natal). 
2.2.9 Antibody Production 
Antibodies are proteins made by the immune system of animals as part of a defence 
mechanism against infection by foreign organisms. Antibodies play a role in being able to 
distinguish 'self and 'non-self. Because of their specificity and versatility, antibodies are 
useful reagents in identifying and analyzing proteins (Dennison, 1999). 
The injection of a foreign molecule, usually a protein into an animal will elicit an immune 
response that includes the products of antibodies that react with the foreign protein and 
target it for removal from the system. The foreign protein is called the immunogen and the 
antibody produced in response to this protein will react with a molecule called the antigen. 
The foreign protein used to be known as the antigen, but some molecules that are antigenic 
(react with antibody) may not be immunogenic (that is, they will not elicit an antibody 
response when injected into an animal). A single injection of an immunogen is not usually 
effective in eliciting an immune response. In the case of a natural infection, molecules 
from the infecting agent will diffuse from the site of an infection to become exposed to the 
immune system in small amounts, but over a prolonged period. This natural process has to 
be copied to elicit an antibody response. Making an emulsion of the aqueous antibody 
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solution with adjuvant oil does this. An adjuvant releases immunogen slowly in small 
amounts for exposure to the immune system over a period of time. The emulsion is made 
by a process known as trituration and is injected into the breast muscle of a chicken or 
subcutaneously in a rabbit. The injected emulsion will exist at a focal site, and as it 
gradually breaks down, it will be released slowly and thus be exposed to the immune 
system. This is the principle of Freund's incomplete adjuvant. 
2.2.9.1 Immunisation of Chickens to Produce IgY JSRV p26 Antibodies 
In this study we decided to use hens for antibody production because it is not necessary to 
bleed them in order to harvest the antibodies. Further, in a study by PoIson et al (1980), he 
showed that the production of antibodies in rabbits did not differ from that in hens when 
the titre of IgY was examined. This was observed when the two species were immunised 
and hyperimmunised simultaneously. It was also shown that the molecular weight of the 
antigen is important in stimulating antibody production as well as in the visibility of the 
reaction between antigen and antibody. The term IgY denotes immunoglobulin in hen 
serum as well as in yolk (PoIson et aI, 1980). Antibody transfer occurs via the egg yolk, 
which provides a convenient source from which antibody maybe isolated. 
2.2.9.1.1 Preparation of Immunogen for Immunisation 
The immunogen used was GST -JSp26 that had been affinity purified and the concentration 
of which had been determined using the Biorad DC Protein Assay (Bio-Rad Laboratories, 
Inc, USA). 100Jlg of GST -JSp26 equivalent to 200JlI was made up to Iml with sterile PBS 
(phosphate buffered saline) and this was pipetted into a 10ml beaker. An equal amount of 
Freunds complete adjuvant, an attenuated Mycoplasma spp, live, but not virulent, (Sigma 
Aldrich, USA) was added to the immunogenIPBS mix to form an emulsion by a process 
referred to as trituration. Briefly, a sterile syringe was used, the plunger of which is 
removed and the base lubricated with some of the adjuvant. The inside of the syringe is 
also lubricated so that the adjuvant does not adhere to the sides of the syringe when it is 
used to emulsify the immunogen-mix. Drawing the sample up into the syringe and then 
releasing it mixed the sample. This is continued until the mixture is emulsified sufficiently 
in the 10 ml beaker. Once the sample is ready, as much as possible is drawn into the 
syringe. The syringe is turned in such away that the sample tends to move in the direction 
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of the plunger. The plunger is moved slowly so that the sample is moved to the top until all 
the air bubbles have been released. The sample is now ready for immunisation (PoIson et 
aI, 1980). 
2.2.9.1.2 Immunisation of Chickens 
Hens of between 12-14 weeks were kept in isolation for immunisation purposes and egg 
laying production at the Ukulinga Research Farm that is part of the Faculty of Agricultural 
Sciences of the University of KwaZulu-Natal, Pietermaritzburg. The breed of hens used 
was Hyaline Brown. Prior to the initial immunization, eggs were collected on a daily basis. 
Ig Y antiserum from these eggs constituted the baseline Ig Y antibodies and has no reaction 
to the immunogen in question that is GST -JSp26. This baseline antiserum is equivalent to 
pre-bleed sera in rabbits. 
The prepared emulsion was used immediately by injecting 50J,tg of immunogen 
intramuscularly on either side of the breastbone of two hensY3 and Y4. Hens Y3 and Y4 
were immunised with about 0.900ml of sample per hen. The area that lies to the left and 
right of the breastbone that is free of feathers is the muscular part of the body of the hen. 
Before injecting, the area is swabbed with a disinfectant and then the needle is plunged into 
the muscle. The needle is not pulled out directly, but turned round and round about five 
times, so that it could be pulled out easily from the muscle. The chicken is returned to the 
cage and fed. Thereafter eggs were collected on a daily basis and kept at 4°C. These eggs 
provided the 2-week post-inoculation antisera. 
After two weeks, a booster injection was given using a similar amount of immunogen 
together with Freund's incomplete adjuvant. Booster injections are essential to obtain 
antisera of high titre and avidity (good fitting antibody). 
Two weeks after the first injection, chicken Y3 developed swellings on either side of the 
breastbone, but this was not considered a problem. Chickens were immunised a month 
later, as well as a further month and 10 days thereafter. Eggs were collected on a daily 
basis from the time of immunisation. 
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2.2.9.1.3 Procedure for the Isolation of IgY from Chicken Egg Yolks 
Eggs were separated from the egg whites and washed carefully under running water to 
remove all traces of albumen. The yolk sac was punctured and the yolk released into a 
measuring cylinder, so that the volume of yolk could be determined. Two volumes of 
100mM Na-phosphate buffer pH 7.6 was added to the yolk and thoroughly mixed. Solid 
PEG (Mr 6000) was added to 3.5% (m/v) and dissolved by gentle stirring. PEG was used 
for the fractionation of the egg yolk (PoIson et ai, 1980). The precipitated vitellin fraction 
was removed upon centrifugation at 5000rpm for 30 min at room temperature by filtering 
the supematant through absorbent cotton wool to remove the lipid fraction. The PEG 
concentration was increased to 12% by adding 8.5% (m/v) to the supematant. The solution 
was mixed thoroughly and centrifuged at 10,000 rpm for 15 min at room temperature. The 
supematant was discarded and the pellet dissolved in PBS buffer in a volume equal to that 
obtained after filtration. The final PEG concentration in the solution was increased to 12% 
(m/v). The solution was mixed thoroughly by stirring and centrifuged as before. The 
supematant fluid was discarded and the final antibody pellet dissolved in 1/6 ofthe original 
egg yolk volume using PBS pH 7.6 (PoIson et ai, 1980; PoIson et ai, 1985). 
2.2.9.1.4 Collection and Storage 
The antibody was stored in the presence of 0.02% Sodium Azide at 4°C. The Sodium 
Azide was used to preserve the Ig Y. 
2.2.9.2 Polyclonal Antiserum used in Enzyme-linked Immunoassays 
2.2.9.2.1 Effectivity of Polyclonal Antiserum in an Immunoblot Assay 
SDS-P AGE gel was prepared as in section 2.2.4. GST -JSp26 (lOOj.tg) was run on a 
prepared 12% SDS-PAGE gel. The following antisera were used: 
Y3 (BASELINE 111111998) 
Y3 (WEEK 1-7/11/1998) 
Y3 (WEEK 2-1211111998) 
Y3 (WEEK 3-2111111998) 
Y3 (WEEK 4-29/1111998) 
Y3 (WEEK 5-0611211998) 
Y3 (WEEK 6-1311211998) 




The immunoblot assay was perfonned as described in section 2.2.7.2. Anti---<;hicken 
antibody (Sigma Aldrich, USA) was used as the enzyme-labelled conjugate for the 
antiserum prepared in chicken and Protein-G (Sigma Aldrich, USA) for the others. 
2.2.9.3 Use of Polyclonal Antiserum used in Enzyme-linked Immunoassays 
2.2.9.3.1 Indirect Enzyme-linked Immunoassay 
Wells of nunc microtitre plates (Nunc-Immuno Module MaxiSorp F8 Frame, catalogue no. 
469949), NUNC Brand products, Denmark) were first coated with GST -JSp26 antigen 
(9f..tg or 22.5f..t1 in 1777.5f..t1 of 0.05M carbonate-bicarbonate buffer pH 9.6 starting with 
1f..tg/well in the first row and serially diluted across the plate, with the most concentrated 
antigen to the left of the plate and the least concentrated towards the right. After blocking, 
antiserum from the eighth week after inoculation was used as antibody at a 1110 dilution. 
The antibody was added in a serial dilution down the plate with the most concentrated in 
the top row and the most dilute at the bottom (1110-111280). The protocol followed was 
that of section 2.2.8.1. 
2.2.9.3.2 Use of the Different Antisera Extracted against GST -JSp26 Fusion Protein 
Wells of nunc microtitre plates were coated at 10nglwell (results obtained from indirect 
immunoassay section 2.2.9.3.1). Wells were blocked, antisera from section 2.2.9.2.1 were 
diluted 115 and added in a serial dilution down the plate. The method thereafter was as per 
section 2.2.8.1. 
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2.2.9.3.3 To Determine the Effect if any upon the addition of GST to the Antiserum 
in an ELISA 
Two rows of wells of nunc microtitre plates were coated at 10nglwell for both GST -JSp26 
and GST -HIVp24 and blocked as in section 2.2.8.1. Antiserum (IgY GST -JSp26) 
extracted from the fifth week (6/12/1998) was used. The antiserum was treated as follows 
and added to the test wells as presented in Table 2.5. 
Table 2.5 Different Concentrations of GST (1.6"glql) Added to a Constant Amount of GST-
JSp26 Antibody (IgY) 
ROW A B C D E F G H 
AB! 1150 1150 1150 1150 1150 1/50 1/50 Blocking 
buffer 
GST 10 ~l 5 ~l 1 ~l 1 ~l of 1 ~l of 1 ~l of 1150 of Added only 
115 dil. 1125 dil. 11125 dil. AB only 
Total 500 ~l 500 ~l 500 ~l 500 ~l 500 ~l 500 ~l 
volume 
1: GST-JSp26Antibody-fifth week after lInmumzatlOn (6/12/1998). 
The above preparation was incubated at 37°C for 10 min. This was to allow the GST to 
bind to the GST -JSp26 antiserum. 100JlI of this preparation was added to the wells and the 
protocol for ELISA tests followed as in 2.2.8.1 . 
2.3 RESULTS 
2.3.1 Extraction of DNA from Sheep Tissue 
There are a number of protocols available for the isolation of genomic DNA as mentioned 
in 2.2.1.1. In this study the two protocols that were used (FastPrep and Salting Out 
methods), were selected for their ease of use and availability of reagents. Genomic DNA 
was isolated from normal lung (obtained from the KwaZulu-Natal Abattoir based in Cato 
Ridge) using the Salting out method. The FastPrep method was used in the isolation of 
genomic DNA from sheep muscle tissue of three Australian sheep (LPW, MSCU and 
230909). The yield of genomic DNA obtained for the different tissue is presented in the 
following Table 2.6. A 1/50 dilution (lOJlI of DNA in 490JlI water) of the DNA was added 
to a glass quartz cuvette and measured using a spectrophotometer (Beckman Du® 5 
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spectrophometer from Beckman Instruments Inc. Fullerton, California). Water was used 
first to blank: the spectrophotometer. Readings were made in duplicate and the average 
taken as the corrected optical density reading. A value of 1.8 -2.0 obtained as a 260/280 
ratio was indicative of pure genomic DNA. 
Table 2.6 Genomic DNA extracted from four sources of sheep tissue 
Tissue Extraction Starting OD OD 280 Ratio Concen.Jig! Total 
amount 260 260/280 ml or ng/Jil Yield(J12) 
LPW Fast Prep 8x200mg 0.182 0.094 1.94 455 182 
MSCU Fast Prep 8x200mg. 0.038 0.021 1.8 95 38 
230909 Fast Prep 8x200mg 0.112 0.060 1.6 280 112 
Normal Salting Out 2xl00mg 0.153 0.082 1.86 382.5 153 
lun2 
The genomic DNA isolated was used as template DNA in PCR reactions with JSp26 and 
JSorf-X primers. Other sources of DNA were also used such as JS 382 plasmid (cloned gag 
segment of a South African strain of JSRV used as a positive control), JS DNA 7 (A cell 
line derived from a JS infected Scottish sheep provided by Professor J. De Martini) and JS 
4844 (lung tissue from a natural case of exogenous OP A). These samples were obtained 
from Dr D.F. York (Department of Virology, University of KwaZulu-Natal; Nelson R. 
Mandela School of Medicine). The cloned DNA was used as positive controls for 
exogenous JSRV. 3 Australian sources of sheep muscle DNA viz. LPW, MSCU and 
230909 were also included as templates. In 1997 South Africa imported full sheep 
carcasses without the offal from Australlia and this was the only available tissue at that 
time. DNA was isolated from these tissues to investigate for the presence of endogenous 
JSRV. 
2.3.2 Amplification JSp26 gag gene 
DNA from JS 382, JS DNA 7, JS 4844, Normal sheep lung, and 3 Australian sources of 
sheep DNA viz. LPW, MSCU and 230909 were used as templates together with forward 
primer JSp26BamHl (5'tataggatccccgtcttcgaaaataacaac 3'-position, 1035-1053) and 
reverse primer JSRTp26BamHI (5' ggatcctgcatagcaatgcctgca 3', position 1699-1679) in an 
optimised PCR reaction to amplify a 653 bp fragment. The amplified fragments are 
presented in Figure 2.1. The primers used here, amplified a highly conserved region 
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corresponding to the capsid region (CA) of the gag gene of JSRV. This protein is 
recognised by anti-MPMV p27 serum (York et ai, 1992). The sequences of the capsid 
proteins obtained from amplification of endogenous JSRV (Normal lung, LPW, MSCU and 
23909) and exogenous JSRV (JS 382, JS 7 and JS 4844) DNA were analysed and aligned 
with the published sequence of a South African strain of JSRV (York et ai, 1992). 
Figure 2.1 
M 2 3 4 5 6 7 8 
oil 653 bp 
An ethidium bromide stained agarose gel (0.8%) analysis of JSp26 peR products 
(653bp) from endogenous and exogenous sources of DNA 
Lanes M. Molecular weight marker VI (Boeringher Mannheim), 1. JS 382 plasmid, 
2. DNA 7, 3. sheep 4844, 4. Normal lung, 5. Normal Australian Sheep DNA 
LPW, 6. Normal Australian Sheep DNA 230909, 7. Normal Australian Sheep 
DNA MSCU and 8. Negative 
2.3.3 Cloning of JS p26 fragments into a T -A Cloning Vector 
The PCR amplicons were purified usmg either the Wizard DNA PCR purification 
(Promega) or Qiagen DNA PCR purification system. These fragments were purified to 
remove all traces of Taq DNA Polymerase as well as any other contaminants. The purified 
products were cloned into the pMOSS T -A cloning vector based on the assumption that 
Taq DNA Polymerase adds a single 3'A nucleotide onto each amplicon. This 3'A overhang 
is used to ligate the amplicon to a compatible single T nucleotide overhang present on the 
vector. Once ligated, the recombinant plasmids were then transformed into the highly 
efficient pMOSS Blue competent cells. As mentioned in section 2.2.1.11 the 653 bp 
fragment amplified from plasmid JS 382 was used as an example throughout this study. 
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2.3.3.1 Selection of Recombinant Clones 
A quick assay used to screen for recombinants is by direct colony peR. A typical direct 
colony screen of JSp26 is presented in Figure 2.2. This reaction was performed according 
to the manufacturer's protocol (Amersham Pharmacia Biotech). 
Figure 2.2 
2.3.3.2 
M 1 2 3 4 5 6 7 8 9 10 11 
653 bp 
543 bp 
An ethidium bromide stained agarose gel (0.8%) analysis of 24 transformed 
colonies that have been screened to identify those that contain the JSp26 
recombinant fragment 
Lanes M. Marker 11 (Boerhinger Mannheim), 1-23. Clones screened to amplify fragment, 
24. Positive PCR product and 25. Negative colony 
Screening of Clones by Alkaline Lysis Method 
Those recombinant plasmid colonies that were positive upon amplification were screened 
further, using the alkaline lysis method. The purified plasmid DNA was subjected to 
restriction digest using BamHI restriction enzyme (see Figure 2.3). The pMOSS linearized 
vector is 2887 base pairs in length. The cloned fragment is 653 base pairs in size (with 
BamHI restriction sites at each end). To ensure that this is the correct recombinant clone 
and more importantly that the insert was in frame with the vector, the plasmid DNA was 
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sequenced. The sequence obtained in text format has been compared to that published by 
York et aI, 1992 and stored in the Genbank (data not shown). 
Figure 2.3 
Ml 2 Ml 
+-- 2887bp 
+-- 653bp 
An ethidium bromide stained agarose gel (0.8%) analysis ofthe products obtained 
from the BamHI restriction digest of pMOSS JSp26 plasmid showing the pMOSS 
linearized vector (2887bp) and the digested p26 fragment (653 bps) 
Lanes M. Molecular Marker VI (Boerhinger Mannheim), 1. Restriction Digest of 
pMOSS JSp26 with BamHI, 2. JSp26 peR fragment, and Mt. Molecular Marker 11 
(Boehringer Mannheim 
2.3.4 Large Scale Isolation of pMOSS JSp26 DNA and Restriction 
Digest 
A large-scale plasmid culture was purified using the Qiagen Maxi-Plasmid isolation kit 
(Southern Cross Biotechnology) (methods 2.2.1 .11.1). To prepare the insert for cloning, the 
purified plasmid DNA (lOug) was digested with BamHl overnight in a 37°C incubator and 
run on a 0.8% agarose gel. The result of this electrophoretic run is not shown here. 
2.3.5 Cloning of the Digested JSp26 Capsid Protein into pGEX-l Expression 
Vector 
The circularised expression vector was linearised by digesting the plasmid with restriction 
enzyme BamHl. This linearised pGEX-I vector was dephosphorylated to ensure that the 
vector does not re-circularise in any ligation reaction. A series of ligation experiments with 
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the vector ensured that the vector was able to participate in a ligation reaction without re-
circularising. The linearised vector together with the insert DNA (JSp26) were added to a 
0.5JlI Eppendorf microcentrifuge tube with Ix ligase buffer and 10 units (lJlI) of ligase 
enzyme and left overnight at 4 QC to incubate. The ligation samples were transformed with 
strain JM105 E.coli competent cells. Screening for recombinant clones was followed 
according to section 2.2.1.11 Recombinant pGEX-1 JSp26 clones can be seen in Figure 
2.4. This photograph displays pGEX-1 JSp26 recombinant clones obtained by direct colony 
peR. The next picture (Figure 2.5) displays recombinant clones that have been isolated by 




Ethidium bromide agarose stained gel (0.8%) depicting the peR screened pGEX-1 
JSp26 clones 
Lanes M. Molecular Marker 11 (Boehringer Mannheim), 1-23. Colonies amplified by 




M uncut! cut2 
~ pGEX-l (4900 bp) 
~ p26(653 bp) 
pGEX-l JSp26 clones isolated using alkaline lysis and thereafter digested with BamHI 
restriction enzyme 
Lanes M. Molecular Marker 11 (Roche/Boehringer Mannheim), 1. Uncut (not digested) 
pGEX-IJSp26 recombinant clone and 2. Cut (digested) pGEX-IJSp26 clone 
Confirmation of Successful Cloning of JSp26 into pGEX-l 
The positive pGEX-l p26 recombinant clones, which were obtained, were subsequently 
sequenced using the ALF DNA Sequencer. This was done to ensure that the fragment was 
inserted into the correct reading frame and aligned in the correct direction as the JSp26 
capsid gene had BamHl restriction sites at both the 5' ends. The sequences obtained upon 
sequencing of the recombinant clones in text format can be seen in Appendix A (only the 
5' end of DNA sequence of pGEX-IJSp26). This was then analysed by comparison with 
the published South African strain of JSRV that had been deposited in Genbank under 
accession number M80216 (York et aI, 1992) using DNASIS software. The sequencing 
confirmed that the fragment cloned was identical to the original sequence. The comparison 
displayed 100% homology with no amino-acid changes. 
2.3.6 Optimisation of Expression 
Mini-protein expression experiments were carried out as described in section 2.2.3 to 
ascertain the presence of expression. The presence or absence was confirmed by running 
the expressed products on a 12% SDS-PAGE gel. The samples were run alongside a 
protein calibration marker (Combithek-Boehringer Mannheim Biochemica, Cat.No. 
1317474) so that the correct size of the expressed protein would be known. The molecular 
size of Glutathione-S-Transferase (GST) is 26 kDa and that of JSp26 also 26 kDa and that 
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of the combined fusion protein 52 kDa. The expected size of the fusion protein to be seen 
on a gel is therefore 52 kDa and this is exactly what is shown in Figure 2.6. 
Once expressIOn was confirmed, a large-scale expressIOn of the fusion protein was 
performed as described in section 2.2.5 to establish optimal conditions for expression, such 
as concentration of IPTG, length of time for induction of expression of protein, sonification 









M 1 2 3 4 5 6 7 8 9 
---. 
------------. 52kDa ---. 
---. 26kDa 
---. ---. 











Calibration Protein for SDS-gel Electrophoresis (Combithek®-Boehringer 
Mannheim, Germany) 
Sonicate of E.coli JM105 cells containing a pGEX-l plasmid that codes for 
GST-JSp26. 
Pellet of sonicate of E.coli JMI05 cells containing a pGEX-l plasmid that codes 
for GST -JSp26. 
Eluate following purification of sonicate through a gluthathione agarose column 
Flow through after washing with lOmIs ofPBS. Note some of the sonicate. 
Flow through that is clear of any sonicate 
JSp26 fusion protein eluted with 10mM reduced gluthathione 
Bovine Serum Albumin (68 kDa) reference marker 
Sonicate of E.coli JM105 containing a pGex-l plasmid that codes for GST-
JSp26 that has not been induced with IPTG. 
Purified GST 
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2.3.6.1 Large-scale Expression and Purification of pGEX-IJSp26 and pGEX-l 
A culture of lL of pGEX-I-JSp26 was expressed according to the method outlined in 
section 2.2.5. Purification of GST-JSp26 was carried out using an affinity chromatography 
column packed with gluthathione agarose. Figure 2.6 shows the lysate expressing GST -p26 
that was loaded onto an immobilised gluthathione column and the various washes that 
were carried out, as well as the purified protein that was thereafter eluted from the column. 
2.3.6.2 Estimation of Protein Concentration 
The concentration of fusion protein eluted from the gel was determined using the Bio-Rad 
DC Protein assay as described in section 2.2.6.2. A protein standard was set up against 
which the concentration of the unknown fusion protein was estimated. The protein used for 
the standard being Bovine Serum Albumin. The concentration of the standard protein 
(known) used, the unknown amount used for GST, and that of the unknown GST-JSp26 
fusion protein is shown in Table 2.7. A standard curve was drawn for this as can be seen in 
Figure 2.7 and from this curve; the approximate concentration of the fusion proteins was 
extrapolated. From the Standard Curve (not shown) the concentration of GST at an 
absorbance of 0.0338 is equivalent to 8000ng. Therefore a volume of 4J.lI of GST contains 
8000ng of protein and IJ.lI has a volume of 1600ng protein. Figure 2.8 shows a SDS page 
analysis of GST -JSp26 in relation to GST alone. 
Table 2.7 Absorbance and Concentration of BSA and GST Protein 
X Absorbance at 750nm 0.0015 0.0038 0.0129 0.0232 0.05 0.0714 
37 
Y Volnme of BSA in "I 0 10 20 40 80 100 
(lOOngl"l) 
Volume of water in "I 100 90 80 60 20 0 
Absorbance of GST 0.0042 0.0307 0.0338 0.0591 
Unknown concentration of GST "I 0 1 2 5 
Volume of water in "I 100 99 98 95 
Absorbance of JSp26 0.038 0.054 
Unknown conc.of JSp26 in "I 20 40 
Volume of water in "I 80 60 
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PROTEIN CALIBRATION CURVE 
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ABSORBANCE at 750nm 
Figure 2.7 Protein Calibration Curve for Bovine Serum Albumen 
From the Standard Curve of BSA, the fusion protein GST -JSp26 has a concentration of 
200ng/1l1. 
Figure 2.8 




12% SDS-PAGE Analysis of the GST-JSp26 Affinity Chromatography 
purified fusion protein 
Lanes M. Protein Calibration Marker, 1. GST -JSp26 Fusion Protein-52 kDa and 
2. GST-26 kDa 
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2.3.7 Immunoblot Detection 
The antigenicity of the purified GST -p26 fusion protein was evaluated by means of an 
immunoblot detection assay as described in section 2.2.7. The purified GST -p26 fusion 
protein, GST and Bovine Serum Albumin (negative control) was fractionated on a 12% 
SDS-page gel using a Mini-Protean®II Dual Slab Cell (Biorad) apparatus and transferred 
to a nitrocellulose membrane using a Trans-blot electrophoretic transfer cell (Biorad). The 
SDS-page gel was run in duplicate. The membrane was processed using anti-MPMV and 
anti-GST antibody and horseradish-peroxidase Protein G (anti-goat IgG horseradish-
peroxidase conjugate) and 4-chloro-l-Naphthol substrate. The results for the immunoblot 
detection of GST-p26 fusion protein using anti-MPMV are shown in Figure 2.9A and that 
of Figure 2.9B is an immunoblot assay displaying the reaction between GST -JSp26, GST 
and BSA with anti-GST being used as antibody. 






A Western blot analysis of GST-JSp26 fusion protein using: (A) anti-
MPMV sera and (B) anti-GST 
Lanes: M. Rainbow Protein Marker (Amersham Life Sciences, UK), 1. 3/-lg of 





2.3.8 Use of JSRVp26 fusion protein in an ELISA 
2.3.8.1 Enzyme-linked Immunosorbent Assay (ELISA) 
Once the antigenicity/immunogenicity of the JSRVp26 fusion protein was confirmed to 
cross-react with anti-MPMV antibody in an immunoblot assay, further experiments were 
performed to test whether this antigenicity was also true for sera obtained from sheep 
positive for OP A using a microtritre plate format. Most of the sera used in the following 
experiments were obtained from Ondersterpoort Veterinary Research Centre in Pretoria. 
Diagnosis of the sheep was based upon pathological examination of the lungs of the sheep 
during post-mortem. Antibody to Mason-Pfizer monkey virus was used as a positive 
control and negative sheep serum as negative control. 
2.3.8.1.1 Indirect or non-competitive Enzyme-linked Immunosorbent Assay 
The JSRVp26 fusion protein was coated onto the wells of microtitre plates (Nunc 
maxisorb) starting with a concentration of 125~g (500~1) in 2000~1 of 0.05M carbonate 
bicarbonate buffer. The antigen was coated in serial dilution down the plate starting with 
1/5 (25~g) and ending at 1/80 (0.19~g) with the most concentrated solution in the top row 
and the most dilute in the bottom row. Sheep sera used as antibody was obtained from 
Onderstepoort as well as a Merino sheep farm in Uitenhage. Five of the sera (Bruwer, 05, 
013, and R3) were used at both a 1/5 and 1/10 dilutions. Two sera (1S784 and JS1943) 
were used at a 1/5 dilution. MPMV antibody was used at 1/5000. The negative sheep 
serum was used at a dilution of 1110 in blocking buffer. Protein G at a dilution of 114000 
was used as the conjugate that was linked to peroxidase. Following the addition of the 
substrate (OPD), ten-minute incubation and stopping of the reaction, the plates were read 
at 492 nm using the Biorad microtitre plate reader. The absorbance readings are presented 
in a tabulated form in Table 2.8. 
TABLE 2.8 
SERA - BR 
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Investigation into the use of the GST -JSp26 fusion protein as a possible antigen 
(125Qg in buffer) to detect the presence of JSRV antibodies in sheep sera using an 
indirect ELISA (enzyme linked immunosorbent assay) 
DILUTION OF DIFFERENT SHEEP SERA USED 
BR 05 05 013 013 R3 R3 784 1943 MP/MV 






25 105 133 158 131 127 118 134 087 160 520 245 
12.5 208 194 123 103 103 103 120 082 107 529 210 
6.25 107 154 063 063 092 065 106 054 049 407 148 
3.13 041 057 050 055 052 068 064 061 058 390 090 
1.57 045 042 056 052 062 063 089 064 044 456 059 
PoslN eg Cut-off values greater than 101 (ave. of negative sera x 1.8) regarded as positive. 
The negative control showed no reaction to the fusion protein as is expected. The antibody 
used as a positive control (MPMV) was used at 115000 and showed lower absorbance 
values than expected. Background absorbance was taken as 101 (calculated by multiplying 
the mean of the negative by a constant factor of 1.8). One of the concerns that were 
expressed was whether the expressed protein was purified of all bacterial proteins. To 
assess this, a control protein also expressed in pGEX was purified using the same method 
and microtitre wells coated at a similar concentration. 
2.3.8.1.2 Use of Indirect ELISA to Determine the Specificity of the GST -p26 Fusion 
Protein. 
The following experiment was designed to assess the specificity/purity of the GST 
expressed JSp26 protein. Equivalent concentrations of GST-JSp26 (0.250p,g/pJ) and GST-
HNp24 (0.250Ilg/IlI) antigen were coated onto microtitre plates starting with a 1110 
dilution of each antigen. Serum from Bruwer sheep was used as the antiserum against both 









TABLE 2.9 ELISA results showing absorbance readings when Bruwer (JS positive sheep serum) 
serum was used as antibody at a dilution of 1110 to 11320 against antigen GST-JSP26 
AB (BRUWERl -+ 1110 1120 1140 1180 11160 11320 
(Antigen] in pg/well 
1110 12.5 0.400 0.352 0.231 0.208 0.098 0.134 
1120 6.25 0.394 0.182 0.263 0.280 0.094 0.101 
1140 3.13 0.264 0.161 0.157 0.193 0.114 0.126 
1180 1.56 0.223 0.160 0.168 0.176 0.129 0.192 
11160 0.78 0.221 0.129 0.123 0.165 0.156 0.165 
11320 0.39 0.247 0.158 0.153 0.157 0.132 0.197 
11640 0.20 0.267 0.186 0.140 0.127 0.129 0.192 
111280 0.10 0.232 0.165 0.155 0.126 0.127 0.245 
500~1 (125pg) ill 2000ul of buffer, see 2.3.8.1.1 
TABLE 2.10 ELISA results showing absorbance readings when Bruwer serum was used as 
antibody at a dilution of 1/10 to 11320 against antigen GST -HIVP24 
AB (BRUWER) -+ 1/10 1/20 1140 1180 11160 11320 
(AntiS!en] in pg/well 
1110 12.5 0.509 0.377 0.360 0.204 0.138 0.097 
1120 6.25 0.381 0.246 0.190 0.142 0.131 0.102 
1140 3.13 0.390 0.238 0.195 0133 0.127 0.113 
1180 1.56 0.293 0.271 0.181 0.152 0.122 0.122 
11160 0.78 0.468 0.256 0.168 0.162 0.128 0.117 
11320 0.39 0.384 0.306 0.162 0.138 0.120 0.126 
11640 0.20 0.519 0.304 0.163 0.154 0.119 0.143 
1/1280 0.10 0.422 0.282 0.153 0.129 0.106 0.121 
125pg ill 2000ul ofbufIer 
The results presented in both Table 2.9 and 2.10 revealed that the antibody (Bruwer serum) 
is reactive to both GST -JSp26 and GST -HIV p24 antigens and showed no difference. 
Various experiments were made in an attempt to compete out or absorb out antibodies that 
were non-specifically present in the Bruwer serum to establish if indeed there were specific 
antibodies to the JS p26 capsid proteins. The conclusion was that the concentration of 
antibodies to the JSp26 in the Bruwer serum was low. A comparison is shown in Table 
2.11 where the Bruwer serum is used against both JSp26 and HIVp24 expressed and 
purified proteins following an attempt to absorb out the non-specific proteins using the 




A comparison between the JSp26 and HIV p24 expressed proteins using the sera from 
a sheep with JSRV before and after absorbing out the sera with the HIV p24 proteins. 
BRUWERAB 
AB- 1/5 BRUWERAB ABSORBED OUT WITH 
HIVP24AG 
[Anti2en] in pg/well JSp26 HIVp24 JSP26 HIVP24 
1110 12.5 0.400 0.509 0.110 0.306 
1120 6.25 0.394 0.381 0.131 0.245 
1140 3.13 0.264 0.390 0.106 0.166 
1180 1.56 0.223 0.293 0.092 0.134 
11160 0.78 0.221 0.468 0.092 0.106 
11320 0.39 0.247 0.384 0.098 0.107 
11640 0.20 0.267 0.519 0.106 0.141 
111280 0.10 0.232 0.422 0.099 0.222 
From the results in Table 2.11, it can be seen that the addition of the competitor did lower 
absorbance readings obtained for both OP A and RIV. 
The conclusion that was arrived at was that the Bruwer antiserum (as an example of serum 
from a naturally infected sheep with OP A) clearly does not contain any antibodies to JSp26 
or that they were present at too Iowa concentration for the sensitivity of this assay. 
The question was then asked as to whether the antibody response might be localised to the 
lungs of infected sheep. For this purpose an experiment was planned to look for the 
presence of JS anti-p26 antibodies in lung wash pellets. The only source of viral material 
that was available for analysis, were lung wash samples that had been concentrated by ultra 
centrifugation. A few samples of nasal fluid from JS affected sheep were also available. 
There were a few problems that needed to be overcome however. Firstly, a p26 peroxidase-
conjugate, using the purified GST - JSp26 protein needed to be produced. The use of an 
anti-sheep conjugate was not feasible, as it would react directly with all sheep antibodies, 
irrespective of their specificity. Secondly, the lung wash pellets were fairly old. A method 
needed to be used to demonstrate the presence of antibodies in these samples. This was 
demonstrated using Mab 59G11 (as described in the following results section 2.3.9). 
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2.3.9 The Use of MAb 59GB to Assess for the Presence of Antibodies in the 
Lung Wash and Nasal Fluid Pellets 
2.3.9.1 Indirect Antibody Enzyme-Linked Immunoassay 
One of the concerns that arose from the above studies was that we could not detect any 
anti-p26 antibodies in the sera of JSRV infected sheep. We therefore decided to look for 
the presence of anti-p26 antibodies in the lung lavage of JS affected and JS negative sheep. 
We used MAb 59Gll (MAb 59Gll is a sheep IgA specific monoc1onal antibody) to 
establish that antibodies (most specifically IgA) were present in the lung lavage samples. 
Two representative JS and NL wash pellets were diluted (l/5) and then titrated as a five 
fold dilution with 0.05M carbonate bicarbonate buffer (PH 9.6), and bound to microtitre 
plates and tested for the presence of antibodies using MAb 59Gll (see methods 2.2.8.1). 
The results are present in Table 2.12. 
TABLE 2.12 Indirect ELISA Using Mab 59Gll (Monoclonal antibody specific for sheep IgA) 
against two representative JS and NL Pellets. Both MABs were used at a dilution of 
1150 
MAB59Gll MAB59Gll 
Dilution of Antil!ens NL JS 
1/5 1.191 0.830 
1/10 1.155 0.637 
1/20 1.194 0.658 
1/50 1.309 0.699 
1/100 1.195 0.626 
1/200 0.895 0.490 
1/400 0.675 0.300 
1/800 0.244 0.192 
The results presented in Table 2.12 indicated that 59G 11 was detecting antibodies in both 
NL and JS lung. A series of JS and NL wash pellets were diluted at 1110 and 11100 with 
carbonate buffer and bound to microtitre plates and tested, as before, for the presence of 
antigen with which the MAbs reacted (see methods 2.2.8.1). The results are presented in 
Table 2.13. 
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TABLE 2.13 ELISA Test Showing Reaction to MAB 59Gll, When JS AND NL Pellets Were 
Diluted At 1110 and 11100 and Used As Antigen 
Sheep tested Number of samples %+VE %-VE 
59Gll 59Gll 
JS 16 100 0 
NL 3 100 0 
The results presented in Table 2.13 confirm that all lung wash pellets (both JS and NL) 
contain sheep IgA antibodies. The samples could then be analysed for the presence of anti 
p26 antibodies using an antigen sandwich assay. To this end a p26 peroxidase conjugate 
would need to be prepared. 
2.3.9.2 Preparation of an In-house GST -JSp26 Conjugate Labelled with 
Peroxidase 
2.3.9.2.1 Titration of Peroxidase Labelled GST -JSp26 Conjugate 
Wells of a microtitre plate were coated with the peroxidase labelled GST-JSp26-HRP in-
house conjugate. The conjugate was titrated down the plate with the most concentrated 
solution (1/100) top and the most dilute (1/7812500) in the bottom row. One row was also 
titrated with GST-JSp26 fusion protein (see methods 2.2.8.2.2 for concentration of Ag) 
only. The results of this titration are presented in Table 2.14. 
TABLE 2.14 Direct titration of in house GST-JS p26 horseradish peroxidase labelled conjugate 
Dilution of conjugate and anti2en GST-JSp26-HRP CONJ GST -JSp26 AG (12.5p2) 
11100 1.334 0.079 
11500 0.829 0.089 
112500 0.367 0.085 
1112500 0.109 0.089 
1162500 0.091 0.097 
11312500 0.094 0.137 
111562500 0.093 0.116 
117812500 0.130 0.108 
From the absorbance values presented above in Table 2.14 it was concluded that the 
conjugate could be used at a dilution as high as 112500 and still provide a good positive to 
negative ratio. It was however decided to use the conjugate GST -JSp26-HRP at a dilution 
of 1150 for the antigen capture assay. 
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2.3.9.2.2 Use of the Conjugate GST -JSp26-HRP in Two Antibody Capture Assays 
2.3.9.2.2A Use of the Conjugate against Lung Wash and Nasal Fluid Samples from JS 
Affected and Negative Sheep 
A preliminary assessment of the conjugate against seven positive and seven negative lung 
wash and nasal fluids, revealed that the optimal conditions for the conjugate to be used was 
1180 for the antigen and 1150 for the conjugate. The data confirming this was not included 
in the thesis. 
TABLE 2.15 Presentation of Data for Antibody Capture ELISA Using In-House Conjugate GST-
JSp26-HRP 









No of True Positives 0 7 
No of True Negatives 7 0 
No of False Positives 1 0 
No of False Negatives 0 1 
Percentage 87.50 87.50 
Cut-off IS 0.197 (average ofnegatlVe OD tImes 1.8) 
The data presented in Table 2.15 show that the antibody capture ELISA using the in-house 
conjugate GST -JSp26-HRP was encouraging and prompted an investigation of a larger 
number of samples. 
2.3.9.2.2B Use of Antibody Capture ELISA against a Larger Sample Size 
Eighty samples were tested using the in-house conjugate GST-JSp26-HRP. The data from 
the experiment are presented in Table 2.16. 
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TABLE 2.16 Absorbance Values Obtained for Antibody Capture Assay Evaluated against 80 
Samples 
1 2 3 4 5 6 7 8 9 10 
A 1.039 0.362 0.156 0.138 0.133 0.097 0.126 0.081 0.151 0.073 
B 0.408 0.155 0.071 0.104 0.071 0.067 0.080 0.063 0.189 0.081 
C 0.189 0.076 0.081 0.114 0.144 0.092 0.084 0.067 0.137 0.071 
D 0.102 0.059 0.066 0.063 0.062 0.095 0.135 0.074 0.066 0.064 
E 0.192 0.062 0.073 0.064 0.066 0.066 0.081 0.082 0.076 0.067 
F 0.235 0.069 0.101 0.068 0.065 0.065 0.066 0.066 0.065 0.069 
G 0.409 0.070 0.098 0.070 0.073 0.074 0.067 0.072 0.073 0.080 
H 0.073 0.065 0.065 0.070 0.067 0.073 0.068 0.068 0.068 0.067 
ALL OD FOR POSITIVE SERA IN BOLD OD FOR NEGATIVE SERA NOT IN BOLD 
A positive cut-off value of 0.132 was calculated from the average absorbance values 
obtained for the three negative samples times a constant value of 1.8. 
The cut-off is therefore equal to the average of the absorbance values of calf serum plus a 
known negative (0.068+0.073+0.080) divided by 3 times l.8, which is 0.132. In the test 
there were 39 positive and 41 negative samples. A summary of the results is presented in 
Table 2.17. The positive samples were from field cases obtained from the Ondersterpoort 
Veterinary Research Institute (Pretoria) and were diagnosed with OPA at post-mortem and 
histologic ally confirmed. 
TABLE 2.17 Summary of Results 
NO.OF POS. (39) 
True Positive 12 
True Negative 0 
False Positive 0 
False Negative 27 
Sensitivity = 12/39 (31 %) 
Specificity = 37/41 (90%) 
NO.OF NEG. (41l % POSITIVE % NEGATIVE. 
0 20 0 
37 0 80 
4 25 0 
0 0 42.18 
From the data presented in Table 2.17, it can be seen that although the in-house conjugate 
was able to detect a few positive samples the assay clearly lacked sensitivity. The 
specificity was a little better but is still not acceptable as a diagnostic tool for OP A. 
2.3.9.3 
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Applications of GST -JSp26 Polyclonal Antibodies to Detect Antigen in JS 
Positive Samples 
All investigations designed to look for antibodies to JSp26 in sera and lung fluid revealed 
that very few anti-p26 antibodies, if at all in some cases, were being produced. There was 
now a need to develop a method to look for the presence of the JSRV p26. The tool 
required was an anti p26 antibody. This was achieved by making anti-p26 antibodies in a 
chicken. 
2.3.9.3.1A Assessment of the chicken anti-p26 Polyclonal serum using an Indirect 
ELISA 
To test for the presence of anti-p26 antibodies the purified GST-JSp26 antigen was diluted 
1110 with carbonate bicarbonate buffer (PH 9.6), so that IJ.tg of antigen was bound to each 
well of the first row of a micro titre plate, The antigen was then titrated across the 
microtitre plate, with the most concentrated antigen being towards the left of the plate and 
the less concentrated on the right of the plate. The antiserum (Y3 of 25/12/98-8 week after 
immunisation) was used at a 1110 dilution and titrated down the plate, with the highest 
concentration at the top and weakest towards the bottom. The checkerboard titration of 
antigen against antiserum is presented in Table 2.18. 
TABLE 2.18 Titration of Antigen (GST-JSp26) and Antibody (Y3) 
AI! GST- JS-p26 ~ concentration of GST-JSp26 (nanograms/well) 
lb 1000 500 250 125 62.5 31.25 15.62 7.81 3.90 1.95 0.97 0.49 
1110 >3 >3 >3 >3 >3 >3 >3 >3 >3 >3 2.38 0.82 
1120 >3 >3 >3 >3 >3 >3 >3 3.13 1.62 1.07 0.91 0.63 
1140 >3 >3 >3 >3 >3 >3 >3 2.50 1.30 0.94 0.92 0.68 
1180 >3 >3 >3 >3 >3 >3 >3 2.31 1.21 0.63 0.53 0.32 
11160 >3 >3 >3 >3 >3 >3 2.61 1.26 0.65 0.67 0.38 0.28 
11320 >3 >3 >3 >3 >3 2.75 2.19 1.24 0.56 0.67 0.36 0.22 
11640 >3 >3 >3 >3 0.44 1.554 0.99 0.98 0.89 0.63 0.45 0.17 
111280 >3 >3 >3 2.62 1.07 0,63 1.23 1.35 1.41 1.26 0.67 
The results in Table 2.18 show that no end point was reached for the antibody titration. 
There is still a strong response even at 1 Ongl J..ll of antigen. 
97 
2.3.9.3.1B Indirect ELISA Utilising the Different Antisera Extracted Against Both 
GST -HIVp24 and GST -JSp26 
Eggs were collected from a number of time points following immunisation. To determine 
which collection point had the highest titre of antibodies all collection points were tested 
against lOng of JSp26 protein. 
Using the results obtained from Table 2.18, lOng of antigen per well was diluted in 
carbonate buffer and bound to the microtitre plate and tested for the presence of antigen 
using the extracted antisera. The antisera were used as follows: 
1: Baseline antiserum 31110/98 
2: 7 days 8/11198 
3: 12 days 12/11198 
4: 22 days 22/11198 
5: 29 days 29/11198 
6: 35 days 6/12/98 
7: 42 days 13/12/98 
8: 54 days 25/12/98 
The antisera were diluted starting at a 115 dilution and going down the plate ti1111390625. 
The results are presented in Table 2.19 (for GST-JSp26) and Table 2.20 (for GST-
HIVp24). 
TABLE 2.19 TITRATION OF DIFFERENT ANTISERA AGAINST A CONSTANT AMOUNT OF 
GST-JS p26 ANTIGEN 
Time points -+ 
Ab ~ 1 2 3 4 5 6 7 8 
5 0.981 0.416 1.511 >3.00 >3.00 >3.00 1.626 >3.00 
25 0.267 0.110 0.079 >3.00 3.023 >3.00 >3.00 3.331 
125 0.092 0.051 0.146 3.054 1.649 >3.00 3.219 2.997 
625 0.055 0.040 0.060 1.666 0.558 2.614 1.879 1.211 
3125 0.031 0.057 0.048 0.739 0.153 1.258 0.712 0.123 
15625 0.045 0.045 0.042 0.255 0.068 0.425 0.230 0.260 
78125 0.060 0.061 0.069 0.176 0.235 0.435 
390625 0.249 0.240 0.318 0.264 0.311 0.381 
The results in Table 2.19 show that the antiserum extracted at 22 and 35 days after 
immunization gave the best set of absorbance values when compared to the antisera 
extracted at other times. When observing the absorbance values in column four and six the , 
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values in six are better with the antiserum giving a relatively good titration. The choice of 
antibody titre was between 115 and 11125. So an in between titre of 1150 was used. 
To confirm that the antibodies were specific to the JSp26 an equivalently expressed control 
protein was used as antigen instead of the JSp26 protein. 
TABLE 2.20 TITRATION OF ANTISERA AGAINST A CONSTANT AMOUNT OF GST-
HIVp24ANTIGEN 
1 2 3 4 5 6 7 8 
5 1.023 0.682 1.488 2.271 1.262 3.220 2.692 3.074 
25 0.575 0.168 0.654 1.706 0.610 2.315 2.262 2.141 
125 0.113 0.068 0.259 1.193 0.093 0.939 0.779 0.972 
625 0.097 0.056 0.089 0.252 0.059 0.241 0.266 0.207 
3125 0.640 0.050 0.046 0.067 0.043 0.110 0.077 0.099 
15625 0.114 0.037 0.036 0.036 0.048 0.110 0.055 0.054 
78125 0.082 0.038 0.057 0.058 0.032 0.039 0.048 0.062 
309625 0.217 0.082 0.093 0.055 0.055 0.060 
The results presented in Table 2.20 indicated that there was a cross-reaction of the antisera 
to the GST portion of the fusion protein. 
2.3.9.3.2 Effect of Adding GST to the Antiserum in an ELISA Immunoassay 
In an attempt to reduce the non-specific cross-reaction to the fusion portion of the protein, 
the sera was absorbed against the GST fusion protein. The JSp26 antiserum from the 35-
day collection was selected for this blocking out experiment. The procedure simply 
involved incubating the sera in nunc microtitre wells coated with lOng/well of GST-JSp26 
and GST-HIVp4 antigen. Incubation was at 37°C for 10 min. The antibody was added as 
presented in Table 2.21. A comparison is made using pure GSTp26 and GSTp24. 
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TABLE 2.21 Absorbance Values Presented After Addition ofGST to p26 antibody 
GST-JSP26 AG GST-HIVP24 AG 
A 10ulGST 3.300 1.254 
B 5ulGST 3.140 0.906 
C lul GST 2.985 0.915 
D lulof1l5 3.248 1.075 
E lul of 1125. 3.114 0.946 
F lul of 11125 3.179 0.987 
G AB 1150 3.088 0.827 
H Blocking buffer 0.143 0.055 
The results presented in Table 2.21 indicate that the addition of GST had very little effect 
on the reaction between antibody alone, and antibody and GST together. It is indicative of a 
reaction to the GST. Since the GST-JSp26 antigen was used to immunise the chickens, 
antibody was probably produced to the GST component of the fusion protein as well as to 
the whole antigen. At this stage we believed that we needed to produce the antiserum again, 
but this time against a JSp26 protein only. 
2.3.10 Polyclonal Rabbit Antiserum to JSRV Viral Capsid Antigen 
At about this time we were made aware of the fact that Professor De Martini of Fort 
Collins, USA, had produced a high-titred antiserum against the JSRV viral capsid antigen 
(JSp26) in rabbits. This antibody became available at a time that I was planning on re-
cloning the JSRVp26 viral capsid gene into an expression vector with a thrombin cleavage 
site. I envisaged that once I had achieved this, I could then immunise a new set of chickens 
with the JSp26 protein only. Due to the non-specificity of the polyclonal antiserum that 
had been produced in chickens, a decision was made to test the potential of this rabbit 
antiserum in both an ELISA and immunoblot assay as a diagnostic tool. 
2.3.10.1 Use of Rabbit polyclonal viral capsid antiserum in an immunoblot assay 
The sensitivity of the antiserum was tested by means of an immunoblot detection assay as 
described in section 2.2.7. Purified JSRV-GSTp26 was used as antigen. The purified 
JSRV -GSTp26 (500ng and 250ng), 1 ug of bovine serum albumen and 1 ug of GST -alone 
was fractionated on a 12% SDS-polyacrylamide gel as described in section 2.2.4 along 
with a protein calibration marker (Rainbow marker-Amersham). After electrophoresis, the 
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proteins were transferred to a nitrocellulose membrane using a Trans-blot electrophoretic 
transfer cell (Biorad). The SDS-P AGE gel was run in duplicate on two sets of gels. One 
SDS-Page gel was stained with Coomassie blue and this is shown in Figure 2.10. The 
membrane was processed using the polyc1onal antiserum at a dilution of 11250, anti-GST at 
111000 and a gold- labelled antibody at 1150 (not shown). The secondary antibody was 
horseradish peroxide Protein G (anti-goat IgG horseradish peroxidase) and 4-chloro-l-
naphthol as substrate. The results are shown in the following Figures 2.11 and 2.12. 
Figure 2.10 
2 3 4 




Lanes 1. 500 ng GST -JSp26 fusion protein, 2. 250 ng GST -JSp26 fusion protein, 
3. 1 Ilg of Bovine Serum Albumen and 4. 1.6 Ilg GST-alone 
Figure 2.11 
Figure 2.12 
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GST-JSp26 
Immunoblot Analysis of pGEX-JS p26 Fusion Protein using the Rabbit 
Viral Capsid as antiserum 
1) Protein Calibration Marker (Amersham Life Sciences, UK) 
2) and (3) pGEX-JSp26 Fusion Protein Detected by the Rabbit Viral Capsid Antiserum 
4)BSA 
5) GST-alone. Note that the Rabbit Viral Capsid Antiserum does not detect it 




Immunoblot Detection of pGEX-JSp26 Fusion Protein using Anti-GST as antiserum 
Lanes 1. and 2. pGEX-JSp26 detected by anti-GST antiserum, 3. BSA not detected and 
4. GST detected by Anti-GST Antiserum 
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2.3.10.2 Use of Viral Capsid Antibody in an Indirect Enzyme Immunoassay 
In an attempt to investigate the reactivity of the rabbit antisera to JSRVp26 an indirect 
ELISA test was performed as described in section 2.2.8.1 but a slight change in the method 
was the use of a biotinylated labelled affinity isolated goat anti-rabbit and goat anti-mouse 
that was complexed to conjugated strepavidin horseradish peroxidase as well as Protein G 
as the secondary antibody or conjugate. The wells were coated with different affected JS 
lung and NL antigens at dilutions of 115 in 0.05M carbonate bicarbonate buffer (PH 9.6) 
and tested for the presence for antigens using rabbit polyclonal viral capsid antibody. The 
results are presented in Table 2.22 
Table 2.22 ELISA Test Showing Reaction to the Rabbit Polyclonal Viral Capsid Antibody When 
JS and NL Pellets were Diluted at 115 and Used as Antigens 
Antigen 1 
Ab Rab anti Capsid 
Conjugate Protein G and 
Goat anti mouse Biotin 
Ag1/5 VCp25 VCp25 PreBleed PreBld BlkBuf BlkBuf 
Conj Anti Rab Biotin Protein G Anti RabBio Protein G Anti Rab Protein G 
Bio 
NL3310 407 JS5926/5 2109 175 III 465 287 449 115 264 199 524 220 
NL3253 331 JS4133/9 258 195 80 256 149 278 85 161 99 260 78 
NL7 223 JS481110 1474 57 128 130 154 73 181 102 115 69 148 
JS 5818/4 1523 JS4844/1 543 419 70 248 133 569 85 163 92 487 102 
JS4546/4 1625 JS3685/9 781 156 86 213 172 216 118 134 120 179 91 
JS3330/5 1719 JSp26115 3000 117 2901 219 165 132 55 113 72 119 50 
JS4084/3 1813 JSp2611l0 3000 94 2829 197 138 132 52 112 75 142 46 
JS3224 2626 JSp2611100 3000 178 2414 257 226 181 45 159 186 189 46 
PoslNeg Cut off 576.6 191.4 354 228.6 247.8 267.6 .. 1 PosItIve and negatIve lung wash pellets 
Sensitivity: 8/10 (80%) 
Specificity: 3/3 (100%) 
There was a strong reaction of the rabbit antisera against nearly all the JS positive samples 
(8/10). There was a noticeable difference between the Protein G conjugate and the Anti-
Rabbit Biotin-Streptavidin conjugate. The rabbit prebleed sera results were used to confirm 
the non-specific reaction of the normal lung antigens. 
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The above result confirmed the specificity of the rabbit anti-JSRVp26 sera. It also 
confirmed the fact that the JSp26 antigen was being expressed in the lungs of JSRV 
affected sheep, something that we had been aware of. 
104 
2.4 DISCUSSION 
For years (early 1980's) there has been much debate as to whether circulating antibodies to 
JSRV are present in the sera of sheep with OPA. M. Sharp and Herring in 1983 were the 
first to report on an immunological cross-reaction between the 27 000 molecular weight 
major core protein (P27) of MPMV and a 25 000 molecular weight polypeptide of JSRV. 
However, the p27 used as an antigen in an ELISA to screen sheep, failed to detect any 
circulating antibodies to this cross-reacting protein. It was only when the JSRV genome 
was isolated, cloned and sequenced, did it become apparent that there was an endogenous 
form of the exogenous infectious JSRV. It was then theorised that the reason why sheep 
did not make antibodies to the exogenous JSRV was because the sheep recognised the 
JSRV as self-antigens, due to the expression of the endogenous virus. The hypothesis is 
that during T -cell ontogeny there is a clonal elimination of all T -cells that recognise self-
antigens, hence, the inability of sheep to develop antibodies to the viral antigens (York et 
ai, 1992). Whilst we were aware of this hypothesis, once the virus had been cloned and 
sequenced, the tools became available to clone and express some of the actual JSRV 
antigens and investigate their potential as antigens. 
This study focused on the cloning and expression of three genes, namely, the JSRVp26, 
JSRVTM (envelope) and JSRVorf-X. The object was then to purify the expressed proteins 
and investigate their potential as diagnostic proteins. To achieve this, the cloning and 
expression of the JSRVp26 capsid protein, the ORF-X protein (of unknown function) and 
the JSRV transmembrane protein (part of the envelope gene) were therefore undertaken. 
The cloning and subsequent expression of the JSRVp26 capsid protein was successful. 
This is illustrated in figures 2.5, 2.6 and 2.8 and can be seen in Appendix A where the 
JSRV p26 gene was shown to be in frame with the GST-multicloning site. This was 
achieved by sequencing the resultant recombinant GST-JSRVp26 fusion protein (Sharp 
and Herring, 1983; Ortin et aI, 1998; Palmarini et ai, 1995; Kwang et ai, 1995). 
In this study the JSRVorf-X and TM proteins were successfully cloned. Attempts were 
made to express both the fusion proteins, but difficulties were encountered, due to the 
highly hydrophobic characteristics of these proteins (Bai et aI, 1999). Hydrophobicity 
usually leads to incorrect folding and aggregation of the expressed protein with E.coli host 
proteins and co-aggregation of the fusion protein with the bacterial membranes (Marston, 
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1986). The JSRVorf-X and JSRVTM were cloned into the correct reading frames, but 
failed to express the fusion proteins due to their extreme hydrophobicity. Even though 
optimised expression conditions were used, and denaturants such as 8MUrea, BPer 
(Pierce) and N-Lauroyl sarcosine, we were unable to successfully express these proteins. 
For purposes of this study it was decided to concentrate on the JSRV p26 fusion protein. 
One of the first things that we wanted to establish was whether the endogenous JSRVp26 
was the same as the exogenous JSRVp26 gene. To investigate this, the gene coding for the 
JSRVp26 capsid protein was isolated from three separate Australian sheep genomic DNA 
(LPW, 23909 and MSCU). The three genes were isolated, cloned sequenced and expressed 
in a pGEX-l vector. Since JSRV has never been identified in Australia, this gene could 
only be from an endogenous form of JSRV (York et aI, 1992). The cloning and expression 
of this gene was achieved with little difficulty and sequence analysis revealed that in all 
cases the exogenous JSRVp26 gene was identical to all three endogenous isolates. It was 
therefore not unexpected to find that the endogenous JSRVp26 gene was efficiently 
expressed and cross-reacted with the MPMV antiserum. As there are 15 to 20 endogenous 
JSRV loci in each sheep genome it might be argued that the primers and amplification 
conditions had favoured the isolation of the equivalent gene in all cases. Whilst this is a 
valid criticism we nevertheless established that there was an equivalent endogenous gene 
that was present in normal sheep. This was further supportive evidence for the theory that 
sheep do not produce antibodies to the JSRVp26 because it is recognised as a self-antigen. 
We nevertheless wanted to complete our investigation using a purified viral protein such as 
the JSp26 antigen, which we had not been able to achieve in the past. The purified GST-
p26 fusion protein proved to be immunogenic by its cross- reactivity with the anti-MPMV 
antibody (which is the OPA-associated p27 marker protein) in a Western immunoblot 
assay, Figure 2.9. The purified GST-p26 recombinant antigen was used in an ELISA to 
screen sheep sera for the presence of serum antibodies. The GST -p26 fusion protein was 
applied in an indirect ELISA to screen eight sera (MPMV as positive antiserum, sera from 
six known positive sheep, and one negative serum). Preliminary results were encouraging 
in that six out of eight sera were positive and the negative was not reactive (see Table 2.8). 
Unfortunately, when the capsid gene of another retrovirus i.e. HIV was used as a negative 
control it turned out that the same sheep sera were positive against this antigen (Table 2.9 
and 2.10). It was likely that the sheep had antibodies to some of the co-purified E.coli 
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proteins or to the fusion protein that was derived from S. japonicum, which is a nematode 
that could have infected these sheep. Kwang in 1995 and Ortin in 1998 made a similar 
observation when they claimed that the reactivity reflected the presence of antibodies to 
the GST fusion partner of the recombinant antigen used in the assay (Sharp and Herring, 
1983; Ortin et ai, 1998; Kwang et ai, 1995). 
The non-specificity of the reaction was confirmed when we showed that the reaction could 
be competed out using the HIV expressed fusion protein. We concluded that the non-
specificity of the reaction might be due to interactions between antibody in the sera and 
proteins that contaminate the antigen preparation, such as Escherica coli proteins as well as 
the GST component of the fusion protein that is derived from the parasitic helminth, S. 
japonicum (Smith and Johnson, 1988). Observations made show that although the sheep 
sera were cross-reacting with the GST portion of the two expressed proteins GST -JSp26 
and GST -HIVp24, it was also possible that there could be some cross-reaction between 
GST -HIVp24 and other sheep retroviral proteins that also cross-react with the GST -JSp26 
protein that is being investigated. The presence of antibodies against GST in the sheep sera 
could also be explained if the sheep had been exposed to helminths such as nematodes or 
trematodes. The Bruwer serum was also cross-reactive with the control HIV p24 that 
contained the GST fusion protein. We take into account the possibility that there may be 
cross reactive retroviral proteins that cross react to HIV p24. It is also possible that there 
may be unpurified E coli proteins in the purified preparations of the expressed proteins that 
account for the cross reacting proteins. The fact that there was no difference between the 
JS p26 and the HIV p24 antigens does suggest that the reaction was not specific, this is in 
line with the contention that there are no circulating antibodies to JSRV in sheep (Ortin et 
aI, 1998). 
All evidence so far supported the theory that JSRVp26 did not stimulate a humoral 
immune response in sheep infected with the exogenous JSRV. We therefore decided to 
investigate whether the antibody response was localised to the lungs of the infected sheep. 
Earlier experiments by York 1984 had investigated and reported on the presence of JSRV 
specific antibodies in the lungs of JS affected sheep that were not present in the lung 
lavage of normal unaffected sheep. The predominant antibodies were of the IgA sub class. 
A criticism of these early experiments was that the virus was not pure therefore the 
positive reactions could be due to cross reaction of the antibodies with non-viral proteins 
that had co-purified with the virus. Since we now had relatively pure viral antigens these 
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experiments could be repeated. To investigate this, lung lavage samples from infected and 
normal sheep lungs were analysed for the presence of JS anti-p26 antibodies. To control 
for the integrity (presence and reactivity of the antibodies in these samples which were 
over 10 years old), a mono clonal antibody Mab 59G11 (Mab 59G11 is specific sheep IgA) 
(De Martini and York, 1992) was used. An in-house JS p26 peroxidase conjugate and 
antibody capture assay (Table 2.15) was used to demonstrate that there were anti-p26 
antibodies in the lung wash samples from seven out of eight affected sheep. Only one of 
eight unaffected sheep lung wash was positive. Subsequently, a larger sample size was 
investigated using this assay and it was found that the assay was very specific but lacked 
sensitivity (Tables 2.16 and 2.17). The low sensitivity (31 %) of the assay could be due the 
fact that the lung samples were about 15 years old or that there was a low titre of 
antibodies in the lungs. Nevertheless, the results were encouraging and in line with earlier 
findings that suggested that there was a specific localised immune response to JSRV in the 
lungs of JS affected sheep. However, in view of the finding that quite a few JS affected 
lung wash samples were negative, we felt we needed to investigate alternate diagnostic 
options further. 
One of the earliest and most useful facts from a diagnostic perspective was the observation 
that MPMV antisera detected JSp26 in all lung wash samples and nasal fluids. We 
therefore decided that we should develop an antigen capture assay. Ideally we required a 
JS p26 specific antibody or polyclonal antisera. Extensive work went into the production of 
high titred JSp26 antisera in chickens. Unfortunately, a more detailed analysis of the 
antisera revealed that a significant proportion of the antisera were against the fusion 
portion of the JSp26 protein. The fusion protein was also 26 kDa (based on literature, 
Smith and Johnson, 1988)), the identical size to the JSRVp26 protein. Attempts to absorb 
out the antibodies to the fusion protein were partly successful. Subsequently consideration 
was given to cloning the JSp26 gene into another expression vector so as to remove the 
fusion protein. At this stage, we fortunately received an antiserum to the JSp26 protein 
from Professor DeMartini (University of Colorado, Fort Collins). This enabled us to 
investigate the use of this antiserum in an antigen capture assay. We confirmed the 
specificity of the antiserum using a Western immunoblot assay and went on to show that 
the antigen capture assay detected JS antigen in the lung fluid of JS affected sheep lung 
lavage and not in normal lung lavage. Even though only a limited number of sheep lung 
lavage were available for testing (Table 2.22) the results were very encouraging and 
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showed that it was possible to use the JSp26 antigen capture assay to detect JSp26 in lung 
lavage and nasal fluid (sensitivity of80% and specificity of 100%). 
Using the JSRVp26 expressed protein and antisera; we essentially confirmed earlier 
observations. The conclusions from this study can be summarised as follows: 
1. That there is a poor humoral response to the viral proteins. However this could be 
restricted to the · JSp26 protein as it was shown that an identical gene is present in 
normal Australian sheep not believed to have Jaagsiekte. 
2. That there is a localised immune response in the lungs of JS affected sheep. 
3. That there is a lot of virus present in the lungs and nasal fluids of affected sheep and 
that a JSp26 antigen capture assay could be used to identify JS affected sheep 
In VIew of the present findings, it was felt that a serological/antigenic approach to 
diagnosing JSRV was probably not the best method. More emphasis needed to be given to 
investigate the molecular diagnostic approach. 
The following chapter, therefore, focused on a molecular approach to detect the exogenous 




OPTIMIZATION AND ASSESSMENT OF A MOLECULAR 
APPROACH TO IDENTIFY THE EXOGENOUS INFECTIOUS FORM 
OF JSRV 
3.1 INTRODUCTION 
The development of a molecular diagnostic assay to identify sheep infected with 
JSRV/OPA should have been straightforward once the infectious JSRV genome was 
sequenced (York et ai, 1992). Unfortunately, the finding that there are as many as 15 to 20 
endogenous JSRV loci in all sheep genomes (York et ai, 1992; Hecht et ai, 1994), made 
the designing of a molecular assay for the exogenous JSRV more challenging. Studies 
were thereafter designed to assess the presence of any sequence differences between the 
endogenous and exogenous JSRV -related viruses that could be used to differentiate the two 
viral forms (York et ai, 1992; Palmarini et ai, 1996a; Bai et ai, 1996 and Palmarini et al 
1996b). fuitially the gag and LTR regions of both exogenous and endogenous JSRV were 
sequenced and compared (Bai et ai, 1996). One of the first useful differences that were 
identified was a unique Sea 1 restriction site (at position 1729) that was present in 
exogenous JSRV but not in endogenous forms of the virus. This Seal site was found to be 
exclusively present in the cDNA of OP A-affected sheep and not in unaffected control 
sheep (Palmarini et ai, 1996a). 
Other regions of the genome that have been studied include the U3 region of the long 
terminal repeats [LTR's] (Palmarini et ai, 1996b) and the Variable one and two regions 
found in the matrix (MA) ofthe gag gene (Hallwirth, 2004). 
A comparison of the LTR region of the exogenous JSRV with three endogenous JSRV loci 
revealed some conserved differences between the endogenous and exogenous genomes, in 
this region. These differences in the nucleotide sequences could be responsible for a 
reduction in the pathogenicity of exogenous JSRV compared to the endogenous JSRV 
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(palmarini et aI, 1996b) but for our purposes they could be used to design a molecular 
assay that could distinguish the two viruses. 
To accentuate these differences in the LTR region of both endogenous and exogenous 
JSRV, a long range PCR whose primers were based on the exogenous JSRV sequences, 
was developed to amplify and characterize six endogenous retroviralloci (Bai et ai, 1996). 
These loci could be differentiated based on their restriction enzyme profile and proviral 
genomic size. The endogenous restriction map profiles revealed that the full-length 
endogenous loci could be distinguished from their exogenous JSRV counterparts in the 
same tumour cell by the following restriction sites [Nde1, Hindll1, Seal, Kpn1 and 
EeoR1] (Bai et aI, 1996). Exogenous JSRV from different breeds had a similar restriction 
map profile. A more detailed analysis at the nucleic acid sequence level revealed that the 
endogenous LTR sequences were 94 to 98% identical amongst endogenous JSRV from 
different breeds particularly in the Rand U5 region between the endogenous loci and the 
exogenous JSRV, due to deletions and many point mutations in the U3 of the LTR (Bai et 
aI, 1996). The endogenous LTR's are longer (442-445 bp) than the exogenous JSRV (York 
et ai, 1992) sequence (397 bp) and there are two large deletions of 30bp and 16 bp at 
positions 198 and 261, respectively (Palmarini et ai, 1996b). 
The differences identified in the LTR's, gag, env and orfX genes of some endogenous 
JSRV loci have been useful in distinguishing the endogenous viruses from the exogenous 
viruses, but these data were obtained from PCR amplifications of portions of endogenous 
proviruses and not from full length sequences in the case of the endogenous viruses (Bai et 
aI, 1996; Palmarini et aI, 2000). In 2000 Hallwirth et al cloned and sequenced three full-
length endogenous JSRV loci that have been called enJS5.6A1, enJS5F16, and enJS5.9Al. 
This was the first time that it was possible to compare the full-length genomes of 
endogenous and exogenous JSRV's. When compared to the exogenous JSRV, the exJSRV 
isolates were consistently distinguishable from the enJSRVs in the structural genes in three 
variable regions called VRI, VR2 and VR3. VR1 and VR2 are found in the matrix (MA) 
region of gag, whereas VR3 is located in the transmembrane region of the env gene 
(Palmarini et aI, 2000). VR1 covers nucleotides 624 to 661 (based on JSRV 21) and is a 
proline rich area. Downstream of VR1 (50 amino-acid residues), another region of 
polymorphism between the exogenous and endogenous viruses is located and termed VR2. 
It is fairly rich in proline for both enJSRV and exogenous JSRV (palmarini et aI, 2000). 
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Based on the differences in the VR1 and VR2, a molecular assay using specifically 
designed primers was developed to amplify exogenous specific isolates (Hallwirth, 2004). 
In this chapter, use will be made of the restriction enzyme and sequence differences that 
have been identified between JSRV and JSRV -related endogenous sequences to 
specifically amplify exogenous JSRV that may be present in a background of endogenous 
virus and to detect it in OPA affected animals (Palmarini et ai, 1996a; Palmarini et al 
1996b and Palmarini et ai, 2000). 
The first molecular assay that is investigated targets the LTR-gag region. A hemi-nested 
LTR-gag peR was optimized to amplify a region in the gag gene of both the exogenous 
JSRV and enJSRV related virus present in affected and unaffected tissue, and to 
differentiate them by restriction enzyme digestion using Seal (second Seal site) present 
only in the exogenous form at nucleotide position 1729 (York et ai, 1992). This is a 
definite molecular marker that can be used to identify possible reservoirs of OP A infection 
(De Martini and York, 1997). 
The second assay focused on variable regions I and 2 (VR1 and VR2). This assay uses a 
one step peR that should only amplify the exogenous virus (Hallwirth, 2004). 
The third molecular assay targets a region that is known to have major differences between 
the endogenous and exogenous viral sequences of JSRV i.e. the U3 region of the JSRV 
LTR. This assay uses a sensitive hemi-nested (hn) peR approach. The outer primers 
amplify both the endogenous and exogenous forms of JSRV and an internal hemi-nested 
primer that is specific for the exogenous forms of JSRV. This approach is both sensitive 
and specific (palmarini et ai, 1996b). 
In summary, this chapter will investigate, assess and modify (when needed) three 
molecular assays designed to identify the exogenous JSRV but equally important to 
differentiate the exogenous from the endogenous form. These three molecular assays are 
summarized as: 
1. A LTR-gag based peR that flanks a unique Seal restriction site that is only present in 
the exogenous form of JSRV. 
112 
2. A PCR based single step assay that targets the exogenous variable regions 1 and 2 
(VR1and VR2) and 
3. A hemi-nested PCR assay that targets the U3/LTR region of JSRV. 
These assays will be assessed for sensitivity and specificity against exogenous and 
endogenous cloned DNA templates as well as formalin preserved sheep lung tumor 
samples from positive and negative sheep. 
3.2 MATERIALS AND METHODS 
3.2.1 Source of DNA 
3.2.1.1 Cloned DNA 
Three endogenous proviral clones penJS5.6A1 , penJS5F16 and penJS5.9A1 were obtained 
by screening a lambda phage library from a sheep with JSRV induced OPA (Palmarini et 
ai, 1999). The lengths of the clones were 6915 bp for enJS5F16, 7939 bp for enJS5.6A1 
and 6695 bp for enJS5.9A1 (palmarini et ai, 2000). Clones provided by Dr. D.F.York. 
Plasmid mini-preps (QIAprep®Spin Miniprep Kit, Qiagen, GmbH, Germany) were used to 
purify plasmid DNA for each of the clones. OD ratios at 260nm and 280nm were used to 
determine DNA purity and concentration. 
3.2.1.2 JSRV21 
pJSRV21 is a full length JSRV proviral clone isolated from a genomic DNA library 
derived from a natural case of OP A. The full-length provirus is 7834 bp in length and 
represents the exogenous infectious form of JSRV (Palmarini et ai, 1999). The sequence of 
JSRV21 is 7455 bp in length. The cytomegalovirus promoter-driven infectious expression 
construct pCMV2JS21 is 11,537 bp in length. 
113 
3.2.1.3 JS7DNA 
The JS7 cell line originated from a culture of OP A tumour tissue obtained from an adult 
sheep (Scottish Blackface) with naturally occurring disease in Scotland in 1985 (J assim et 
ai, 1987) was provided by Professor J. De Martini. The JS7 cell line has a single integrated 
copy of the exogenous JSRV in each cell. An infectious and pathogenic JSRV provirus 
called JSRVJS7 was isolated and cloned from this cell line. The full-length provirus is 7841 
bp in length. (De Martini et ai, 2001). Please note that DNA extracts of these cells will also 
contain endogenous JSRV DNA. 
3.2.1.4 JSRV 382 plasmid 
JSRV 382 (position 953-3029) was one of the cDNA clones that was isolated from 
Lambda Zap 11 vector (Strategene). The cDNA library was made from virus purified from 
a South African sheep lung that was infected with JSRV. The cloning into a Bluescript 
vector was performed at the Veterinary Research mstitute, Onderstepoort, Pretoria by Dr 
D.F.York. The gag and pro genes of the JSRV genome formed the JSRV 382 plasmid 
(York et ai, 1992). 
3.2.1.5 Lung Tumour DNA 
Dr. J. Vorster, who had been based at the Ondersterpoort Research mstitute in Pretoria, 
donated the 22 sheep lung tumours that had been used in this study. The tumours were 
preserved in formalin. The tumour samples were examined macroscopically and 
histologically to confirm the diagnosis of OP A in the sheep (Vorster, personal 
communication). To extract the DNA, 200mg of tissue was sliced from each section using 
aseptic conditions. The scalpel blade was dipped into 99% ethanol and flamed between 
different samples to prevent cross- contamination. The tissue was sliced finely into pieces 
and then SUbjected to genomic DNA isolation as described earlier (see section 2.2.1.1). 
3.2.1.6 Australian Sheep DNA 
Genomic DNA was isolated from three unaffected Australian sheep referred to as LPW, 
MSCU, 230909, and lung (normal lung-from a normal South African sheep). Australia has 
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not had any reports of JSRV and it is believed the Island is JSRV free. As all sheep have 
the endogenous virus, the Australian sheep are a good source of negative material. (See 
section 2.3.1. for source oftissue). 
3.2.1.7 Other sources of DNA 
DNA also used in the assays included: 
Genomic DNA from sheep 4844 (South African sheep with natural OP A). 
Genomic DNA from whole blood of three local unaffected merino sheep (Claus 
Hallwirth, Univ ofKZN) 
Plasmid DNA from clone pJSRV120 (concentration of 2ng was used) obtained 
from Dr. D.F. York. (see York et aI1992). 
3.2.2 DNA Extraction Methods 
Genomic DNA was extracted from lung tissue using the BIO 101 Fast DNA Kit (BlO 101, 
Inc., La Jolla, California, USA) with the Fast PrepTM Instrument as mentioned in Methods 
(section 2.2.1.1.1). The DNA obtained with this method was suitable for PCR purposes. 
The DNA purity and concentration were determined as described below (see section 3.2.3). 
3.2.3 DNA Quantitation 
Extracted DNA was diluted 11200 with sterile water and the absorbance measured at both 
260 and 280nm using the Beckman DuR-5 Spectrophotometer (Beckman Instruments Inc. 
Fullerton, California) as described in Methods 2.2.1.2. 
3.2.4 The Polymerase Chain Reaction 
3.2.4.1 PCRPrimers 
The nucleotide sequence and positions of the oligonucleotide primers used have been 
numbered according to the JSRV genome (York et ai, 1992) and are shown in Table 3.1. 
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TABLE 3.1: Primers Utilized in the PCR Reaction 
L TR-gag with Seal digest Sequences Positions * 
PI TGG GAG CTC TIT GGC AAA AGC C 7210-7224 
P2 ATA CTG CAG CCC GAT GGC CAG 1806-1826 
P5 GCT GCT TIG AGA CCT TAT CGA AA 1600 -1622 
(PaImarini et ai, 1996a) 
VRINR2PCR Sequences Positions* 
JS21-613f CTA GTT ATG ATC CTC CTC CTC CTC CT 613 - 638 
JS21-976r AAG GCC CTT TGT AGG GGA GAC AT 953 - 976 
(Hallwirth et aI, 2004; Hallwirth, c., personal communication) 
U3/LTR H-nested PCR Sequences Positions* 
PI TGG GAG CTC TIT GGC AAA AGC C 7210-7224 
P3 CAC CGG ATT TTI ACA CAA TCA CCG G 7361 -7385 
P3M CAC CGG ATT TIT ACA CAA TCA CCG 7361 -7384 
P4 TGA TAT TIC TGT GAA GCA GTG CC 7316-7338 
(Palmarini et ai, 1996a) 
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Genomic structure of JSRV showing the approximate location of primers used as indicated by arrows for the three 
molecular assays used in this Thesis: LTR-gag hemi-nested (*), VIN2 (*) and the U31L TR hemi-nested (*) peR assays. 
Also shown are the sizes of the amplified products in bp. In the case of the L TR-GAG product, the position of the Seal 
site is indicated. The numbered bar at the bottom indicate distances in kb. ...... ...... 
0'1 
3.2.4.2 Single Step peR 
The following reagents (Table 3.2) were used in a one-step PCR. 
Table 3.2 Reagents used in the PCR reactions 
Reagent Volume for reaction 
Variable region 1 and LTR-GagPCR U3ILTRPCR 
2PCR 
10X reaction buffer with S)lJ S/11 S/11 
2.SmMMgClz 
dNTP mix 2.SMm stock 4/11 (200/1M) 10/11 (SOO/1M) 4/11 (200/1M) 
Forward primer 1/11 (20pmoles) 1/11 (lSpmoles) 1/11 (6.2Spmoles) 
Reverse primer 1/11 (20pmoles) 1/11 (lSpmoles) 1/11 (6.2Spmoles) 
*Template x/11 Y/11 z/11 
2%DMSO 0/11 1/11 0/11 
DH20 39/1I- x /11 32/1I-Y/11 39/1I-z/11 
Taq 1u//11 2/11 2.S/11 1.5/11 
Final volme SO/11 SO/11 SO/11 
*Dilutions of DNA templates from lng down to lfg were used ID a total volume of S/11 
x, y, and z refer to volumes of DNA template. 
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Plasmid DNA from JSRV 21 (100ng/Jll), JSRV 7 (813ng/Jll), enJSRV5.6Al (216ng/Jll), 
enJSRV5.9Al (174ng/Jll), enJSRV5F16 (250ng/Jll) and JS 382 (6200ng/Jll) were diluted to 
Ing/Jll. Ten-fold dilutions ranging from 100pg/Jll to lfg/Jll were made from the Ing/Jll 
dilution. These lO-fold dilutions were used such that 5JlI contained for example lng and 
this was added to 45Jll ofPCR master mix containing the reagents as seen in Table 3.2. 
Exogenous plasmids DNA from clone JS 120 (lng/Jll) and from the three JSRV 
endogenous plasmids were also used at concentrations of 2ng in the PCR. Genomic DNA 
from sheep 4844 infected with JSRV/OPA, and from lung tumours of 22 sheep infected 
with JSRV were included. Endogenous JSRV genomic DNA templates were provided by 
three Australian sheep LPW, 230909, and MSCU, three merino sheep, and lung from 
normal sheep. The genomic DNA templates were diluted such that there were 500ng of 
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DNA per 10/l1 added to 40/l1 of peR master mix containing the reagents as seen in Table 
3.2 
The peR cycling conditions for the peR assays are presented in a tabulated form in Table 
3.3. The Eppendorf Gradient cyeler (Eppendorf, Netheler-Hinz. GmbH, Germany) was 
used for the purposes of the VRl and VR2 peR. The Perkin Elmer 9600 thermal cyeler 
(P.E. Biosystems) was used for the other peR reactions (LTR-gag and U3ILTR peR). 
Table 3.3 PCR Cycling conditions 
PCR Cycling Conditions 
VRl and VR2 PCR LTR-gagPCR U3ILTRPCR 
1 cycle 94°C 5min 1 cycle 92°C 2min 1 cycle 94°C 1 min 
35 cycles 94°C 35 sec 10 cycles 92°C 10 sec 35 cycles 94°C 30 sec 
55,6 +/- 0,3 °e 50sec 61°C 30 sec 59°C 1 min 
n oe 25 sec *68°e 90 sec n oe 1 min 
*11-30 cycles: progressive 
increase of 20 sec per cycle for 
step 3 
extension n oe 5min extension 68°C 7min extension noe 3 min 
3.2.4.3 Hemi-nested peR 
The following peR assays (LTR-gag and U3/LTR) were hemi-nested with differing 
concentrations of reagents and cyeling conditions as shown in Table 3.4. One micro litre of 
the first round of amplification from the first step (section 3.2.4.2) peR reaction was added 
to 49/l1 of second round peR master mix. The reagents and volumes for this master mix 
are presented in Table 3.4. 
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Table 3.4 Reagents and volumes (,.1) used in PCR reactions 
Reagent Volume for reaction 
LTR-gag hn PCR U31L TR hn PCR 
lOX reaction buffer with 2.5mM MgCh 5.51l1 5 III 
dNTP mix 2.5mM stock 4 III 4111 (200IlM) 
Forward primer I III I III (6.25pmoles) 
Reverse primer I III I III (6.25pmoles) 
*Template I III I III 
DH20 37.51l1 38111 
Taq 1u/IlI 1.251l1 1.51l1 
Final volume 5Oll1 50lll 
Cycling conditions for the hemi-nested PCR differ to that of the one-step PCR. These 
cycling conditions are presented in Table 3.5. 
Table 3.5 Cycling condition for hemi-nested PCR 
PCR Cycling Condition for Hemi-nested assays 
LTR-gag Hemi-nested PCR U31L TR Hemi-nested PCR 
1 cycle 94°C 1 min 1 cycle 94°C 1 min 
35 cycles 94°C 45 sec 35 cycles 94°C 30 sec 
57°C 60 sec 57°C 1 min 
n oc 60 sec n oc 1 min 
extension noc 2min extension noc 3min 
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3.2.4.4 Restriction Digest of peR fragments 
Half of the PCR product (25111) obtained from the hemi-nested LTR-gag PCR in section 
3.2.4.3 was digested with IOu of Seal (Roche Diagnostics, Mannheim, Germany) enzyme 
and the appropriate buffer H supplied by the manufacturer at 37°C for one hour in a 
Labotec incubator. The digested products were run in parallel with the undigested products 
on a 2% ethidium bromide stained agarose gel together with a DNA molecular standard 
(Roche Diagnostics, Mannheim, Germany). 
3.2.4.5 Sensitivity Titration 
To investigate the sensitivity of the assays, five plasmids (see section 3.2.4.2) were titrated 
starting at lng and going down to lfg to determine which of the three PCR assays (see 
sections 3.2.4.2 and 3.2.4.3) was specific and sensitive enough to be used to test further 
infectious tumour samples. 
3.2.4.6 Agarose Gel Electrophoresis 
Amplified products were detected by electrophoresis of 10J1.1 of sample through a 2% 
agarose gel containing 0.5J1.glml ethidium bromide (Chapter 2: Methods-section 2.2.1.8.1). 
A more concentrated agarose is used here because the final amplified product was between 
90 bp to 250 bp in size. The amplified products were run alongside molecular weight 
marker IX (Roche Diagnostics, Mannheim, Germany). 
3.2.4.7 Viewing and Photography of Gels 
Agarose gels were visualized using a SYNGENE Gene Genius imaging system that is 
comprehensive and fully automated gel documentation and analysis system (SYNGENE, a 
division of Synoptics Ltd, UK) that is attached to a computer. Once the image is captured, 
it can be stored or improved using the Gene tool software and eventually printed using the 
HP Laser Jet 1100 printer. 
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3.3 RESULTS 
3.3.1 An Assessment of three Molecular Assays to determine their sensitivity and 
ability to distinguish the endogenous from the exogenous infectious form of 
JSRV 
Three endogenous plasmids (penJSRV5F16, penJSRV5.6A1 and penJSRV5.9A1), an 
infectious JSRV clone JSRV21 and JS7 DNA were diluted lO-fold from 1ng down to lfg 
and used as templates for the three molecular assays, the LTR-gag hemi-nested peR, 
Variable region 1 and 2 and the U3/LTR hemi-nested peR. The genomic structure of 
JSRV showing the approximate locations of primers used in the three molecular assays 
mentioned can be seen in Appendix B. 
3.3.1.1 Titration of Plasmids using the L TR-gag hemi-nested peR and Seal 
enzyme digestion 
Primers PI and P2 (see methods Table 3.1) were used in the first round peR to amplify 
both the endogenous and exogenous target gene that flanked the unique Seal site. To 
improve the sensitivity, a hemi-nested second round of amplification was performed using 
primers P5 and P2 (see Table 3.1). The second round amplified a gag product of 229 base 
pairs (see Fig. 3.2) for JS 7 (exogenous and endogenous JSRV), JS 21 (exogenous), JS382 
(exogenous), JS5.6A1 (endogenous), JS5.9A1 (endogenous) and JS5fl6 (endogenous). 
The amount of DNA used was the same for each of the clones and the lanes at which the 
DNA is detected are shown in bold. 
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M 28 29 30 31 3233343536 M 37 38 39 40 41424344 
Ethidium bromide agarose gel (2%) analysis of the hemi-nested LTR-gag peR 
showing different dilutions of exogenous and endogenous JSRV plasmids to determine 
the specificity and sensitivity of the test 
Lanes M. Marker IX, Lanes 1-7 dilutions ofen+exJS 7 from I fg, 10 fg, 100 fg, I pg, 
10 pg, 100 pg and I ng; Lanes 8-14 dilutions ofexJSRV 21; Lanes 15-21 dilutions ofexJS 
382 from I fg to I pg; Lanes 22-28 of enJSS.6AI ; Lanes 29-35 of enJSS.9AI; Lanes 36-
42 of enJSSFl6 showing a product size of 229 bp before Seal digestion. Lane's 43-44 
negative controls. The lanes in bold indicate those concentrations at which the 229 bp 
product was detected. 
On digestion of the 229 bp products with Seal, only the exogenous infectious clones were 
digested to two products of sizes 131 bp and 98 bp (see Fig. 3.3). This Seal restriction site 
in the gag gene represents an important molecular marker for the exogenous form of 
JSRV. The result of this hemi-nested LTR-gag peR titration is presented in Figure 3.2 and 
that of the Seal restriction enzyme digest in Figure 3.3. Note the two products of 131 bp 
and 98 bp that are only present in the exogenous form. Figure 3.3 also shows lane 4, lane 5 
and lane 6 as uncut fragments because these are endogenous JSRV clones and do not have 
the second Seal site. 
Figure 3.3 
3.3.1.2 
1 2 3 4 5 
U C U cuc ucuc 
---- 229 bp 133 bp 98 bp 
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Ethidium bromide stained agarose gel (2%) analysis of JSRV LTR-gag peR products 
digested with restriction enzyme Seal 
Lane 1: lng ex+enJS7, Lane 2: lng exJSRV2l, Lane 3: lng exJS382, Lane 4: lng 
enJSRV5.6Al, Lane 5: lng enJSRV5.9Al and Lane 6: lng enJSRV5Fl6. U represents 
uncut PCR product and C-cut PCR product. 
An investigation into the sensitivity and specificity of the Variable Region 1 
and 2 PCR 
The variable region 1 and 2 (VRI and VR2) PCR targets and amplifies a product of 
approximately 363 bp that should only be amplified if the exogenous form is present. 
Primers 613f (primer that binds upstream ofVRl) and 976r (primer that binds downstream 
of VR2) were used in a one-step PCR reaction on a titration of the cloned DNA. The 
sequence alignment for the VI and V2 regions of the exogenous JSRV 21, JSRV 382 or 
JSRV-SA and the endogenous enJS5.9AI, enJS5.6AI and enJS5FI6 is shown in Appendix 
B. The results ofthis titration can be viewed in Figures 3.4. 
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M123456789 MIO 111213 1415161718 M 19202122232425 2627 
Figure 3.4 
3.3.1.3 
M 28 293031 3233 343536 M 37 38 39 40 414243 44 
Ethidium bromide stained agarose gel (2%) depicting the results of the Variable 
region 1 and 2 peR. The templates were exogenous and endogenous JSRV plasmids 
ranging from 1 ng to lfg. 
Lanes M: Marker IX, Lanes 1-7: ex+enJS 7 DNA, Lanes 8-14: exJSRV 21 , Lanes 15-21: 
exJS 382, Lanes 22-28: enJSRV5.6A1, Lanes 29-35: enJSRV5.9A1, Lanes 36-42: 
enJSRV5F16 and Lanes 43-44: Negative controls. 
An assessment of the JSRV U31L TR hemi-nested peR 
The sensitivities of the JSRV U3hn peR were improved using a hemi-nested peR. A 
primer internal to the peR product, primer 4 (see Table 3.1) was paired with primer l(see 
Table 3.1) in a second round hemi-nested peR (JSRV U3hn peR). The specificity of the 
assay was determined by the inclusion of three endogenous plasmid controls as part of the 
investigation. The hypothesis being to use an outer primer pair that amplified both the 
endogenous and exogenous viral genomes, but in the second round, only the exogenous 
forms would be amplified and detected due to the one internal primer being exogenous 
specific. Obviously, being a hemi-nested peR had the disadvantage of amplicon 
contamination. The outcome of this titration using the JSRV U3-and hemi-nested peR is 
presented in Figure 3.5. An amplicon of 176 bp was expected after the first round, but only 




M123456789 M192021222324252627 M 3738394041424344 
Ethidium bromide stained agarose gel (2%) showing titration of JSRV plasmids with 
the JSRV U3/L TR hemi-nested peR 
Lanes M. Marker IX, Lanes 1-7: lfg to lng of ex+enJS7, Lanes 8-14: lfg to lng 
exJSRV21, Lanes: 15-21: lfg to lng exJS382. Lanes 22-28: lfg to lng enJSRV5.6AI; 
Lanes 29-35: lfg to lng enJSRV5.9AI, Lanes 36-42: lfg to lng enJSRV5Fl6 and Lanes 
43-44: Negative controls. Note the partial amplification of products in lanes 32-35 
(enJSRV5.9Al) 
3.3.2 An Investigation into the use of an exogenous specific Seal site to 
differentiate between endogenous and exogenous L TR-gag sequences using 
lung tumour samples 
The products obtained upon amplification using primers PI and P2 (Table 3.1) were 
subjected to a second round of amplification using primers P5 and P2 (Table 3.1). The 
second round amplification amplified a gag product of 229 base pairs. Restriction enzyme 
digest of this product using Seal revealed a Seal site that was present only in the 
exogenous OP A affected tissue, but was absent in the endogenous unaffected tissues. This 
restriction site in the gag gene represents an important molecular marker for the exogenous 
formofOPA 
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3.3.2.1 Amplification of Endogenous L TR-gag Sequences 
A product of229 base pairs was detected in clone JSRV382; clone JSRV120, sheep 4844 
(South African sheep affected with OPA), DNA 7 (Scottish strain of JSRV -Note that this 
genomic DNA is from the cell line JS7 which also has some endogenous JSRV DNA) that 
were used as positive controls as well as ten endogenous sheep samples. The results of the 
hemi-nested LTR-gag peR are presented in Figure 3.6. 
229bp 
Figure 3.6 
M 123 456789 10111213141516171819 M 
An Ethidium Bromide stained agarose gel (2%) showing the hemi-nested LTR-gag 
PCR products of JSRV382, JSRVI20, sheep 4844, DNA7 and ten endogenous sheep 
controls 
Lane 1 Sheep 4844 with OPA, Lane 2: JSRV 382, Lane 3: JSRV 120, Lane 4: DNA 7, 
Lanes 5, 9 and 19: Negative control (water), Lanes 6, 7, and 8: Full-length endogenous 
JSRV, Lanes 10, 11 and 12: Three Australian tissue samples from unaffected sheep, 
Lanes 13, 14 and 15:are three unaffected merino sheep, Lane 16; Normal sheep lung, 
Lane 17 and 18: sheep lung tumourC5 (very faint bands seen). Lane M: Marker IX 
(Roche Diagnostics). 
The results presented in Figures 3.7 are those of the amplified products followed by 
digestion with Seal restriction enzyme to enable differentiation of endogenous from 
exogenous sheep DNA. The successful digestion is indicated by the presence of two 




M lU lC2U2C 3U3C4U 4C M 5U 5C 6U 6C 7U 7C 8U 8C 
229bp 
M 9U 9C lOUlOCllUllC12Ul2C M13U13 14Ul4C 
Ethidium bromide stained agarose gel (2%) of LTR-gag PCR products that have been 
digested with Seal restriction enzyme together with the undigested PCR products. 
Two smaller fragments of 131 bp and 98 bp are obtained upon digestion 
Lanes 1U and 1C: exogenous sheep 4844, Lanes 2U and 2C: JS 382, Lanes 3U and 3C: 
JS 120, Lanes 4U and 4C: DNA 7 has detected endogenous JSRV DNA, Lanes 5, 6 and 7 
represent endogenous clones JS5 6A1, JS5 9AI and JS5F16, Lanes 8, 9 and 10: belong to 
the three Australian sheep LPW, MSCU and 230909 with endogenous JSRV, Lanes 11, 12 
and 13: three unaffected merino sheep and Lanes 14: normal sheep lung. 
Detection of Exogenous JSRV in Tumours of OPA-affected sheep using the 
LTR-gag peR. 
The LTR-gag hemi-nested PCR was also employed to amplify the 229 bp products from 
genomic DNA extracted from 22 sheep lung tumours. The amplified products as well as 
the results of restriction digest with Seal are displayed in Appendix C, but the figures are 
not too clear. 
A table of the results obtained using the LTR-gag Seal digest can be seen in Table 3.6. 
The results in Table 3.6 show that the LTR-gag hemi-nested PCR only detected 16 lung 
tumour samples out of 22. There were 6 samples that were not detected by the LTR-gag 
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hemi-nested peR. Of the 16 lung tumours that were peR positive, seven did not have the 
exogenous specific Sea 1 digested fragments of 131 bp and 98bp. 
Table 3.6 A summary of the results of L TR-gag hemi-nested PCR Amplified Products and 
Products of Lung tumours that have been restricted with Seal restriction enzyme 
Sample No. peR Seal Sample No. PCR Seal 
269 + + 211 + + 
195 - - 250 + + 
3000 - - 244 + -
229 + - 181 - -
247 + - 233 + -
252 + + 205 + -
227 + + 251 + -
214 + - 266 + + 
238 + + 268 + + 
210 - - 141 - -
234 - - 226 + + 
The failure to amplify DNA from all 22 sheep DNA extracts was either an indication that 
there was insufficient DNA or that there was poor amplification due to inhibitors. The 
JSRV U3/LTR hemi-nested peR was therefore investigated to assess its sensitivity. The 
failure to detect the unique Sea 1 digest products also suggests that the exogenous virus was 
absent or that it was in too Iowa concentration for amplification. 
3.3.3 An assessment of the Variable Region 1 and 2 peR on sheep lung extracts 
The peR reaction for the variable region 1 and 2 was used to amplify the exogenous virus 
from the 22 lung tumour samples. No amplicons were observed when the amplified 
products were run on a 2% agarose electrophoresis gel (data not shown). 
3.3.4 JSRV U3/L TR hemi-nested peR 
An investigation into the reason why the endogenous clone JSRV5.9A1 was amplified 
with the JSRV U3ILTR hemi-nested peR revealed that the JSRV5.9A1 sequence, at the 
region of the exogenous specific internal primer was the only one of the three endogenous 
clones that had a nucleic acid sequence similar to the exogenous internal primer sequence. 
An alignment of the U3/LTR sequences of sheep type D retroviruses (exogenous JSRV 21, 
JSRV-SA and the endogenous enJS5.9A1 , enJS5.6Al and enJS5F16) is shown in Figure 
3.8. 
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The specificity ofthe JSRV U3/LTRhn peR was improved by the design of a new internal 
reverse primer 3 (P3M, see Table 3.1). This primer differed from the earlier by one base 
pair (see Table 3.1 for modified P3M). New P3 was paired with forward primer 1 in the 
first round of the hemi-nested peR (JSRV U3/LTRhn peR). The new assay was used to 
amplify DNA from the 22 tumour DNA extracts and against a panel of normal lung DNA 
that had been extracted from 3 Australian sheep. The total panel consisted of twenty-two 
samples of lung tumour DNA, one exogenous JSRV sheep genomic DNA, DNA extracts 
from seven normal sheep lungs, and three full-length endogenous JSRV clones. The peR 
used primers P1 and P3M for the first round and 50011g of DNA from the lung extracts. 
This assay targeted a 176 bp gene. The hemi-nested peR used primers P1 and P4. A 
product of the size of 133 base pairs is expected if exogenous DNA is present. A photo of 
the amplified products obtained for the endogenous genomic DNA and a few lung tumours 




























P4 REV (inner) 
P3 REV (outer) 
P3 REV Modified (outer) 
7190 7200 7210 7220 7230 7240 7250 
····I····I····I····'· .. ·I·· .. ! .. ··! .. ··, · · · ·! .. .. I····! .. ··I .. · · 1 
CGACCCG- TGAAGGGTTAAGTCCT"GGGAGCTCTTTGGC- AAA - A- GCCAAAGCCTAGGACAAAT 
CGACCCG- TGAAGGGTTAAGTCTT - GGGAGCTCCCTGGC- AGGTATGCCGGGCCCTAGGACACGT 
CGACCCG- TGAAGGGTTAAGTCTT - GGGAGCTCCCTGGC- AGGTATGCCGGGCCCTAGGACATGT 
CTGCCCG- TGAAGGGTCAAGTCTT - GGGAGCTGCTCAGC- AGGTATGCAGAGCCCTAGGACATGT 
CGACCCG- TGAAGGGTTAAGTCCT- GGGAGCTCTTTGGC- AAA - A- GCCAAAGCCTAGGACAAAT 
CGACCCG- TGAAGGGTTAAGTCCT- GGGAGCTCTTTGGC- AGA- A- GCCAAAGCCTAGGACAAGT 
--- -- - ---- -- - - -- - ------ T- GGGAGCTCTTTGGC- AAA - A- GCC------------- - - -
7260 7270 7280 7290 7300 7310 







7320 7330 7340 7350 7360 7370 7380 
.... I .... I·· .. !· .. · I .... ! .. .. I .... I .... I .... I .. ··I .. · ·I .... I· .. ·I 
GCTGCCGGCATTACTTCACAGAAATGACGGGAAATC- TGATTATGTA------- .. AG- AA-- T--
GGTTTCGGCAACATTTCATAGAAG- AT- AGATTATC- TTATTGTGTATATTTCATAG- AAGATAG 
GGTTTCGGCAACATTTCATAGAAG- AT- AGATTATC- TTATTGTGTATACTTCATAG- AAGATAG 
AGTTCCTGCAACATGTCCTAGAAG- AT- AGATTATC- TTATTATGTATAC-- AAT- GGTA- A-GG 
GCTGCCGGCATTACTTCACAGAAATGACGGGAAATC- TGATTATGTA--------AG- AA-- T- -
GCTTTTGGCACTGCTTCATAGAAATACCAGGAAATC- TGATTATATA-- - -----AG- AA-- T--









P4 REV (inner) 
P3 REV (outer) 
7390 7400 7410 7420 7430 7440 
i . I I i I I I i I . I I .. .. : . .. ·1 ·· · · . . . ... · ·1···· i· . " .... , .. . . , .... I · ···1···· .... i 
T- - CCGGTGATTGT- - - - - -.- - - - - - - - - GTAAAAATCCGGTGGGTGTAGT - TTGAGA- - TGAAT 
-ATATTCTGATTGTGTTCTGTATACAATGGTAAGGGTCTGGTGATTGTAT - CCTGAGA--TTAAA 
TATATTCTGATTGTGTTCTGTATACAATGGTAAGGGTCTGGTGATTATAT - CCTGAGA-- TTAAA 
- GTCTGGTGATT - - -- - CTCTGTACA- C- --AA---- CTGGTGATTGTAT - CCTGAGA--TTAAA 
T - - CCGGTGATTGT- -- -- -- --------GTAAGAATCCGGTGGGTGTAGT - TTGAGA--TGAAT 
T-- CCGGTGATTGT---- - ------ - -- - GTAAGAATCCGGTGGGTGTA---GTGAATAATGAAT 
--- CCGGTGATTGT- ------------- - GTAAAAATCCGGTG-- -- - -- - ---·- - -- ----- - -
P3 REV Modified (outer) - - - .. CGGTGATTGT .. .. .. .. - - - .. .... .. .... GT AAAAA TCCGGTG .. .. .. ...... - - .. - .... .... .. - .. - - -
FIGURE 3.8 Showing alignment of the U3/LTR sequences of Sheep type d retroviruses 
(exogenous JSRV 21; JSRV SA; and three endogenous JSRV loci viz. enJS5.6Al; 
enJS5F16 and enJS5.9Al) • 
Dashes indicate lack of sequences. Sequences and position of the U3/LTR 
hemi-nested primers are also indicated. (P1 and P3 are outer primer pairs 
while Pl and P4 are the internal pairs) . 
Nucleotide sequences obtained from GENBANK using accession numbers for 
JSRV21 (AF105220); JSRV-SA (M80216); enJSS.6A1 (AF1S361S); enJSSF16 
(AF136224) and enJSS.9A1 (AF13622S) 




M123456789 M 19 20 21 22 23 24 25 26 27 
133 bp 
133 bp 
M 10111213 14 15 161718 M28 29 
Ethidium bromide stained agarose gel (2%) analysis of JSRV U3/LTR hemi-nested 
peR. The lanes showing the 133bp product are in bold 
Lane 1: Exogenous sheep genomic DNA 4844. Lanes 3,5,7,9 and 11 Products of 
amplification of 500ng of genomic DNA from lung tumors of sheep (OPA). Lanes 2, 4, 6, 
8,10,12,14,16 and 18: Negative controls (water). Lanes 13, 15, and 17: Genomic DNA 
of healthy merino sheep. Lane M: Marker IX (Boehringer Mannbeim) 
Lanes 19: plasmid DNA of endogenous JSRV5.6Al. Lanes 21, 23, 25 and 27: Genomic 
DNA belonging to normal sheep (three Australian sheep and normal lung). Lanes 20, 22, 
24.26,28 and 29: Negative controls (water). 
Further results of the amplification are presented in Figures 3.10. A summary of all the 
results obtained from the LTR-gag and U3/LTR hemi-nested peR for the 22 lung tumours 



















--.76 bp (First step PCR product) 
33 bp 
(Second step PCR product) 
133 bp 
M 10 1112 13 14 15 16 
Ethidium bromide staimed gel (2%) showing amplified products from both the first 
step (176bp) and second step (133bp) of the U31L TR hemi-nested PCR 
Lane 1: contains both the first step U3 PCR product of 176 bp and the product from the 
second round of amplification (U3-hnPCR) of 133 bp. The product was amplified from the 
genomic DNA of a South African sheep 4844 with OP A. This represented the positive 
control. Lanes 2 to 16: Products of amplification of genomic DNA from sheep lung 
tumours (OPA). Lane M: Marker1X (Boehringer Mannheim) 
A summary of the results of LTR-gag hemi-nested PCR amplified products and 
products of lung tumours that have been restricted with Seal restriction enzyme 
together with those results obtained from theU3/LTR hemi-nested PCR 
PCR Seal U3ILTRhn Sample No. PCR Seal U3ILTRhn 
PCR PCR 
+ + + 244 + - + 
- - + 181 - - + 
- - + 233 + - + 
+ - + 205 + - + 
+ - + 251 + - + 
+ + + 266 + + + 
+ + + 268 + + + 
+ - + 141 - - + 
+ + + 226 + + + 
- - + Normal lung + - -
- - + *LPW + - -
+ + + *MSCU + - -
+ + + *230909 + - -
* Represents the three Australian sheep 
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3.4 DISCUSSION 
The cloning and ultimate sequencing of the full length JSRV genome proved to be a major 
breakthrough for JSRV research as it opened the way for further molecular studies of 
JSRV/OPA (York et aI, 1992). The hybridization studies of JSRV DNA with normal sheep 
tissue revealed the presence in the sheep genome of 15 to 20 copies of endogenous JSRV-
related retroviruses [enJSRV] (Hecht et aI, 1994; York et aI, 1992). This similarity 
between the exogenous and endogenous JSRV meant that the probes designed for the 
exogenous JSRV cross-reacted with that of the enJSRV and this made detection of the 
exJSRV amidst a high background of enJSRV difficult (Palmarini et ai, 1996a). 
With perseverance potential molecular markers unique to exJSRV were identified in gag, 
env, the LTR and major differences were found in the U3 region as well (Palmarini et ai, 
1996a; Palmarini et ai, 1996b; Bai et ai, 1996). Molecular assays based on these 
differences (LTR-gag, V1N2 and U3/LTR region) were designed. All the parameters to 
ensure that these diagnostic tests had the capacity to distinguish JSRV-like virus from that 
of enJSRV-re1ated forms with regard to their sensitivity and specificity in detecting JSRV 
were assessed. 
Exogenous plasmids (JSRV21-11, 537 bp in length, JSRV 382 at position 953-3029 and 
JS 7 which is 7841 bp in length has both exogenous and endogenous DNA extracts) and 
endogenous plasmids (JS5.6A1 which is 7939 bp in length, JS5.9A1 which is 6695 bp in 
length and JS5F 16 which is 6915 bp in length) were used to assess the sensitivities of the 
three molecular assays (LTR-gag hemi-nested peR, V1N2 peR and U3ILTR hemi-nested 
peR) by making lO-fold dilutions ranging from 1ng to lfg. These dilutions were used as 
templates for amplification in both a one-step (V1N2 peR) and a hemi-nested (LTR-gag 
and U3/LTR hn peR) assay using primers specifically designed for the regions in the 
LTR-gag, VlIV2 and U3ILTR. 
The first molecular assay was based on the LTR-gag region where the presence of the 
second Sea 1 site (position 1729) identified the sample as being exogenous. Palmarini et al 
optimized this peR for the detection of 1 to lO copies ofpJSRV 382 in 1996. This study 
was able to detect up to ten pg of the plasmid. The first step of the LTR-gag peR used 
primers PI (internal to the LTR region) and P2 (gag primer-see Table 3.1) that amplified a 
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product of 2064 bp. The hemi-nested step used PI and a primer internal to the gag primer 
(P2), P5 that amplified a product spanning 229 bp within the gag gene for both the 
exogenous and endogenous DNA extracts. Only upon digestion of this 229 bp product with 
Sea 1 enzyme into two fragments of 131 bp and 98 bp, was one able to deduce whether the 
extracts were from affected or unaffected sheep. The explanation being that the exogenous 
JSRV has two Seal sites, while the endogenous has just one. The primers were designed so 
that only the second Seal site was amplified (Palmarini et aI, 1996a). 
Similar dilutions of samples were also used as templates for two other molecular assays, 
the U3/LTR hemi-nested peR and the V1N2 peR. The U3/LTR first step peR identified 
a 176 bp product (data not shown), while the hemi-nested step identified a 133 bp (Fig. 
3.5) exogenous JSRV product and the peR covering the V1N2 region a 363 bp (Fig. 3.4) 
product (exogenous specific). 
In assessing all three assays it was found that the VRlIVR2 peR detected only 
JS 21 at a low concentration of 1pg equivalent to 82,000 copies. According to calculations 
based on JS21 being 11571 bp long, 82 X 109 copies of JS21 should be detected per fig of 
DNA. In this study only 82 X 106 copies were detected per fig that was below that of the 
theoretical detection level of 82 X 109 copies/fig. In addition, JS 7 and JS 382 were not 
detected with this primer set. JS 382 was not detected by primers VR1 and VR2 because 
the region targeted was not present in the clone. 
According to Holland et aI, 1999, the JS7 cell line has one copy of exogenous target (as 
measured by the U3/LTRhemi-nested peR) per 5.98pg of DNA. If the weight of the 
genomic DNA contained in 1 cell is 6.66pg, then each JS 7 cell line is estimated to have 
5.98pg/6.66pg copies (0.9+/-0.07 copies). This is equivalent to nearly 1 copy per cell. For 
the LTR-gag peR in this study, the detection level for JS 7 was 100pg, which should then 
theoretically have 16.7 copies (l00pg/5.98pg) and at 1 fig 167 copies. This is in line with 
the detection limits according to Holland et aI, 1999. But according to calculations for 
JS21, there should be 82 X 109 copies/fig of DNA detected. In other words lfg should have 
82 copies, 10fg 820 and 100fg 8200 etc. The JSRV U3/LTR hemi-nested peR (Fig. 3.5 
lanes 8-14) did detect JS 21 at a concentration of lfg.These calculations have been based 
on the fact that JSRV 21 is 11571 bp in length. 
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Since the detection endpoint for JS 7 was the same i.e. 16.7 copies per 100pg for both the 
LTR-gag and U3/LTR hemi-nested PCR, one cannot state that one assay was more 
sensitive than the other. However, it is evident from the titration profile for JS 21 (Fig 3.2, 
lanes 1O-14100fg-lllg and Fig 3.S, lanes 8-131fg-lOpg), that the U3ILTR hemi-nested PCR is 
definitely more sensitive than the LTR-gag PCR in that it detected 82 copies (lfg) as 
opposed to that of 8200 copies at 100fg. 
JS 382 was detected at a concentration of 10pg by the LTR-gag PCR and was detected as a 
contaminant by the U3/LTR hemi-nested PCR. Upon retesting with a fresh stock of JS382, 
the U3/LTR hn PCR was negative. Looking at the results for the exogenous plasmids, it 
can be stated that of the three assays used, the LTR-gag and U3/LTR hn PCR proved to be 
equally sensitive, but the U3/LTR hn PCR was 2 logs more sensitive when assessed 
against exogenous JSRV DNA. 
The endogenous plasmids JSS.9A1, JSS.6A1 and JSSF16 were not detectable by the 
V1N2PCR assay. Although the plasmids were detectable upon amplification with the 
LTR-gag PCR, the second Seal site was not in evidence upon restriction digest with the 
Seal enzyme proving that these were truly endogenous JSRV products. The endogenous 
plasmids on the other hand were completely undetectable with the U3 hemi-nested PCR, 
although the plasmid JSS.9A1 was detected at a concentration of 100pg. Closer 
examination of the nucleic acid sequences of the three endogenous plasmids with the 
exogenous JSRV, revealed that whereas JSS.6A1 and JSSF16 had a S' ATTC 3' at position 
7361-7364, JSS.9A1 had a S' CTGG 3' sequence at this position and the exogenous 
sequence was S' CCGG 3' at this position. The presence of this S' C at position 7361 could 
be responsible for the amplification of this endogenous plasmid (see Figure 3.8). The 
reverse primer P3 for the first round of the PCR was therefore redesigned as can be seen in 
Table 3.1 (P3M). The endogenous plasmid JSS.9A1 was retested with the U3-hemi-nested 
PCR assay using the new reverse primer (P3M) as well as AmpliTaq Gold DNA 
polymerase enzyme by Applied Biosystems in a real time setting (Lightcycler by Roche 
Diagnostics). This enzyme is a chemically modified enzyme that requires a high 
temperature incubation to activate the enzyme thus reducing enzyme extensions at lower 
temperature and improving specific binding between primer and template. The endogenous 
plasmid JSS.9A1 was not detected when the hot start Taq was used. When all three assays 
137 
were compared for specificity in detecting endogenous JSRV, both the LTR-gag and U3 
hemi-nested were found to be equally specific. 
On comparing all three assays and their detection levels, all three were found to be 
specific. The VIN2 PCR did not detect JS7 because this cell line has both exogenous and 
endogenous extracts. On the question of sensitivity, the U3-hemi-nested was found to be 2 
logs more sensitive than the LTR-gag assay. Palmarini also confirmed this sensitivity in 
1996, when the U3 hemi-nested technique was found to be 105-foldmore sensitive than the 
LTR-gag PCR/Sea1 digestion method. Holland et ai, 1999 and Gonzalez et ai, 2001, also 
confirmed this. 
Both assays were tested against 22 sheep lung tumours. It was concluded that the U3/LTR 
hemi-nested assay was the most sensitive. The number of positive results obtained with the 
LTR-gagPCR/Sea1 digestion assay was 9/22 compared to that of the U3/LTR hemi-nested 
technique were 100% of the positives were detected (22/22). The LTR-gag PCR/Sea1 
digestion did not detect 6/22 lung tumours. Of the 16 samples that were positive by this 
combination assay, 7 samples were detected by PCR, but their digestion products were not 
seen when run on a 2% agarose gel. Either the products were too faint to be seen or the 
material was of endogenous origin. The detection of few Sea 1 sensitive sequences at the 
DNA level may be due to there being a greater amount of endogenous JSRV template 
compared to exogenous JSRV template available (there are probably as much as 20 
endogenous copies as compared to only 1 exogenous copy per cell) (Palmarini et ai, 
1996a) . Two weaknesses have been revealed in this study. The first is that an internal 
house keeping gene was not included for each assay. Whilst the concentration of DNA 
using OD 260nm and a ratio of 260nm to 280nm is useful it is not as powerful as an 
internal housekeeping gene. The other potential weakness is in those cases where the 
exogenous virus might be present in low copies. It is possible that the endogenous virus 
might be preferentially amplified. Such a scenario could result in a false positive result.. 
Preliminary investigations into the U3/LTR hemi-nested on the light cycler (Roche 
Diagnostics) using Taq gold and the improved primer set has proven to be excellent. It is 
now possible to include concentration standards to make the assay quantitative which has 




GENERAL DISCUSSION AND CONCLUSION 
The diagnosis of OP A has traditionally relied on the clinical history and physical 
examination of the affected animal. Laboratory confirmation at necropsy has been by the 
histopathological examination of infected lung tissue. For such an examination, it is a 
prerequisite to take specimens from several affected sites and from more than one animal. 
The reason for this being that secondary bacterial pneumonia which can be the immediate 
cause of death often masks the lesions (both macroscopic and microscopic) of the primary 
disease. In the absence of specific serological and molecular diagnostic tests, disease 
control relied on regular flock inspections and prompt culling of suspected cases and their 
offspring (Sharp, 2000). 
The absence of any specific humoral immune response to JSRV has made JSRV unique 
amongst retroviruses. Even though JSRV is responsible for highly productive infections in 
the lungs as well as a disseminated infection of the lymphoreticular system, the absence of 
circulating antibodies in the sera of the affected sheep has made detection of the infection 
very difficult (Sharp and De Martini, 2003). There has been some controversy relating to 
the presence or absence of circulating antibodies in the sera of affected sheep (Ortin et aI, 
1998). 
Many studies have failed to detect antibodies to JSRV in sera or lung fluid of affected 
sheep by Western blotting or ELISA (Sharp and Herring, 1983; De Martini et ai, 1987; 
Kajikawa et ai, 1990; He et ai, 1992; Kwang et ai, 1995; Ortin et ai, 1998; Summers et ai, 
2002 and Sharp and De Martini, 2003 text book). It was Sharp and Herring in 1983 that 
were the first to describe an immunological cross-reaction by Western blotting between the 
27 kDa core protein (P27) of MPMV, MMTV and a 25 kDa protein in OPA tumours and 
lung fluids. They failed to detect any antibodies to p25 in the sera of sheep with terminal 
OP A or in lambs where the tumours were induced (Sharp and Herring, 1983) 
139 
However, in 1992 the complete viral genomic sequence for JSRV was determined from a 
virus (constructed from a cDNA library) purified from lung wash of an OPA affected 
sheep from South Africa (York et aI, 1992). This paved the way for immunoassays based 
on recombinant antigens expressed in the form of GST fusion proteins (K wang et aI, 1995; 
Ortin et aI, 1998 and Palmarini et aI, 1995). Recombinant proteins have been frequently 
used as diagnostic antigens in the detection of antibodies to indicate infection and disease. 
The sensitivity and specificity of these assays is much better than using purified whole 
virus preparations. The first available marker for direct or indirect detection of OP A-
affected sheep was the MPMV capsid-related antigen p27. This soon became the 
internationally accepted OPA marker protein (Kwang et al 1995). A recombinant form of 
MPMV -p27 (expressed as a GST -p27 fusion protein) was used in the development of a 
simple, rapid and sensitive ELISA. This ELISA was used to detect JSRV-CA antibodies in 
Italian sheep flocks with a high prevalence of OP A and in North American sheep flocks 
with a high prevalence of chronic pneumonia (Kwang et aI, 1995). This study detected 
JSRV -CA antibodies in infected and diseased sheep, but the specificity of these reactions 
were still to be confirmed by others. 
Our studies on the expression of some JSRV genes also started soon after the JSRV 
genome had been identified, cloned and sequenced. At the time we also believed that 
purified recombinant antigens would once and for all address the question of whether there 
were specific antibodies being produced against the viral proteins. We felt that even the 
most pure preparations of JSRV from lung fluid were still contaminated with non-viral 
proteins. 
We targeted three genes, the orf-X because it was unique, the transmembrane and the 
capsid gene, that is the JSRVp26 gene. Our attempts at expressing the orf-X and 
transmembrane were not successful. The genes were successfully cloned into the 
expression vectors, but all attempts at purification of these extremely hydrophobic proteins 
failed. We continued with the JSRVp26 expression, purification and analysis. We 
established that the JSRV p26 gene was identical to that present in three full-length 
endogenous JSRV isolates. If the endogenous viruses were expressing an identical protein 
to the exogenous virus, then this would support the theory that sheep do not produce 
antibodies to JSRVp26 because they are recognised as self-antigens. Nevertheless, we 
continued with our assessment of the purified protein using many assay formats such as an 
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indirect ELISA, Western immunoblot assay, antigen sandwich and direct conjugation. We 
confirmed that the purified p26 cross-reacted with the anti-MPMVp27 antibody in the 
Western blot immunoassay in accord with the findings of Sharp and Herring, 1983. We 
went on to demonstrate that an indirect ELlS A using this recombinant antigen detected 
JSRV positive sera (6/8), however, further investigations revealed that the reaction was 
non-specific. Using an equivalently expressed gene we showed that the reaction was not 
specific to JSRV but also to the proteins associated with the expression vector. We were 
able to demonstrate that the "p26 specific antibodies" were competed out using an 
unrelated protein that was purified and expressed in the same vector. This non-specificity 
concurred with fmdings reported by Ortin et ai, 1998. 
Ortin and co-workers also expressed JSRVp26, which he called JSRV-CA, in a pGEX 
expression vector. Ortin showed that sheep that had been tested to have positive antisera to 
the JSRV -CA had no detectable tumours at necropsy and further that they came from 
flocks with no clinical history of OPA or ENT. Final confirmation that the assay was not 
specific came from a study where 7 out of 8 sera were positive from sheep that were in 
Australia and Falkland where neither OP A nor ENTV exist. To understand these findings 
all sera were preabsorbed with a lysate containing GST, but with no proteins related to 
JSRV or ENTV. This procedure removed all reactivity to the sera and confirmed the non-
specificity ofthese reactions (Ortin et ai, 1998). 
All findings strongly support the conclusion that there are no circulating antibodies to 
JSRV CA (Ortin et ai, 1998; Sharp et ai, 1983). In light of the overwhelming evidence that 
that JSRVp26 does not stimulate a humoral response we believed that there might be a 
localized immune response in the lungs that could be detected. We therefore developed an 
antigen assay to investigate this. Earlier work by our group had suggested that JSRV 
specific IgG and IgA were being produced in the lungs of infected sheep. In this study we 
analysed lung lavage samples from infected and normal sheep for the presence of JS anti-
p26 antibodies using an in-house JSp26 peroxidase conjugate in an antigen capture assay 
format (Table 2.18). Although the assay lacked sensitivity (31 %), the results were 
encouraging and in line with our earlier findings using a much cruder preparation of viral 
antigens, and Palmarini et ai, 1995, in that there was a specific localized immune response 
to JSRV in the lungs of OPA affected sheep. Since there were a significant number of 
samples that were negative we needed to improve the sensitivity of the assay but more 
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importantly develop an antigen capture assay in view of the absence of antibodies detected 
in those few JS lungs. This assay however required a specific JSRV CA antiserum. Our 
attempts to produce a JSRVp26 antiserum in chickens were partially successful but use 
was made of an alternative antiserum that became available at the time. This antiserum to 
the JSp26 was produced in a rabbit and was provided by Professor De Martini (University 
of Colorado, Fort Collins). The rabbit polyclonal viral capsid antibody facilitated the 
development of an antigen capture assay. This assay detected JS antigen in the lung fluid 
and nasal fluid of JS affected sheep and not in normal lung lavage (Table 2.22). 
The conclusion from our studies were that the poor humoral response to the JSp26 protein 
is likely due to the fact that there are identical genes being expressed by the endogenous 
(normal) virus that are present in all sheep genomes. Further, that there is a predominantly 
localized immune response in the lungs of JS affected sheep and that the antigen capture 
assay is a useful method to detect the presence of virus in both the lungs and nasal fluid of 
affected sheep. This assay does have its limitations in that the disease in an infected animal 
needs to be sufficiently advanced for sufficient virus to be released before it can be 
detected. 
It has been mentioned earlier that the complete sequencing of the JSRV genome opened 
many doors for Jaagsiekte research and facilitated research into the molecular aspects of 
JSRV (York et ai, 1992). However, the discovery of the presence of 15 to 20 copies of 
endogenous JSRV-related sequences in the normal sheep genome made the obvious 
development of a molecular assay that much more challenging (Hecht et ai, 1994; York et 
ai, 1992). One of the immediate objectives was therefore to obtain more information on the 
endogenous and exogenous JSRV-related viruses. The gag and LTR regions of both the 
exogenous and endogenous JSRV were sequenced and compared (Bai et ai, 1996). A long 
range PCR based on the exogenous JSRV sequences (York et ai, 1992) was developed to 
characterize six endogenous retroviral loci based on restriction enzyme profiles and 
proviral genomic size. Restriction sites that were identified that could distinguish the 
exogenous JSRV from the endogenous counterparts in the same cell were Ndel, Hindlll, 
Sca 1, Kpn 1 and EcaRl in the gag region There were also significant differences in the U3 
region between the endogenous loci and the exogenous JSRV, due to deletions and many 
point mutations in the U3 of the LTR (Bai et ai, 1996). The endogenous LTR's were 
longer (442-445 bp) than the exogenous JSRV sequence (397 bp) and there were two large 
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deletions of 30 bp and 16 bp at positions 198 and 261, respectively (York et al 1992). 
However, over time more endogenous sequences were added to the database. Many of the 
restriction enzyme sites that had been suggested as being signatures of either an 
endogenous or exogenous JSRV, did not withstand the test of time. 
The most useful one is a unique Seal restriction site (at position 1729) that was only found 
in the exogenous forms of JSRV. This site was found exclusively in the cDNA of OPA-
affected sheep and not in unaffected control sheep (Palmarini et aI, 1996a). A molecular 
based peR assay, LTR-gag hemi-nested assay was designed to specifically target 
exogenous proviral DNA with sense primer PI (based on an area of sequence divergence 
between endogenous LTR clones and the exogenous LTR sequence (JSRV) and antisense 
primer P2 (gag region) (see Table 3.1) to amplify a 2 kb product. The second round of 
amplification used PI and P5 to amplify a 229 bp fragment were upon Seal digestion, 
enabled the detection of Seal-sensitive sequences in tumour samples only and not in non-
tumour samples (Palmarini et aI, 1996a). JSRV was detected in tumour and in draining 
lymph nodes of OP A affected sheep. Since it was not detected outside the respiratory 
tissues of OP A affected sheep or in any tissue of control sheep, it was felt that the detection 
of low copies of exogenous JSRV were masked due to the high background of sheep 
endogenous retroviruses. To obviate this issue, an exogenous JSRV specific D3/LTR 
hemi-nested peR was designed to detect the anatomical distribution of JSRV in sheep 
tissues with naturally and experimentally induced OP A (Palmarini et ai, 1996b). 
This D3/LTR hemi-nested peR primer PI (located almost at the 5' end of the D3 region 
(see Table 3.1) was paired with antisense primer P3 (in the D3 region- Table 3.1) to 
amplify a 176 bp product. The sensitivity of this reaction was improved by including a 
primer P4 (see Table 3.1) internal to the peR product. This primer was paired with primer 
PI in a second round hemi-nested peR so that a product of 133 bp was amplified from all 
lung fluid and lung tumour peR products. This assay detected a single molecule of 
template in 500ng of normal sheep genomic DNA, whereas the LTRlgag hemi-nested peR 
followed by Sea 1 digestion was 105 -fold less sensitive, because it was not able to detect 
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copies of the exogenous clone, pGem-T LTR-gag in a background of 500ng of normal 
sheep kidney DNA (Palmarini et ai, 1996b). Moreover, exogenous sequences were 
detected only when the ratio of exogenous/endogenous sequences were 1: 10 and not I: 100 
(palmarini et ai, 1996b) 
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This study, besides assessing the sensitivity and specificity of the LTR-gag peR and the 
U3/LTR hemi-nested peR, also included a further assay that covered the V1N2 region, 
which was a single step peR. This was possible when our group sequenced three full-
length endogenous JSRV genomes. The outcome of the present molecular study is in line 
with those findings ofPalmarini et aI, 1996b, Holland et aI, 1999 and GonzaIez et aI, 2001 
where the U3/LTR hemi-nested assay was found to be a more sensitive assay than the 
LTR-gag peR. In this study the U3/LTR hemi-nested peR detected the JS 21 infectious 
clone at a concentration of lfg compared to 100fg for the LTR-gag peR being 2 logs more 
sensitive. The extreme sensitivity of the U3/LTR hemi-nested assay detected a minor 
contamination of the JS 382 plasmid that contains a portion of the gag gene. The 
experiment was repeated with dilutions from fresh stocks of JS 382 not previously used 
and turned out to be negative. Further assessment of the assay revealed that this assay also 
detected the endogenous JSRV5.9A1 loci. This was overcome by redesigning a more 
specific primer P3M (see Table 3.1 and Figure 3.8) for the first step of the U3/LTR hemi-
nested peR. This primer together with the use of AmpliTaq Gold DNA polymerase 
improved the specificity of the assay. We concluded that this assay was both the most 
sensitive and specific. 
The U3/LTR hemi-nested peR has been the molecular assay of choice for many of the 
recent studies (Holland et aI, 1999; GonzaIez et aI, 2001 and Summers et aI, 2002) to 
determine in which organs JSRV could be detected. This assay is becoming the 
internationally accepted molecular method to identify sheep infected with the exogenous 
infectious form of JSRV. Recently the assay was used to confirm an outbreak of OPA in 
Patagonia, Argentina, which would normally have been diagnosed using gross and 
histological changes (Uzal et aI, 2004). 
In our study, JSRV antigens were detected using an antigen capture assay in nasal fluids 
and lung washes, but not in the sera of affected sheep. The U3/LTR hemi-nested peR 
detected JSRV in the tumours of lungs obtained from affected sheep. These lung tumours 
were the only sheep organs available for the purposes of this molecular study. Early studies 
identified the epithelial tumour cells of the lungs as sites of JSRV replication (Palmarini et 
aI, 1995). Viral RNA has been found in lung tumours, lung fluid and draining lymph nodes 
of OPA affected sheep (palmarini et aI, 1996a). With the introduction of a much more 
sensitive assay, the U3/LTR hemi-nested assay has been extended to other anatomical sites 
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where JSRV DNA has been detected in the mediastinal lymph nodes, spleen, and bone 
marrow. Viral RNA was found in these sites as well as the thymus and peripheral blood 
mononuclear cells (PBMC). Proviral DNA was not detected at these sites (Palmarini et aI, 
1 996b ). The adherent cell population consisting of macrophages/monocytes of the 
lymphoid cells was identified as having the greatest proviral burden. In OP A affected 
animals these are the cells that are most abundantly found in the lungs. In the non-adherent 
cell population, the surface immunoglobulin positive B cells contained the greatest proviral 
burden, whilst the CD4+ and CDS+ T cells the lowest levels of JSRV proviral DNA. JSRV 
provirus was also found in the PBMC population (Holland et aI, 1999). The most 
interesting information from this study of Holland et aI, 1999, was the detection of JSRV 
as early as 7 days after experimental inoculation of new born lambs with JSRV before the 
onset of OP A or any histological signs. 
In a recent study sheep peripheral blood leukocytes (PBL's) and tissue samples were 
examined from 36 sheep, of which 10 were non-affected sheep from OPA-affected flocks 
(in contact sheep) and 10 from non-affected OPA-free flocks. The other 16 sheep were 
from classical OP A cases and sheep with atypical OP A. This study was the first to detect 
JSRV in naturally infected sheep (4/10 PBL's) from the in-contact group and in a lower 
number from the mediastinal lymph node, spleen, mammary lymph node and neo-plastic 
lung samples using the U3/LTR hemi-nested assay before the onset of any clinical disease 
or development oftumours (Gonzalez et aI, 2001). 
Overall the lung tissue contained the highest number of PCR positive results, in agreement 
with previous fmdings on JSRV detection by immunohistochemistry or blocking ELISA 
techniques (Palmarini et aI, 1996a and GonzaIez et aI, 2001). 
The present study confIrmed the sensitivity of the U3/LTRhemi-nested PCR and improved 
its specifIcityby redesigning one of the primers used in the fIrst step (P3M-Figure 3.1) and 
the utilization of a thermally activated AmpliTaq Gold DNA polymerase (PE Biosystems, 
Applied Biosystems, USA) that enhances the specificity of the primers. We also developed 
a real-time U3/LTR hemi-nested PCR assay using sybr green and the Light cycler 
(RocheDiagnostics) real time machine. This technology has a number of advantages in that 
there is less handling of the samples and it has the capability of being quantitative. 
Collaborative work will continue and the assay will be modified to include a house keeping 
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gene as an internal control and primers will be modified to improve the amplification of 
the exogenous virus at a low copy number in the presence of high copies of the 
endogenous viruses. 
In concluding, this study has spanned nearly a decade of research that has included many 
different techniques and experiments, many of which have not been presented or discussed 
in this thesis. Only aspects that were associated with the development of a JSRV diagnostic 
assay have been included. The serological study confirmed the work of others in that there 
are no circulating antibodies to the JSRV p26 capsid gene but it is possible to detect viral 
antigens using an optimal p26 antigen assay. However sufficient virus needs to be present 
before it is detected. Future studies looking for circulating viral antibodies will involve the 
expression of other JSRV proteins or fragments, especially those peptides that differ 
between the endogenous and exogenous isolates. The development of a molecular assay 
had to initially overcome the problem of the endogenous JSRV sequences. However, as 
more sequences became available it became possible to target regions that were uniquely 
exogenous. hnproving the sensitivity of the assay using a hemi-nested format has finally 
resulted in a molecular diagnostic assay that can now be used to detect the presence of the 
infectious exogenous virus even in sheep that are asymptomatic. It is therefore possible to 
use this assay to screen infected sheep populations to identify infected sheep and in this 
way eradicate the disease through a selective culling program. Evidence that this is 
possible is the Icelandic story where that country successfully eradicated JSRV following 
an extensive slaughtering out campaign where all sheep on the Island were slaughtered 
except for a small population on the Western peninsular that were not exposed to the virus. 
The Island has been free from JSRV for nearly half a century. 
Future research will focus on understanding the mechanisms of transformation and the 
immune response. The molecular tools are now available to facilitate research into this 
most interesting disease, which remains the best natural outbred animal model of a 
contagious cancer that is caused by a virus. This model will have important implications 
for research into human breast and lung cancer. 
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APPENDIX A 
DNA Sequence of the 5' end of GST -JSp26 in pGEX-l expression vector with p26 
inserted into the correct reading frame. 
Shown in bold print and underlined is the sequence of the 5' pGEX sequencing primer and 
only underlined is the 5' JSp26 BamHI primer. This sequence showed 100% homology 
with the Genbank sequence. Also shown is the amino acid translation of the sequence of 
JSp26. 
1 5' GGACCCAATG TGCCTGGATG CGTTCCCAAA ATTAGTTTGT TTTAAAAAAC 
51 ATTGAAGCTA TCCCACAAAT TGATAAGTAC TTGAAATCCA GCAAGTATAT 
101 TGGCCTTTGC AGGGCTGGCA AGCCACGTTT GGTGGTGGCG ACCATCCTCC 
151 AAAATCGGAT CCTGTcrrCG AAAATAACAA CCAGCGTTAC TATGAATCAC 
201 TGCCGTTTAA ACAACTAAAA GAGTTAAAGA TTGCTTGTTC GCAATATGGT 
251 CCTACCGCTC CATTTACTAT TGCTATGATA GAAAGTTTGG GTACTCAAGC 
301 TTTGCCCCCG AATGACTGGA AACAGACCGC TAGGGCATGT CTCTCAGGGG 
351 GAGATTATTT ATTATGGAAA TCTGAATTTT TTGAACAATG TGCTCGTATA 
401 GCTGATGTTA ACCGACAGCA AGGTATACAG ACCTCCTATG AAATGTTGAT 
451 TGGCGAAGGC CCTTATCAGG CTAC 3' 
Translating fromBamHl: GGATCCT (-1) 
157 DPVFENNNQR YYESLPFKQL KELKIACSQY GPTAPFTIAM IESLGTQALP 
207 PNDWKQTARA CLSGGDYLLW KSEFFEQCAR IADVNRQQGI QTSYEMLIGE 
257 GPYQAXXTX 
APPENDIXB 
Alignment of exogenous and endogenous JSRV gag sequences and positions of primers used for the Vl/V2 region one step 
PCR 
Nucleotide sequences obtained from GENBANK using accession numbers for JSRV21 (AF10s220); JSRV-SA (M80216);enJSs.6Al 









JSRCG Jaagsiekte sheep retrovi 







610 620 630 640 650 660 
.... 1 .... 1 .... 1 .... 1 .... 1 .... 1 .... 1 .... 1 .... 1 .... 1 .... 1 .... 1-




CTGATTCGGTACCTAGTTATGATCCTCCTCCTCCTCCT-------- CCG- CCATCTCTGA 
CCGATTCGGGACCTAGTTATGATCCTCCTCCTCCTCCT-------- CCC - CCATCTCTGA 
-- - - - - - - .. - - - CTAGTTATGATCCTCCTCCTCCTCCT - - - - - - - - - - - - - - - - - - - -
970 980 990 1000 1010 1020 












Ethidium bromide stained agarose gel (2%) analysis of LTR-gag PCR products of 
amplification from lung tumour tissue that have been digested with Seal restriction 
enzyme 
Lanes 1, 2, 3, 4, 6 to 17, and 19 to 24 represent amplified products that have been digested 
with Seal restriction enzyme. U represents undigested PCR products and C digested PCR 
products. Lane M represents DNA Marker IX (Roche Diagnostics, Mannheim, Germany) 
M 1 U 1 C 2U 2C 3U 3C 4U 4C 5 6U 6C 7U 7C 8U 8C M 
M 16U 15C 18U 17C 19U 19C 20U 20C 
-+- 229bp 
-+- 131 bp 
-+- 98bp 












10% SDS (w/v) 
SDS 
APPENDIXD 
Dissolve in d.H20 with gentle stirring 
Make up to 100ml. Store at RT. 
3. Chloroform isoamylalcohol (24:1) 
To 24 volumes of chloroform add 1 volume of isoamylalcohol. 
















6. Deoxyribonucleic triphosphates (dNTP's) 200 p.1M 
Phannacia Biotech supplies 100mM stock each of dATP, dCTP, dGTP and dTTP. 
On arrival stored at _20DC. Working solution is 2.5mM. dNTP's to be diluted at 1:40. 
In a 15ml tube add 100JlI of each dNTP to 3.6ml d.H20. 
Mix well and aliquot 200JlI per 0.5ml eppendorftube. Store at _20De. 
7. Ethidium Bromide (10mg/ml) 
Add O.lg of ethidium bromide to 10ml of H20. 
Stir on a magnetic stirrer for several hours to ensure that the dye has dissolved. 
Transfer solution to a dark bottle. Store at room temperature. 
8. 5x stock Tris-borate buffer (TBE) 
108g Tris base 
55g Boric acid 
20mlofa 0.5M EDTA (PH 8.0) 
Buffer was made up to 2litres with d. H20 
To be diluted 1110 for use. 
9. 6x loading buffer 
0.25% bromophenol blue 
40% (w/v) sucrose in water 
Stored at 4 DC 
10. LB Agar 
109 Bacto-tryptone 
5 g Bacto-yeast extract 
109 NaCI 
Add 900ml dH20. Adjust to pH 7. 
Add 15g Bacto-agar and make up to lL with dH20. Autoclave to sterilize. 
150 
11. Stock Ampicillin (100Jiglml) 
Dissolve SOOmg Ampicillin in Sml d.H20 . 
Aliquot in volumes of SOOIlI using sterile l.5ml tubes covered with foil. 
Store at -20°C. Use at IOOIlg/1l1. 
12. Tetracycline (Smglml) 
Dissolve Smg tetracycline in Iml ethanol. 
Use at ISug/ml (1/333) 
13. X-Gal solution (20mg/ml) 
To SOmg of X-Gal add 2.5ml of dimethyl formamide. 
Store in the dark (foil- covered tubes) as X-Gal is light sensitive at -20°C. 
Use at 3Slll/plate. 
14. IPTG solution (200 mg/ml) 
Dissolve 2.0g IPTG in 8ml distilled water. 
Make up to 10mI. Sterilize by filtration through a 0.221lm disposable filter. 
Aliquot into volumes of SOOlll using sterile I.Sml tubes. 
Store at -20°C. Use at 20lll/plate. 
15. SOC Medium 
2g bacto-tryptone 
O.Sg bacto-yeast extract 
0.OS9g NaCl 
0.019g KClin d.H20 
Adjust pH to 7 with HCl, fill up to a volume of 97ml and autoclave. 
Allow cooling to 60°C. 
Add 2ml of IM MgS04 and Iml of2M Glucose (glucose has been filter sterilised). 
ISI 
152 
16. LB Agar with 100",glml ampicillin 
Prepare LB agar. After autoclaving, cool to 60°C. Add 2mVlitre of 50Ilg/ml ampicillin 
stock and mix. Pour the medium into the petri dish until the bottom of the plate is fully 







Tris.CI (PH 8) 
EDTA (PH 8.0) 
Solution was autoclaved. Stored at 4°C. 
18. Solution 11 
0.2N NaOH 
1% (w/v) SDS 
19. Solution III 
5M Potassium acetate 










10X One-Ph or-All-Buffer plus (OPA) 
Tris acetate 
Magnesium acetate 
Potassium acetate (PH 7.5) 
153 
21. 3M Sodium Acetate (pH 5.2) 
Dissolve 102.25g of sodium acetate.3H20 in 60ml H20. Adjust the pH to 5.2 with glacial 
acetic acid. Adjust volnme to lOOml with H20. 






SOB Agar plates 
Bacto-tryptone 
Bacto- yeast extract 
NaCI 
KClind.H20 
Make up to 475ml with d.H20. 
Adjust to pH 7 with HCI. Add 7.5g bacto agar to medium and adjust volume to 490mI. 
Autoclave to sterilize. Allow cooling to 60°C. Shortly before pouring into petri dishes; add 
lOml of lM MgSO (solution autoclaved separately). 





lOml O.5M KMES (Equilibrate a O.5M solution 
(2 [morpholino ]ethonesulphonicacid) to pH 6.3 using concentrated KOH) 
Make up to lOOml with d.H20. 
Sterilize by filtration through a 0.22Jl disposable filter. 
Store in aliquots at -20°C. 
of MES 
154 
24. Luria Bertani (LB) Broth 
10g Bacto-tryptone 
5 g Bacto-yeast Extract 
109 NaCI 
Add 900ml d.H20. Adjust to pH 7. Make up to llitre. Dispense in aliquots of20mls using 
sterile 50ml Schott bottles. Sterilize by autoclaving. 
25. 10% Ammonium Persulfite (APS) 
19 ammonium persulfite 
Dissolve in 10ml d.H20. 
Dispense in aliquots of 100JLI using sterile O.5ml tubes. 
Store at -20°C. 
Do not refreeze APS. 
26. 10X TBE Buffer 
108g Tris base 
55g Boric acid 
9.3g EDTA 
Make up to 1 litre with d. H20. 
27. IMIPTG 
2.38g IPTG 
Make a solution of IPTG by dissolving in 8ml d.H20. 
Adjust the volume to 10ml with dH20 
Sterilize by filtration through a O.22J.l disposable filter. 
Dispense in 1ml aliquots. 
Store at -20°C. 













2X Denaturing Sample Buffer (10 ml) 
O.5M Tris-HCl pH 6.8 
Glycerol 
10% SDS 
1 % Bromophenol Blue (w/v) 
2-mercapto-ethano1 
deionised water 
Store at -20°C. 
30. 30% Acrylamide:Bis stock (29:1) 
29.2g Acry1amide 
0.8g bis-acrylamide 
Dissolve in 50m1 d.H20 by heating at 3TC. 
Make up to 100ml with d.H20. 








12% Separating Gel 0.375 M Tris pH 8.8 (20 ml) 
Water 
30% Acrya1amide bis acryalamide 
1.5 M Tris HCI pH 8.8 
10% SDS 
Temed 
10% APS (0.1 glml) 
155 
156 
32. Water Saturated n-Butanol 
Add water to n-Butanol until Butanol is saturated. Two phases appear: n-Butanol at the 
top, and water at the bottom 
33. 1.5M Tris (PH 8.8) 
27.23g Tris base 
Dissolve in 80ml d.H20. Adjust to pH 8.8 with IN HCI. Make up to 150ml with d.H20 
34 IM Tris (PH 6.8) 
12.1g Tris base 
Dissolve in 60ml d.H20. Adjust pH to 6.8 with IN HCI. Make up to 100ml with d.H20. 







5% Stacking Gel 0.125M Tris pH 6.8 (5.0 ml) 
Water 
30% Acryalamide bis acryalamide 




36. Staining Solution (100ml) 
40% Methanol 
10% Acetic acid 
0.1 % Coommassie Brilliant Blue G250 

















Make up to 1L with deionised water. Store at RT. 
Dilute 1: 1 0 for use. 
39. Pefabloc (500mM) 
Add 835ml d.H20 to 100mg of Pe fa bloc. 
Use at 1:1000 dilution ie 0.5mM. 
40. 50mM Tris HCl pH 8 
Dissolve 0.61g Tris base in 80ml d.H20. 
Adjust to pH 8 with HCl. 
41. 10mM Reduced Gluthathione 
10mM reduced glutathione in 50mM Tris HCI pH 8, 
42. 10X Transfer Buffer 
30.3g Tris Base 
144.2g Glycine 
Dissolve in d.H20 up to 1000ml. 
Dilute 1: 1 0 for use 
157 
43. Blocking/Incubation Buffer for Immunoblot 
5 g fat free milk powder 
1:5 dilution of 10X Wash buffer 




10X PBS/O.5% Tween 20 Wash Buffer for Immunoblot 
PBS 
Tween20 
Dilute 1: 10 for use as wash buffer 
45. Peroxidase Substrate 
Solution 1: lOml ice cold methanol plus 1 tablet 4-Chloro-1-NaphthoI4CIN. 
Solution 2: Add 30JlI Hydrogen peroxide to 50ml PBS 
Mix together, solution 1 and solution 2, and use.immediately. 
46 3M Sodium chloride 
Dissolve 17.4g in lOOml d.H20. Autoclave dissolved solution and store at 4°C. 
158 
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